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Abstract	  	  
Background	  There	   has	   been	   an	   exponential	   rise	   in	   the	   incidence	   of	   alcohol	   related	   liver	  disease	  (ALD),	  particularly	  in	  the	  UK.	  Alcoholic	  hepatitis	  (AAH)	  is	  the	  most	  florid	  form	  of	  ALD	  and	  has	  a	  high	  mortality	  rate,	  sepsis	  is	  a	  significant	  problem	  and	  a	  major	  contributor	  to	  mortality.	  Treatment	  for	  patients	  with	  AAH	  has	  not	  changed	  in	  decades,	  one	  of	  the	  reasons	  for	  this	  is	  the	  relative	  lack	  of	  understanding	  of	  the	  underlying	  pathophysiology.	  No	  study	  has	  longitudinally	  investigated	  changes	  in	  immune	   function	   in	   this	   condition	  or	   the	   impact	  of	   current	   treatments	  on	  host	  immunity.	   Neutrophil	   dysfunction	   has	   been	   described	   in	   cirrhosis,	   however	  there	  is	  a	  lack	  of	  understanding	  regarding	  the	  mechanisms	  involved	  and	  how	  this	  relates	   to	   alcohol-­‐induced	   liver	   toxicity.	   In	   addition,	   whether	   other	  derangements	  in	  neutrophil	  function	  contribute	  to	  the	  state	  of	  immunoparesis	  in	  ALD	  is	  not	  well	  understood.	  
Aims	  and	  methods	  I	  sought	  to	  characterise	  neutrophil	  phenotype	  and	  responses	  ex	  vivo	  to	  bacterial	  challenge	   in	   patients	   with	   AAH	   compared	   with	   patients	   with	   alcohol	   related	  cirrhosis	  (ARC)	  and	  healthy	  controls	  (HC)	  and	  prospectively	  examine	  neutrophil	  function	   and	   the	   effect	   of	   current	   AAH	   therapies	   on	   innate	   immune	   function	  through	  sequential	  analyses.	  The	  interplay	  between	  neutrophils,	  ethanol	  and	  the	  liver	   was	   also	   examined	   by	   using	   the	   HL-­‐60	   cell	   line	   and	   creating	   an	   in	   vitro	  model.	   Finally,	   I	   sought	   to	   identify	   novel	   targets	   which	   may	   propagate	  immunoparesis	   in	   ALD,	   specifically	   examining	   the	   relationship	   of	   neutrophils	  and	  interferon-­‐λ	  (IFN-­‐λ)	  in	  anti-­‐bacterial	  immune	  defenses	  in	  health	  and	  ARC.	  
Key	  results	  Neutrophils	   from	  patients	  with	  AAH	  display	   increased	   reactive	   oxygen	   species	  production	   and	   lactoferrin	   release	   compared	   to	   ARC	   and	   HCs.	   Neutrophil	  antibacterial	   activities	   and	  key	  detecting	   receptors	   (TLRs)	   are	  dysfunctional	   in	  AAH	   and	   in	   ARC.	   Indeed,	   a	   skewed	   balance	   between	   host-­‐induced	  immunopathology	   and	   protective	   anti-­‐pathogen	   immunity	   in	   AAH	   has	   been	  confirmed.	  Further	  to	  this,	  the	  studies	  have	  shown	  that	  the	  immune	  impairment	  is	   reversible	   and	   that	   the	   antibacterial	   immune	   responses	   can	   be	   restored.	  
ii	  	  
Antibodies	   against	   immunohibitory	   signatures,	   PD1	   and	   TIM3,	   restored	   T-­‐cell	  production	   of	   interferon	   gamma,	   reduced	   the	   numbers	   of	   interleukin	   10-­‐producing	   T	   cells,	   and	   increased	   neutrophil	   antimicrobial	   activities	   without	  exacerbating	  neutrophil	  oxidative	  burst.	  	  The	  most	  notable	  finding	  in	  the	  longitudinal	  study	  was	  the	  impact	  of	  steroids	  on	  phagocytic	  capacity,	  this	  was	  significantly	  reduced	  at	  day	  7	  in	  the	  prednisolone-­‐exposed	   AAH	   patients	   compared	   to	   those	   who	   did	   not	   receive	   prednisolone,	  reinforcing	   the	   concept	   that	   improved	   stratification	   for	   steroid-­‐prescribing	   is	  required.	  The	   differentiated	  HL-­‐60	   cells	   express	  many	   of	   the	   key	   receptors	   examined	   in	  the	  human	  study	  and	  could	  form	  the	  basis	  of	  future	  in	  vitro	  studies	  in	  this	  area	  of	  research.	   The	   exploration	   of	   these	   cells	   led	   to	   further	   questions	   regarding	  neutrophil	  biology	  and	  the	  work	  on	  the	  neutrophil-­‐interferon-­‐λ	  relationship	  both	  in	  health	  and	  ALD.	  The	  role	  of	  IFN-­‐λ	  in	  bacterial	  infection	  was	  not	  known	  and	  the	  question	   as	   to	   whether	   neutrophils	   produce	   IFN-­‐λ	   unanswered.	   Neutrophil	  specific	   IFN-­‐λ	   production	   in	   response	   to	   E.	  coli	   challenge	   was	   found	   to	   be	  compromised	  in	  patients	  with	  ARC	  and	  correlated	  with	  severity	  of	  liver	  disease.	  These	   findings	   reveal	   a	   previously	   unknown	   function	   of	   neutrophils	   in	   the	  context	  of	  bacterial	   infection	  and	  identify	  a	  novel	   impairment	  in	  host	  immunity	  in	  patients	  with	  ARC.	  	  
Conclusions	  Elucidation	   of	   the	   above,	   specifically	   the	   potential	   for	   immune	   dysfunction	  reversibility	  and	  the	  novel	  finding	  of	  the	  deficiency	  in	  neutrophil	  IFN-­‐λ	  function,	  may	   have	   important	   implications	   for	   therapeutic	   developments	   in	   an	   era	   of	  multi-­‐drug	  resistance	  and	  within	  the	  spectrum	  of	  ALD.	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1.1 Alcohol-­‐related	  liver	  disease	  
1.1.1 The	  extent	  of	  the	  problem	  Liver	  disease	  now	  constitutes	  the	  third	  commonest	  cause	  of	  premature	  death	  in	  the	  UK	  [1]	  and	  seventy	  per	  cent	  of	  patients,	  admitted	  with	  cirrhosis,	  have	  alcohol	  as	   the	  major	   aetiological	   factor	   [2].	  Whilst	  mortality	   from	   alcohol-­‐related	   liver	  disease	   (ALD)	   in	   many	   European	   nations	   is	   falling,	   a	   steady	   rise	   in	   alcohol	  related	   liver	   deaths	   in	   England	   and	   Wales	   is	   projected,	   estimated	   to	   reach	  143,000	  over	  the	  next	  twenty	  years	  (Figure	  1.1)	  [3].	  
	  
Figure	  1.1	  Alcohol	  related	  liver	  deaths	  by	  country	  since	  1986	  from	  Sheron	  et	  al,	  Lancet	  2012	  [3]	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Considerable	  advances	  have	  been	  made	   in	  many	  aspects	  of	  healthcare	  over	  the	  last	   few	   decades	   and	   in	   some	   areas,	   particularly	   cardiovascular	   disease,	   the	  decrease	  in	  mortality	  has	  been	  substantial.	  Liver	  disease	  remains	  the	  exception.	  	  	  Alcohol-­‐related	   liver	   toxicity	   is	   dose-­‐related	   and	   there	   is	   a	   significant	   positive	  correlation	  between	  overall	   alcohol	   consumption	  and	   liver	   related	  mortality	   in	  21	  out	  of	  28	  EU	  member	  states	  [4].	  Public	  health	  measures	  and	  policy	  alterations	  have	  the	  potential	  to	  alter	  the	  predicted	  trend	  over	  years	  to	  come;	  currently	  we	  have	  a	  rising	  mortality	  from	  a	  disease	  where	  no	  pharmaceutical	  therapy	  has	  yet	  been	  shown	  to	  improve	  long-­‐term	  survival.	  	  	  In	   addition,	   the	   2013	   National	   Confidential	   Enquiry	   into	   Patient	   Outcome	   and	  Death	  (NCEPOD)	  report	  showed	  that	  the	  care	  of	  patients	  acutely	  sick	  with	  liver	  disease	  dying	  in	  hospital	  was	  judged	  to	  be	  good	  in	  less	  than	  half	  of	  patients.	  In-­‐hospital	   mortality	   rates	   for	   cirrhosis	   and	   liver	   failure	   vary	   across	   the	   UK	  considerably	   (Figure	   1.2)	   [1],	   with	   some	   acute	   trusts	   consistently	   reporting	  mortality	   rates	   of	  more	   than	   double	   those	   of	   the	   better	   centres.	   The	   need	   for	  improved	  treatments	  and	  a	  standardised	  holistic	  approach	  to	  care	  for	  this	  group	  of	  patients	  is	  clear.	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Figure	  1.2	  In-­‐hospital	  mortality	  rate	  –	  patients	  coded	  for	  liver	  disease	  or	  cirrhosis	  in	  non-­‐specialist	  
trusts	  in	  England,	  2003–13,	  Lancet	  2014	  [1]	  
	  	   	  
5	  	  
1.1.2 Disease	  spectrum	  of	  alcohol-­‐related	  liver	  disease	  ALD	   represents	   a	   spectrum	   of	   liver	   injury	   ranging	   from	   simple	   steatosis,	  alcoholic	   steatohepatitis	   (ASH),	   progressive	   fibrosis	   through	   to	   cirrhosis,	   with	  the	   predisposition	   to	   hepatocellular	   carcinoma	   (HCC).	   	   For	   practical	   and	  diagnostic	  purposes	  three	  distinct	  stages	  are	  recognised:	  
1. Simple	  hepatic	  steatosis	  2. Alcoholic	  steatohepatitis	  	  3. Advanced	  hepatic	  fibrosis	  or	  cirrhosis	  [5].	  
Although	  many	  individuals	  drinking	  more	  than	  60g	  of	  alcohol	  (7.5	  units)	  per	  day	  develop	  steatosis,	  only	  a	  minority	  of	  patients	  with	  steatosis	  progress	  to	  ASH	  and	  10–20%	  eventually	  develop	  cirrhosis	   [6].	  Figure	  1.3	   illustrates	   the	  evolution	  of	  liver	  disease	  in	  heavy	  drinkers.	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Figure	  1.3	  Evolution	  of	  liver	  disease	  in	  heavy	  alcohol	  users,	  adapted	  from	  Orman	  et	  al,	  Alcoholic	  liver	  
disease;	  pathogenesis,	  management	  and	  novel	  targets	  for	  therapy	  [7]	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Predictors	   for	   which	   heavy	   alcohol	   users	   will	   progress	   to	   cirrhosis	   are	   not	  currently	  well	  known,	  although	   it	   is	  well	   recognised	   that	   those	  with	  co-­‐factors,	  for	   example,	   hepatitis	   C	   or	   obesity	   may	   run	   a	   more	   accelerated	   progressive	  disease	  course.	  The	  annual	  incidence	  of	  HCC	  in	  alcohol-­‐related	  cirrhosis	  (ARC)	  is	  approximately	  2.5%,	  even	  in	  those	  with	  compensated	  disease	  [8].	  
1.1.3 Alcoholic	  hepatitis	  Alcoholic	  hepatitis	   (AAH)	   is	   a	   clinical	   syndrome	  defined	  by	   the	   recent	  onset	  of	  jaundice	   with	   or	   without	   other	   features	   of	   hepatic	   decompensation,	   including	  ascites,	   coagulopathy	   and	   encephalopathy,	   in	   a	   patient	   with	   recent	   and	  prolonged	  heavy	  alcohol	  consumption.	  For	   the	  diagnosis	  of	  AAH,	  heavy	  alcohol	  use	  should	  have	  occurred	  for	  >6	  months,	  with	  <60	  days	  of	  abstinence	  before	  the	  onset	   of	   jaundice	   [9].	   ASH	   is	   a	   histological	   diagnosis	   and	   is	   defined	   by	   the	  coexistence	  of	  steatosis,	  hepatocyte	  ballooning	  and	  an	  inflammatory	  infiltrate	  by	  polymorphonuclear	   cells	   (PMN).	   The	   lesions	   defining	   ASH	   do	   not	   differ	   from	  those	   described	   in	   non-­‐alcoholic	   steatohepatitis	   (NASH),	   but	   ASH	   is	   usually	  associated	  with	  more	  severe	  histological	  lesions	  and	  a	  worse	  clinical	  course.	  The	  presence	  of	  Mallory-­‐Denk’s	  bodies	   and	  megamitochondria	   are	  often	   associated	  with	  the	  lesions	  described	  above	  [10].	  	  In	  most	  patients	  histological	  analysis	  demonstrates	  the	  presence	  of	  ASH	  and	  co-­‐existent	  advanced	  fibrosis	  or	  cirrhosis.	  	  AAH	   should	   be	   suspected	   in	   patients	   with	   a	   history	   of	   excess	   alcohol	  consumption	  (>60g/day	  male,	  >40g/day	  female)	  and:	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 Recent	  onset	  or	  rapid	  progression	  of	  jaundice	  with	  serum	  bilirubin	  >50	  μmol/L,	  defined	  as	  within	  last	  8	  weeks	  
 Leukocytosis	  +/-­‐	  fever	  
 AST	  elevation	  2-­‐6	  x	  ULN	  
 AST	  to	  ALT	  ratio	  >1.5	  
 Elevated	  GGT	  levels	  and	  high	  MCV	  
 Prolonged	   prothrombin	   time,	   decreased	   albumin,	  thrombocytopenia	  	  	  Bacterial	  and	   fungal	   infection	  occurs	   in	  up	   to	  40%	  [11,	  12],	  and	   it	   is	  estimated	  that	  25%	  of	  patients	  with	  AAH	  have	  active	  infection	  at	  the	  time	  of	  presentation	  [13].	  This	  can	  be	  difficult	  to	  differentiate	  clinically	  from	  features	  of	  the	  systemic	  inflammatory	   response	   syndrome	   (SIRS)	   arising	   from	  hepatic	   inflammation.	   In	  addition	   those	  with	   underlying	   cirrhosis	  may	   not	  mount	   the	   classical	   immune	  response	   to	   sepsis.	   Therefore,	   a	   full	   septic	   screen	   (blood,	   urine,	   ascitic	   culture	  and	  chest	  X-­‐ray)	  should	  be	  sent	  promptly	  on	  admission	  and	  at	  any	   time	  a	  new	  fever	  or	  clinical	  deterioration	  becomes	  apparent.   	  AAH	  is	  unlikely	  in	  the	  presence	  of	  very	  high	  transaminase	  levels	  (AST	  >	  500	  or	  ALT	   >	   300),	   which	   is	   suggestive	   of	   other	   causes	   of	   liver	   disease,	   such	   as	  ischaemic	  hepatitis	  (e.g.	  due	  to	  concomitant	  use	  of	  cocaine),	  drug-­‐induced	   liver	  injury	   (DILI),	   autoimmune	   hepatitis	   (AIH),	   or	   viral	   hepatitis.	   Similarly,	   high	  serum	   levels	   of	   alkaline	   phosphatase	   are	   unusual	   and	   suggest	   a	   possible	  obstructive	  cause	  of	  jaundice.	  A	  liver	  screen	  should	  be	  done	  to	  look	  for	  co-­‐factors	  or	   co-­‐existence	   of	   a	   second	   aetiology	   of	   liver	   disease.	   Imaging	   including	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ultrasound,	   computed	   tomography	   or	   magnetic	   resonance	   imaging	   may	   allow	  detection	  of	  fatty	  infiltration	  and	  contribute	  to	  the	  staging	  of	  liver	  disease,	  but	  is	  particularly	  useful	   in	   identifying	  abscess,	  HCC	  or	  biliary	  obstruction	  which	  may	  mimic	  AAH	  [14].	  The	  diagnosis	  of	  AAH	  usually	  can	  be	  made	  on	  clinical	  history,	  typical	  biochemical	  pattern	  and	  exclusion	  of	  other	  causes	  of	  acute	  liver	  injury	  [15].	  The	  histological	  lesion	  (Figure	  1.4)	  need	  not	  be	  accompanied	  by	  the	  clinical	  syndrome	  of	  severe	  AAH	   and	   ASH	   is	   often	   used	   to	   denote	   the	   pathological	   as	   opposed	   to	   clinical	  diagnosis.	  	  
	  
Figure	   1.4	   Histopathological	   features	   in	   a	   liver	   biopsy	   specimen	   from	   a	   patient	   with	   Alcoholic	  
Hepatitis.	  	  There	   are	   ballooned	   hepatocytes	   (curved	   arrow),	   some	   hepatocytes	   contain	   fat	   droplets	   (steatosis,	  arrowhead),	   whereas	   others	   may	   contain	   intracellular	   amorphous	   eosinophilic	   inclusion	   bodies	   called	  Mallory	  Denk	  bodies	  (short	  arrow)	  which	  are	  often	  surrounded	  by	  neutrophils	  (long	  arrow)	  (haematoxylin	  and	  eosin).	  [14]	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The	  need	  for	  biopsy	  to	  confidently	  diagnose	  AAH	  remains	  contentious	  [16].	  The	  reported	  inaccuracy	  of	  a	  clinical	  diagnosis	  of	  severe	  AAH	  varies	  widely	  [17,	  18].	  Steatohepatitis	   can	   be	   detected	   in	   liver	   tissue	   from	   approximately	   80%	   of	  patients	  undergoing	  liver	  biopsy	  for	  presumed	  AAH	  [19,	  20].	  Due	  to	  the	  common	  existence	   of	   thrombocytopenia,	   coagulopathy	   and	   ascites	   in	   these	   patients,	   a	  transjugular	   liver	   biopsy	   (TJLB)	   rather	   than	   percutaneous	   biopsy	   is	   frequently	  indicated	   in	   this	   setting	  and	   the	  availability	  of	   this	  outside	   specialist	   centres	   is	  limited.	  One	  validated	  AAH-­‐specific	  histologic	   classification	  has	  been	  published	  to	   date;	   here	   the	   degree	   of	   fibrosis,	   degree	   of	   neutrophil	   infiltration,	   type	   of	  bilirubinostasis,	   and	   presence	   of	   megamitochondria	   were	   independently	  associated	   with	   90-­‐day	   mortality	   [21].	   The	   finding	   that	   neutrophil	   infiltration	  and	  megamitochondria	  identifies	  patients	  with	  better	  outcomes	  may	  relate	  to	  an	  earlier	  stage	  of	  disease	  in	  these	  individuals,	  but	  the	  protective	  mechanisms	  and	  potential	  association	  with	  regeneration	  requires	  further	  investigation.	  	  Current	   published	   guidelines	   recommend	   histological	   confirmation	   of	   severe	  AAH	   in	   cases	   of	   diagnostic	   uncertainty	   or	   where	   medical	   therapy	   is	  contemplated	  and	  the	  European	  Association	  for	  the	  Study	  of	  the	  Liver	  guidelines	  recommend	  use	  of	  histologic	  analysis	  in	  clinical	  trials	  [5,	  10].	  	  	  Towards	   the	   end	   of	   my	   period	   of	   research	   the	   National	   Institute	   on	   Alcohol	  Abuse	   and	   Alcoholism	   (NIAAA)	   formulated	   definitions	   to	   specifically	   facilitate	  trial	  design	  and	  uniformity	   in	   clinical	   trials	   [9].	  These	   suggest	   that	  patients	   for	  clinical	   trials	   are	   classified	   as	   definite	   AAH;	   clinically	   diagnosed	   and	   biopsy-­‐proven,	  probable	  AAH;	  clinically	  diagnosed	  without	  any	  confounding	  factors	  and	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possible	   AAH;	   clinically	   diagnosed	   but	   with	   confounding	   factors	   such	   as	  ischaemic	   hepatitis	   or	   drug-­‐induced	   liver	   injury,	   uncertain	   alcohol	   use	   or	  atypical	  laboratory	  tests.	  It	  is	  recommended	  that	  the	  latter	  group	  undergo	  biopsy	  for	  confirmation	  prior	  to	  clinical	  trial	  entry.	  	  Ultimately	  individual	  patient	  management	  with	  regard	  to	  biopsy	  is	  dependent	  on	  local	   expertise	   and	   the	  aim	  should	  be	   to	   assess	   and	  manage	  patients	  promptly	  with	  appropriate	  recognition	  of	  severity	  of	  illness.	  Management	  currently	  centres	  around	  supportive	  care	  with	  focus	  on	  abstinence,	  nutrition	  and	  monitoring	  for	  sepsis.	  Treatment,	  including	  specific	  therapies,	  will	  be	  discussed	  in	  1.6.	  	  
1.2 Prognostic	  scores	  in	  liver	  disease	  




Figure	  1.5	  Child-­‐Pugh	  score	  
	  
Figure	  1.6	  Child-­‐Pugh	  score	  and	  percentage	  survival	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1.2.2 MELD	  Score	  The	   inter-­‐observer	   variability	   for	   the	   subjective	   parameters	   in	   the	   CPS	  classification	   led	   to	   the	  development	  of	   the	   “model	   for	  end	  stage	   liver	  disease”	  (MELD)	   score.	   The	   MELD	   score	   was	   originally	   developed	   to	   predict	   survival	  following	   transjugular	   portosystemic	   shunts	   (TIPS)	   for	   treatment	   of	   variceal	  bleeding	   or	   refractory	   ascites	   [30].	   It	   was	   then	   modified	   slightly	   to	   predict	  survival	   in	  patients	  with	  cirrhosis	   in	  general	  [31].	   It	   is	  a	  continuous	  function	  of	  bilirubin,	   international	  normalized	  ration	  (INR)	  and	  creatinine	  to	  predict	  short-­‐term	   (three-­‐month)	   survival	   and	   has	   subsequently	   been	   applied	   to	   prioritise	  allocation	  of	  donor	  livers	  for	  transplantation	  [32].	  MELD	  has	  also	  been	  used	  to	  predict	  mortality	  specifically	   in	  AAH	  and	  has	  been	  compared	  with	  Maddrey’s	  discriminant	   function	  and	  CPS	   in	   this	   condition	   [33-­‐35].	  
1.2.3 Maddrey’s	  Discriminant	  Function	  The	   Discriminant	   Function	   (DF),	   comprising	   bilirubin	   and	   prothrombin	   time	  (PT)	   was	   described	   by	   Maddrey	   in	   1978	   during	   a	   therapeutic	   trial	   of	  methylprednisolone	   [36]	   in	   AAH.	   Due	   to	   the	   variability	   in	   PT	   between	  laboratories	   the	   DF	   was	   modified	   in	   1989	   for	   a	   multi-­‐centre	   trial	   to	   use	  prolongation	  in	  PT	  above	  laboratory	  control	  time	  [37].	  A	  cut-­‐off	  value	  of	  32	  was	  used	   to	   identify	  patients	  with	   severe	  AAH.	  By	  using	   the	  DF,	   large	   variations	   in	  mortality	   were	   observed	   between	   patients	   with	   DF	   values	   of	   32	   or	   more	  compared	   with	   patients	   with	   lower	   DF	   values	   [38].	   Although	   trials	   pre-­‐2000	  enrolled	   relatively	   small	   numbers	   of	   patients,	   the	  DF	   remains	   the	  most	  widely	  used	   criteria	   to	  define	   severe	  AAH	  and	   the	  point	   at	  which	   to	   consider	  medical	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therapy.	  	  
1.2.4 Glasgow	  Alcoholic	  Hepatitis	  Score	  (GAHS)	  The	  Glasgow	  Alcoholic	  Hepatitis	  Score	  (GAHS)	  is	  based	  on	  a	  multivariable	  model	  that	  includes	  age,	  serum	  bilirubin,	  blood	  urea	  nitrogen,	  PT	  and	  peripheral	  white	  blood	  cell	  count	  [39].	  An	  initial	  validation	  study	  found	  that	  a	  GAHS	  ≥9	  had	  lower	  sensitivity	  but	  higher	  specificity	  for	  predicting	  28-­‐day	  mortality	  than	  a	  DF	  of	  ≥32	  (81	   versus	   96	   percent	   and	   61	   versus	   27	   percent,	   respectively).	   In	   a	   follow-­‐up	  study	   three-­‐month	   survival	   in	   cases	   where	   GAHS<9	   was	   unchanged	   by	  corticosteroid	  therapy	  whereas	  those	  with	  higher	  scores	  appeared	  to	  benefit	  (28	  day	  survival	  78%	  versus	  52%,	  59%	  versus	  38%	  at	  84	  days)	  [40].	  
1.2.5 The	  Lille	  score	  This	  model	  specific	  for	  AAH	  uses	  five	  routine	  pre-­‐treatment	  variables	  and	  change	  in	  bilirubin	  level	  at	  day	  7	  [41].	  Above	  the	  cutoff	  of	  0.45,	  the	  Lille	  model	  is	  able	  to	  predict	   76%	   of	   the	   observed	   6-­‐month	   deaths.	   The	   absence	   of	   differences	   in	  survival	   among	   patients	   with	   a	   Lille	   score	   0.45	   who	  were	   treated	   with	   either	  corticosteroids	  or	  placebo	  suggests	   that	  continuing	  corticosteroids	  after	  7	  days	  may	  be	  futile.	  
1.2.6 ABIC	  score	  In	  2008	  a	  further	  AAH-­‐specific	  prognostic	  score	  was	  identified	  and	  this	  used	  age,	  bilirubin,	   INR	   and	   creatinine	   (ABIC)	   as	   independent	   predictors	   of	   90	   day	  mortality	   in	   a	   prospective	   study	   [42].	   Using	   two	   points	   in	   the	   ABIC	   score	  investigators	   defined	   three	   groups	   with	   no	   (0%),	   moderate	   (32.5%)	   and	   high	  (72.5%)	  risk	  of	  death	  at	  90	  days.	  Admission	  ABIC	  scores	  remained	  predictive	  of	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survival	   at	   one	   year	   and	   suggests	   that	   corticosteroids	   appear	   to	   be	   most	  efficacious	  in	  cases	  of	  intermediate	  disease	  severity.	  
In	   summary	   there	   are	  multiple	   prognostic	   scoring	   systems	   for	   use	   in	   AAH.	   As	  above,	   some	   have	   been	   developed	   specifically	   for	   this	   cohort	   perhaps	   as	   a	  consequence	   of	   the	   inadequacy	   of	   existing	   medical	   therapies,	   others,	   namely	  MELD,	   have	   been	   validated	   for	   prognostic	   use	   in	   this	   population.	   In	   a	   cross	  validation	   study	  of	  nine	   scoring	  models	   for	  mortality	   in	  AAH,	  MELD,	  DF,	  GAHS	  and	   the	  ABIC	  proved	   to	  be	  clinically	  useful	   scores,	  performing	  comparably	  and	  with	  an	  acceptable	  accuracy	  (AUROCs	  exceeding	  0.70)	   for	  both	  30-­‐	  and	  90-­‐day	  mortality	   [43].	   	   The	   difficulty	   comes	   in	   predicting	   longer-­‐term	   outcome.	   In	  another	  study,	  MELD,	  DF,	  ABIC	  and	  GAHS	  performed	  equally	  in	  predicting	  short-­‐term	   (30-­‐	   and	   90-­‐day)	   survival;	   all	  models	  were	   uniformly	   poor	   in	   predicting	  longer-­‐term	  (6-­‐month	  and	  1-­‐year)	  outcome	  [44].	  By	  combining	  MELD	  and	  Lille	  scores	  mortality	  may	  be	  better	  predicted,	  this	  applies	  currently	  to	  2-­‐month	  and	  6-­‐month	  mortality	  [45].	  Abstinence	  has	  been	  found	  to	  be	  the	  only	   independent	  predictor	  of	  long-­‐term	  survival	  [46]	  and	  a	  more	  recent	  study	  concludes	  that	  new	  therapeutic	  development	  for	  severe	  AAH	  should	  target	  liver	  injury	  in	  the	  short-­‐term	  and	  alcohol	  consumption	  in	  the	  long	  term	  [47].	  
It	  is	  clear	  that	  AAH	  has	  a	  spectrum	  of	  severity.	  Consensus	  is	  needed	  to	  select	  the	  prognostic	   factors	   and	   the	   time	   points	   for	   measurement	   to	   make	   this	   disease	  area	  more	  amenable	  for	  drug	  development	  [15].	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1.3 Pathogenesis	  of	  alcohol-­‐related	  liver	  disease	  The	  mechanisms	  by	  which	   long-­‐term	  alcohol	  exposure	  causes	   liver	  disease	  are	  complex	  and	  not	  fully	  understood.	  It	  is	  likely	  that	  multiple	  mechanisms	  combine	  to	   produce	   the	   varying	   stages	   of	   liver	   injury	   dependent	   on	   drinking	   pattern,	  environmental	   and	   individual	   factors.	   In	   this	   section	   an	   overview	   of	   key	  pathways	  will	  be	  described.	  
1.3.1 Ethanol	  metabolism	  and	  cell	  injury	  Ethanol	  is	  mainly	  metabolized	  by	  alcohol	  dehydrogenase	  (ADH)	  and	  microsomal	  ethanol	   oxidation	   system	   (MEOS)	   into	   acetaldehyde	   [48].	   MEOS	   incorporates	  cytochromes	   p450	   and	   in	   particular	   CYP2E1.	   Most	   acetaldehyde	   is	   converted	  into	   acetate	   by	   aldehyde	   dehydrogenase	   (ALDH),	   this	   reaction	   requires	  NAD+/NADH	  and	  increases	  the	  amount	  of	  NADH	  in	  the	  liver.	  ADH,	  CYP2E1	  and	  ALDH	   are	   mainly	   expressed	   in	   hepatocytes	   and	   therefore	   most	   of	   the	   direct	  cellular	   toxicity	   of	   ethanol	   affects	   these	   cells.	   Ethanol	   metabolism	   leads	   to	  accumulation	  of	  reactive	  oxygen	  species	  (ROS),	  these	  radicals	  bind	  to	  ethanol	  or	  iron	  atoms	  to	  form	  reactive	  metabolites	  responsible	  for	  lipid	  peroxidation	  of	  cell	  membranes.	  	  The	   cytotoxic	   effects	   of	   ethanol	   metabolism	   and	   ROS	   lead	   to	   cell	   death,	   this	  results	   in	   a	   cascade	   of	   damage-­‐associated	  molecular	   patterns	   (DAMPs)	   release	  and	   activation	   of	   neutrophils	   and	   macrophages,	   fibrogenesis	   and	   hepatic	  regeneration	   [49].	   Glutathione	   protects	   cells	   against	   ROS	   but	   chronic	   ethanol	  exposure	  leads	  to	  glutathione	  depletion.	  	  There	   is	  also	  enhanced	  endoplasmic	  reticulum	  (ER)	  stress,	  and	  inflammation	  is	  compounded	  by	  stimulation	  of	  the	  interferon	  and	  NF-­‐kB	  pathways	  [50].	  Another	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consequence	   of	   ER	   stress	   is	   the	   activation	   of	   steatogenic	   pathways	   in	  hepatocytes	  [51].	  
1.3.2 Alcohol-­‐induced	  steatosis	  Chronic	   alcohol	   consumption	   leads	   to	   steatosis	   via	   generation	  of	   acetaldehyde,	  ROS	  and	  ER	  stress.	  The	  consequences	  are	  blockade	  of	  peroxisome	  proliferator-­‐activated	   receptor	   α	   (PPAR	   α)	   and	   of	   adenosine	   monophosphate-­‐activated	  protein	  kinase	  (AMPK),	  which	   is	   responsibe	   for	   fatty	  acid	  oxidation	  and	  export	  via	   acetyl	   CoA	   carboxylase	   (ACC)	   and	   carnitine	   palmioyltransferase	   1	   (CPT1).	  Chronic	   alcohol	   consumption	   and	   increased	   tumour	   necrosis	   factor	   (TNF)	   also	  induces	   sterol	   regulatory	   element-­‐binding	   protein	   1c	   (SREBP1c)	   activation	  which	   is	   responsible	   for	   fatty	   acid	   synthesis	   [48].	   These	   mechanisms	   lead	   to	  increased	  lipogenesis	  and	  decreased	  fatty	  acid	  oxidation	  and	  export.	  	  
1.3.3 Dysbiosis	  and	  endotoxin	  exposure	  The	  role	  of	  bacterial	  translocation	  and	  endotoxin	  in	  the	  pathogenesis	  of	  ALD	  has	  been	  clearly	  established.	  Chronic	  alcohol	  exposure	  in	  humans	  and	  animal	  models	  increases	   circulating	   levels	   of	   lipopolysaccharide	   (LPS)	   and	   the	   severity	   of	  hepatic	   injury	  correlates	  with	  serum	  LPS	   levels	   [52-­‐55].	  LPS	   is	  a	  component	  of	  Gram-­‐negative	   bacteria	   and,	   biochemically,	   consists	   of	   an	   O-­‐antigen,	   a	   core	  polysaccharide	   and	   a	   lipid-­‐A	   component	   [56].	   After	   translocation	   from	   the	   gut	  lumen	   to	   the	   liver,	   LPS	   and	   other	   pathogen-­‐associated	   molecular	   patterns	  (PAMPs)	   are	   recognized	   by	   receptors,	   including	   toll-­‐like	   receptors	   (TLRs)	  activating	   Kupffer	   cells.	   Upon	   activation	   Kupffer	   cells	   release	   ROS,	   adhesion	  molecules	  (intracellular	  adhesion	  molecule	  1,	  ICAM-­‐1	  and	  vascular	  cell	  adhesion	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protein	   1,	   VCAM-­‐1),	   chemokines	   (IL-­‐8,	   CCL2)	   and	   proinflammatory	   cytokines	  (TNF,	  IL-­‐1	  and	  IL-­‐6)	  [57].	  AAH	   is	   characterised	   by	   the	   presence	   of	   large	   amounts	   of	   cytokines	   highly	  sensitive	  to	  PAMPs	  (IL-­‐8,	  Gro-­‐α,	  CCL2),	  leading	  to	  neutrophil	  recruitment	  in	  the	  liver	   [58-­‐61].	   Kupffer	   cells	   can	   also	   ameliorate	   hepatocellular	   damage	   from	  alcohol,	  adopting	  an	  anti-­‐inflammatory	  phenotype	  and	  releasing	  IL-­‐10	  [62-­‐64].	  The	   gut	  microbiota	   and	   susceptibility	   to	   ALD	  has	   become	   a	   focus	   of	   increased	  research	   in	   recent	   years.	   Animal	   models	   demonstrate	   leaky	   gut	   and	   patients	  have	   impairments	  to	  the	   intestinal	  barrier,	   this	  contributes	  to	  the	  development	  of	   ALD	   [65].	   Probiotics	   and	   prebiotics	   have	   subsequently	   been	   investigated	   as	  potential	   therapies	   [66],	   with	   increasing	   evidence	   that	   it	   may	   be	   possible	   to	  prevent	  ALD	  by	  intestinal	  microbiota	  manipulation	  [67].	  
1.3.4 Innate	  immune	  response	  Dysregulation	  of	  many	  components	  of	  the	  innate	  immunity	  in	  the	  liver	  is	  thought	  to	   contribute	   additively	   or	   synergistically	   to	   alcohol-­‐induced	   liver	   injury,	  acceleration	  of	  viral	  infection	  and	  tumour	  formation	  (Figure	  1.7).	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Figure	  1.7	  Ethanol	  dysregulation	  of	  innate	  immunity	  contributes	  to	  the	  pathogenesis	  of	  ALD.	  	  Chronic	  alcohol	  consumption	  results	  in	  activation	  of	  innate	  immunity	  components	  such	  as	  Kupffer	  cells	  and	  complements	   or	   inhibition	   of	   innate	   immunity	   components	   such	   as	   natural	   killer	   (NK)	   cells.	   First,	   as	  previously	  described,	  alcohol	  consumption	  increases	  gut	  permeability	  and	  subsequently	  hepatic	  LPS	  levels	  via	  binding	  to	  TLR4;	  Kupffer	  cells	  are	  then	  stimulated	  to	  produce	  TNF-­‐α	  in	  a	  TRIF/IRF-­‐3	  dependent	  manner.	  LPS	   can	   also	   directly	   target	   hepatic	   stellate	   cells	   (HSCs)	   and	   enhance	   TGF-­‐β	   signaling	   and	   expression	   of	  chemokines,	   adding	   to	   liver	   fibrosis.	   Second,	   alcohol	   consumption	   results	   in	   activation	   of	   complement	  components	  C3a	  and	  C5a,	  again	  stimulating	  Kupffer	  cells	  to	  produce	  TNF-­‐α,	  contributing	  to	  hepatocellular	  damage.	  Third,	  alcohol	  consumption	  inhibits	  the	  anti-­‐fibrotic	  effects	  of	  NK	  cells	  and	  interferon	  (IFN)-­‐γ	  via	  multiple	   mechanisms.	   NK	   cell	   functions	   are	   blocked	   via	   blocking	   IFN-­‐γ	   and	   TRAIL	   production,	   IFN-­‐γ	  signaling	  in	  HSCs	  is	  also	  inhibited	  and	  HSC	  are	  rendered	  resistant	  to	  NK	  cell	  killing.	  [68]	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Kupffer	  cells	  The	  key	  role	  of	  LPS	  in	  alcohol-­‐induced	  steatohepatitis	  is	  believed	  to	  be	  mediated	   via	   targeting	   TLR4	   on	   Kupffer	   cells.	   The	   TLR4	   adaptor	  molecule,	  MD-­‐2,	  and	   its	  co-­‐receptor,	  CD14	  bind	  LPS	  and	  bring	   it	   to	   the	  receptor	  complex	  for	   recognition	  by	  TLR4.	  Hepatocytes	  also	  express	  TLR4	  but	  at	   low	   levels	  with	  minimal	  response	  to	  LPS	  [69].	  	  Two	   downstream	   signaling	   pathways	   are	   activated	   upon	   Kupffer	   cell	   TLR4	  binding.	  The	  MyD88-­‐dependent	  pathway	  ultimately	   results	   in	  activation	  of	  NF-­‐kB	   and	   induction	   of	   NF-­‐kB	   controlled	   genes.	   Second	   the	   MyD88-­‐independent	  pathway	   results	   in	   IKK/TAK1	   kinase	   and	   IRF-­‐3	   phosphorylation	   and	   late	  activation	   of	   NF-­‐kB.	   Phosphorylated	   IRF-­‐3	   subsequently	   activates	   the	  transcription	  of	  IFN-­‐α	  and	  β	  and	  other	  IFN-­‐induced	  genes	  [56,	  70].	  
NK	   cells	   NK	   cell	   function	   is	   thought	   to	   be	   suppressed	   in	   ALD,	   and	   ethanol-­‐inhibition	  of	  these	  cells	  may	  play	  an	  important	  role	  in	  accelerating	  viral	  infection,	  fibrosis	  and	  HCC	  in	  patients	  with	  viral	  hepatitis	  and	  excess	  alcohol	  intake	  [68].	  
Neutrophils	  Infiltration	  of	  a	  large	  number	  of	  neutrophils	  is	  a	  hallmark	  feature	  of	  AAH	  however	  the	  pathogenic	  role	  of	  neutrophils	  in	  ALD	  is	  not	  fully	  understood.	  It	   is	   believed	   that	   activated	   Kupffer	   cells	   produce	   a	   variety	   of	   cytokines	   and	  chemokines,	  as	  previously	  described	  which	  subsequently	  attract	  neutrophils	   to	  the	   liver.	   Neutrophils	   likely	   contribute	   to	   hepatocellular	   damage	   by	   producing	  ROS	  and	  proteases	  [71].	  This	  will	  be	  discussed	  in	  further	  detail	  in	  1.5.	  
1.3.5 Adaptive	  immune	  response	  The	   mechanisms	   by	   which	   alcohol	   triggers	   the	   adaptive	   immune	   system	   are	  incompletely	  characterised.	  Patients	  with	  advanced	  ALD	  have	  circulating	  IgG	  and	  T-­‐lymphocytes	  which	   recognise	   epitopes	   derived	   from	  protein	  modification	   by	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hydroxyethyl	  free	  radicals	  and	  end	  products	  of	  lipid-­‐peroxidation.	  High	  titres	  of	  IgG	  against	  lipid	  peroxidation-­‐derived	  antigens	  are	  associated	  with	  an	  increased	  hepatic	   production	   of	   proinflammatory	   cytokines/chemokines	   [72].	   In	  particular,	   patients	   with	   AAH	   have	   increased	   levels	   of	   circulating	   antibodies	  against	  lipid	  peroxidation	  adducts	  and	  increased	  numbers	  of	  T	  cells	  in	  the	  liver	  [57].	  	  The	  susceptibility	  to	   infection	  in	  this	  patient	  group	  has	  been	  a	  research	  area	  of	  much	  interest	  for	  some	  years.	  In	  AAH	  there	  appears	  to	  be	  a	  skewed	  homeostatic	  balance	   between	   protective	   anti–pathogen	   immunity	   and	   host-­‐induced	  immunopathology.	   Programmed	   cell	   death	   1	   (PD1),	   the	  T-­‐cell	   immunoglobulin	  and	  mucin	  domain–	  containing	  protein	  3	  (TIM3),	  and	  their	  respective	  ligands—CD274	   (also	   known	   as	   PD	   ligand	   1	   [PDL1])	   and	   galectin-­‐9—are	   inhibitory	  receptors	   that	   regulate	   the	   balance	   between	   protective	   immunity	   and	   host	  immune-­‐mediated	  damage.	  It	  has	  been	  shown	  that	  sustained	  hyperexpression	  of	  PD1	  and	  its	  ligand	  PDL1	  promote	  immune	  exhaustion	  [73,	  74].	  TIM3	  also	  plays	  a	  critical	   role	   in	   regulating	   the	   activities	   of	   innate	   cells,	   including	   monocytes,	  dendritic	   cells,	   and	   NK	   cells	   to	   control	   excessive	   inflammatory	   responses	   that	  could	   otherwise	   lead	   to	   immune-­‐mediated	   damage	   and	   immune	   suppression	  [75].	   TIM3-­‐blockade	   can	   reverse	   immune	   tolerance	   in	   chronic	   viral	   infections	  and	   promote	   the	   clearance	   of	   tumours	   in	   humans	   [76].	   TIM3	   and	   PD1	   up-­‐regulation	   is	   associated	   with	   tumour-­‐specific	   T-­‐cell	   dysfunction	   in	   melanoma	  patients,	   and	   only	   dual	   blockade	   of	   both	   pathways	   allows	   reversal	   of	   these	  defects	  [77].	  These	  studies	  suggest	  that	  manipulation	  of	  both	  immune-­‐inhibitory	  pathways	   represents	   a	   promising	   target	   for	   novel	   immunotherapeutic	  approaches.	   The	   role	   of	   these	   immune	   inhibitory	   receptors	   in	   driving	   immune	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impairments	   in	   patients	   with	   ALD	   and	   the	   interplay	   between	   the	   innate	   and	  adaptive	   immune	   system	   has	   been	   investigated	   in	   this	   work	   and	   is	   discussed	  further	  in	  results	  chapter	  3	  [78].	  
1.3.6 Genetics	  The	  heritability	  of	  alcohol	  dependence	  is	  well	  documented	  and	  although	  variants	  in	  ADH	  and	  ALDH	  have	  been	  shown	  to	  confer	  protection	  in	  East	  Asians,	  no	  strong	  candidate	  genes	  conferring	  risk	  have	  been	  identified.	  Three	  candidate	  genes	  with	  regard	   to	   alcohol-­‐related	   cirrhosis,	   PNPLA3,	   TM6SF2	   and	  MBOAT7,	   have	   been	  identified,	  however,	  the	  mechanisms	  by	  which	  variants	  in	  these	  genes	  confer	  risk	  and	   the	   nature	   of	   the	   functional	   interplay	   between	   them	   remains	   to	   be	  determined	  [79].	  Further	  advances	  may	  be	  made	  by	  the	  GenomALC	  consortium	  which	   has	   implemented	   a	   prospective	  approach	   for	   an	   intended	   genome	  wide	  association	  studies	  of	  alcohol-­‐related	  cirrhosis	  [80].	  
1.3.7 Liver	  regeneration	  Liver	   regeneration	   is	   essential	   in	   restoring	   liver	   function	   after	   insults	   such	   as	  partial	  hepatectomy	  or	   toxic	   insult.	  Regeneration	   is	  of	  particular	   importance	   in	  AAH	  and	  is	  a	  key	  target	  for	  the	  development	  of	  new	  therapies.	  Models	  of	  partial	  hepatectomy	  have	  identified	  TNF,	  IL-­‐6,	  STAT-­‐3	  and	  NF-­‐kB	  as	  the	  key	  drivers	  of	  liver	   regeneration	   [48].	   Data	   are	   lacking	   on	   the	   effect	   of	   accumulation	   of	   liver	  progenitor	   cells	   in	   alcohol-­‐injured	   livers,	   but	   an	   incomplete	   differentiation	  process	  leading	  to	  repopulation	  by	  ductular	  cells	  rather	  than	  mature	  hepatocytes	  could	   explain	   why	   some	   patients	   with	   severe	   AAH	   fail	   to	   recover	   [81,	   82].	   A	  recent	   study	   found	   that	   the	  LPS-­‐TLR4	  pathway	  drives	  accumulation	  of	  KRT23-­‐positive	   ductular	   cells	   [83]	   potentially	   opening	   up	   further	   therapeutic	   targets.	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Mathurin	  and	  colleagues	  have	  shown	  that	  patients	  with	  severe	  AAH	  who	  do	  not	  respond	  to	  medical	  treatment	  have	  low	  hepatic	  expression	  of	  TNF	  and	  IL-­‐6	  and	  an	   aberrant	   regeneration	   process	   in	   which	   hepatic	   progenitor	   cells	   cannot	  differentiate	   into	  mature	  hepatocytes	   [84].	  Neutrophil	   infiltration	   is	  a	  hallmark	  of	  AAH	  and	  is	  believed	  to	  contribute	  to	  hepatocellular	  damage	  and	  inflammation.	  However,	   a	   recent	   study	   reported	   that	   infiltration	   of	   neutrophils	   is	   associated	  with	   better	   prognosis	   in	   AAH,	   suggesting	   that	   neutrophils	   may	   also	   play	  beneficial	  roles	  in	  promoting	  liver	  repair	  [21].	  The	  presence	  of	  neutrophils	  and,	  by	   inference,	   active	   inflammation	   may	   indicate	   an	   early	   stage	   of	   disease;	   and	  those	  with	  more	  advanced	  forms	  of	  AAH	  are	  characterised	  by	  poor	  regenerative	  response	   [82].	   Clearly	   neutrophils	   are	   involved	   in	   driving	   the	   process	   at	   the	  outset	  but	  once	  AAH	  is	  established	  they	  may	  have	  additional	  roles	  in	  relation	  to	  regeneration	  which	  are	  yet	   to	  be	   recognised.	  Again,	   some	  of	   the	  difficulty	  here	  relates	  to	  when	  patients	  present	  and	  the	  lack	  of	  studies	  investigating	  sequential	  biopsies	  and	  histological	  evolution.	  Neutrophils	  are	  discussed	  further	  in	  1.5.	  
It	   is	   likely	   that	   further	   information	   regarding	   histological	   characteristics	   and	  regenerative	   potential/survival	   will	   be	   published	   and	   further	   individualise	  patient	  management	  in	  the	  future.	  
1.3.8 Animal	  models	  There	  is	  a	  lack	  of	  animal	  models	  that	  mimic	  the	  entire	  spectrum	  of	  ALD	  seen	  in	  humans.	  The	  first	  model	  of	  chronic	  alcohol	  exposure	  was	  developed	  in	  rats	  and	  induced	  isolated	  steatosis	  [85].	  This	  was	  then	  modified	  so	  that	  larger	  quantities	  of	  ethanol	  could	  be	  administered	  for	  4-­‐12	  weeks,	  the	  Lieber-­‐De-­‐Carli	  model	  [86].	  Animal	  models	  with	  severe	  inflammatory	  lesions	  do	  exist	  (the	  chronic	  plus	  binge	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drinking	  model	  [87]	  and	  the	  modified	  Tsukamoto-­‐French	  model	  [88])	  but	  these	  do	   not	   have	   underlying	   cirrhosis	   or	   bilirubinostasis.	   Extrapolation	   from	   these	  models	   is	   clearly	   useful,	   but	   data	   from	   human	   samples	   are	   the	   best	   way	   to	  further	  the	  understanding	  of	  the	  pathogenesis	  and	  treatment	  of	  ALD	  [48].	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1.4 Sepsis	  in	  alcohol-­‐related	  liver	  disease	  
1.4.1 Prevalence	  of	  infection	  and	  impact	  on	  mortality	  in	  cirrhosis	  Bacterial	   infections	   are	   more	   common	   in	   patients	   with	   cirrhosis	   than	   in	   the	  general	   population	   [89]	   and	   infection	   is	   more	   common	   in	   decompensated	  cirrhosis	  than	  in	  compensated	  cirrhosis	  [90].	  Infections	  are	  present	  at	  admission	  or	   develop	   during	   hospitalization	   in	   25-­‐35%	   of	   patients	   [89,	   91].	   The	   exact	  mechanisms	  of	   increased	   susceptibility	   to	   infections	   in	   cirrhosis	   are	  unclear.	   It	  has	  been	  suggested	  there	  is	  a	  role	  for	  deficiencies	  in	  C3	  and	  C4,	  down-­‐regulation	  of	   monocyte	   human	   leukocyte	   antigen–DR	   expression	   and	   impairment	   of	  macrophage	   Fc-­‐receptor–mediated	   clearance	   of	   antibody-­‐coated	   bacteria	   [92].	  Work	   in	   the	  1980s	   revealed	   that	  patients	  with	  ARC	  have	  depressed	  neutrophil	  phagocytic	   and	   intracellular	   killing	   [93].	   It	   is	   now	   thought	   that	   multiple	  mechanisms	   are	   likely	   to	   synergistically	   contribute	   to	   the	   increased	   risk	   of	  infection	  in	  cirrhosis	  (Figure	  1.8).	  	  The	  aim	  of	  the	  work	  presented	  in	  this	  thesis	  is	  to	   further	  explore	   the	   increased	  susceptibility	  and	  neutrophil	   impairment	   seen	  both	  in	  ARC	  and	  AAH.	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Figure	  1.8	  Pathogenesis	  of	  bacterial	  infection	  in	  cirrhosis.	  	  The	   risk	   of	   infection	   is	   due	   to	   multiple	   factors	   that	   include	   liver	   dysfunction,	   porto-­‐systemic	   shunting,	  dysbiosis	   and	   bacterial	   translocation,	   cirrhosis-­‐associated	   immune	   dysfunction	   (AID)	   and	   genetic	   factors	  [94].	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Bacterial	   infection	   increases	   the	   probability	   of	   death	   of	   patients	   with	  decompensated	  cirrhosis	  3.75	  fold,	  with	  mortality	  rates	  of	  30%	  at	  1	  month	  and	  63%	  at	  1	  year	  [95,	  96].	  Two	  important	  findings	  were	  highlighted	  by	  Arvaniti	  et	  
al’s	  review.	  First,	  for	  infection	  there	  was	  no	  improvement	  in	  survival	  over	  several	  decades;	   this	  was	   seen	  across	   all	   the	   subtypes	  of	   infection	  except	   spontaneous	  bacterial	   peritonitis	   (SBP).	   Second,	   prognosis	   was	   significantly	   adversely	  affected	  even	  after	  resolution	  of	  infection	  and	  several	  reasons	  were	  put	  forward	  to	   explain	   this,	   including	   persistent	   cytokine	   imbalance,	   cytokine-­‐mediated	  cardiomyopathy	   with	   resultant	   renal	   dysfunction	   and	   persistently	   elevated	  hepatic	   venous	   pressure	   gradient	   following	   SBP	   [96].	   Much	   of	   the	   literature	  involves	  study	  of	  cirrhosis	  of	  all	  aetiology,	  rather	  than	  those	  with	  ARC	  alone.	  	  
1.4.2 Prevalence	  of	  infection	  and	  impact	  on	  mortality	  in	  alcoholic	  hepatitis	  Sepsis	   is	   a	   significant	   problem	   in	   AAH	   and	   impacts	   on	  mortality,	   much	   of	   the	  controversy	  regarding	  steroid	  use	  has	  revolved	  around	  the	  potential	  increase	  in	  susceptibility	  to	  infection	  following	  steroid	  treatment	  (discussed	  further	  in	  1.7).	  The	   first	   study	   to	   comprehensibly	   address	   the	   incidence	   of	   infection	   in	   AAH	  found	   that	  patients	  with	   severe	  AAH	  have	  a	  higher	  prevalence	  of	   septic	  events	  (38%	  versus	  25%)	  compared	  to	  those	  with	  advanced	  cirrhosis	  (Figure	  1.9),	  and	  AAH	   patients	   with	   infection	   have	   significantly	   higher	   mortality	   compared	   to	  those	  without	  (47%	  versus	  16%)	  [11].	  	  
Louvet	  et	  al	  found	  that	  nearly	  25%	  of	  AAH	  patients	  are	  infected	  at	  admission,	  in	  addition	  they	  conclude	  that	  corticosteroid	  treatment	  is	  not	  associated	  with	  a	  higher	  risk	  of	  infection	  and	  propose	  that	  infection	  appears	  to	  be	  a	  consequence	  of	  absence	  of	  improvement	  in	  liver	  function,	  i.e.	  non-­‐response	  to	  steroids	  is	  the	  
28	  	  
main	  factor	  contributing	  to	  the	  development	  of	  infection	  [13].	  Whether	  steroid	  unresponsiveness	  leads	  to	  infection	  or	  whether	  it	  is	  the	  presence	  of	  infection	  that	  leads	  to	  lack	  of	  response	  is	  difficult	  to	  firmly	  answer.	  When	  prednisolone	  is	  not	  used,	  the	  effect	  of	  infection	  on	  90-­‐day	  mortality	  is	  secondary	  to	  baseline	  liver	  impairment	  and	  early	  improvement	  in	  liver	  function;	  patients	  not	  treated	  with	  prednisolone	  but	  who	  have	  poor	  liver	  function	  are	  more	  likely	  to	  develop	  infection	  and	  die	  within	  90	  days	  [97].	  The	  persistent	  severe	  liver	  injury	  per	  se	  is	  probably	  the	  critical	  factor,	  some	  patients	  may	  enter	  a	  loop	  of	  persistent	  infection	  however	  which	  would	  clearly	  impact	  on	  parameters	  such	  as	  bilirubin,	  coagulopathy,	  encephalopathy	  and	  renal	  function.	  
	  
Figure	  1.9	  Histogram	  showing	  prevalence	  (%)	  of	  septic	  events	  and	  hepatorenal	  syndrome	  (HRS)	  in	  
AH	  compared	  to	  cirrhosis,	  stacked	  according	  to	  timing	  of	  adverse	  event	  [11].	  	  HRS	  is	  the	  development	  of	  renal	  failure	  in	  patients	  with	  advanced	  liver	  disease.	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In	   addition	   to	   bacterial	   infection,	   fungal	   infection	  has	   also	  been	   found	   to	  be	   of	  significance	   in	  AAH.	   In	  one	   study	   invasive	  Aspergillosis	  was	  present	   in	  16%	  of	  patients	   with	   severe	   AAH	   and	   despite	   antifungal	   treatment	   was	   a	   lethal	  complication	  in	  almost	  every	  case	  [12].	  It	  often	  occurs	  at	  the	  more	  severe	  end	  of	  the	  spectrum	  and	  in	  those	  requiring	  intensive	  care	  support	  and	  has,	  historically,	  been	  difficult	  to	  diagnose.	  However	  there	  is	  now	  more	  awareness	  of	  the	  potential	  presence	  of	   fungal	   infection	  and	  new	  techniques	   in	  development	  to	  aid	  prompt	  diagnosis.	  	  The	   Steroids	   or	   Pentoxifylline	   for	   Alcoholic	   Hepatitis	   -­‐	   STOPAH	   study	   was	   a	  multicentre,	   double-­‐blind,	   randomized	   trial	   with	   a	   2-­‐by-­‐2	   factorial	   design	   to	  evaluate	   the	   effect	   of	   treatment	   with	   prednisolone	   or	   pentoxifylline	   [98]	  (discussed	   further	   in	   1.7).	   The	   primary	   end-­‐point	   was	   28	   day-­‐mortality.	   The	  incidence	  of	  infection	  was	  also	  studied	  and	  was	  an	  eagerly	  anticipated	  outcome	  given	   previous	   controversy	   surrounding	   steroid-­‐use.	   Patients	   with	   a	   clinical	  diagnosis	  of	  AAH	  and	  severe	  disease	  (Maddrey’s	  >32)	  were	  randomly	  assigned	  to	   one	   of	   four	   groups:	   a	   group	   that	   received	   a	   pentoxifylline-­‐matched	   placebo	  and	  a	  prednisolone-­‐matched	  placebo,	  a	  group	  that	  received	  prednisolone	  and	  a	  pentoxifylline-­‐matched	   placebo,	   a	   group	   that	   received	   pentoxifylline	   and	   a	  prednisolone-­‐matched	  placebo,	  or	  a	  group	  that	  received	  both	  prednisolone	  and	  pentoxifylline.	  Prednisolone	  was	  associated	  with	  a	  reduction	  in	  28-­‐day	  mortality	  that	  did	  not	   reach	   significance	   and	   there	  was	  no	   improvement	   in	  90-­‐day	  or	  1-­‐year	  outcome.	  Infection	  occurred	  in	  71	  of	  the	  547	  patients	  (13%)	  who	  received	  prednisolone	  as	  compared	  with	  38	  of	  the	  545	  patients	  (7%)	  who	  did	  not	  receive	  prednisolone	   (p=	   0.002).	   Mortality	   attributed	   to	   infection	   was	   similar	   across	  groups	   but	   the	   authors	   do	   comment	   that	   infection	   probably	   played	   a	   role	   in	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deaths	  attributed	  to	  other	  causes	  such	  as	  multi-­‐organ	  failure.	  This	  perhaps	  also	  highlights	  the	  difficulty	  in	  diagnosing	  occult	  infection	  in	  this	  group.	  
1.4.3 Bacterial	  infection	  SBP	   and	   urinary	   tract	   infections	   are	   the	  most	   frequent	   infections	   observed	   in	  cirrhosis,	   followed	   by	   pneumonia,	   skin	   infections	   and	   bacteraemia	   [94].	   In	   a	  study	  of	  critically	  ill	  cirrhotic	  and	  non-­‐cirrhotic	  patients	  the	  lungs	  were	  the	  most	  common	   site	   of	   infection	   in	   all	   patients,	   but	   abdominal	   infections	   were	   more	  common	   in	   cirrhotic	   than	   non-­‐cirrhotic	   patients	   [99].	   On	   review	   of	   the	  supplementary	   data	   from	   the	   STOPAH	   trial,	   lung	   infection	   appeared	   to	   be	   the	  most	   common	   infection	   [98].	   	   Enterobacteriaceae	   and	   non-­‐enterococcal	  streptococci	   cause	   the	   majority	   of	   spontaneous	   infections	   in	   patients	   with	  cirrhosis	   [94].	   The	   epidemiological	   pattern	   of	   bacteria	   however	   differs	   widely	  among	   geographical	   areas,	   as	   do	   resistance	   patterns,	   and	   therefore	   local	  antibiotic	   policy	   derived	   from	   local	   patterns	   of	   infection	   are	   key	   in	   ensuring	  appropriate	  antimicrobial	  treatment	  is	  delivered.	  	  
1.4.4 Fungal	  infection	  As	   discussed	   above,	   invasive	   Aspergillosis	   in	   AAH	   has	   a	   significant	   impact	   on	  mortality	   and	   is	   often	   a	   late	   diagnosis.	   In	   the	   study	   examining	   early	   liver	  transplantation	  for	  AAH,	  26	  patients	  underwent	  liver	  transplantation	  (discussed	  further	   in	   1.7),	   five	   of	   six	   deaths	   were	   related	   to	   infection	   occurring	  within	   2	  weeks	  after	  surgery;	  the	  infection	  was	  invasive	  aspergillus	  infection	  in	  four	  cases	  [100].	   There	   has	   been	   increasing	   interest	   in	   fungal	   infection	   in	   cirrhosis.	   In	   a	  study	   that	   examined	   a	   large	   number	   of	   cirrhotic	   patients	   admitted	   to	   the	  intensive	  care	  unit	   the	   incidence	  of	   invasive	   fungal	  disease	  was	   low	  at	  1%,	  but	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higher	   than	   in	   another	   high	   risk	   group	   [101].	   Techniques	   for	   diagnosis	   are	  improving	   and	   fungal	   infection	   should	   always	   be	   considered	   in	   severe	   AAH,	  although	  there	  are	  no	  clear	  guidance	  on	  the	  role	  of	  antifungals.	  Neutrophils	  are	  key	   immune	   cells	   in	   combating	   fungal	   sepsis	   and	   the	   association	   between	  absolute	  or	  qualitative	  deficiency	  in	  neutrophils	  and	  the	  propensity	  for	  invasive	  fungal	   infection	  has	   been	   recognised	   for	   50	   years	   [102].	   This,	   in	   part,	   explains	  why	  patients	  with	  AAH	  are	  vulnerable	  to	  fungi.	  
1.4.5 Multi-­‐drug	  resistance	  Multidrug	   resistant	   (MDR)	   organisms	   are,	   by	   definition,	   resistant	   to	   three	   or	  more	  antibiotic	  classes	  [94].	  The	  prevalence	  of	  infections	  with	  MDR	  in	  cirrhosis	  has	  become	  alarmingly	  high	   and	   this	   has	  been	   seen	   across	   the	   globe.	   In	   series	  from	   Europe,	   North	   America	   and	   Asia,	   11-­‐45%	   of	   patients	   with	   SBP	   were	  infected	   with	   organisms	   resistant	   to	   first-­‐line	   third-­‐generation	   cephalosporins	  [103].	   Predictors	   of	   resistance	   include	   recent	   and	   frequent	   antibiotic	   use,	  nosocomial	  acquisition	  of	   infection	  and	  recent	   infection	  with	  an	  MDR	  organism	  [89,	   103,	   104].	   Infections	   due	   to	   MDR	   organisms	   are	   associated	   with	   an	  increased	   risk	   of	   death	   in	   both	   the	  pre-­‐transplant	   and	  post-­‐transplant	   settings	  [91,	   103].	   The	   impact	   is	   already	   substantial.	   Antibiotic	   stewardship	   is	   now	  adopted	   in	  UK	  hospitals	  and	  most	   liver	  units	  are	  guided	  by	   local	  epidemiology,	  this	   can,	   however,	   be	  difficult	   to	   track	   in	   certain	   centres	  due	   to	   transfers	   from	  widespread	   areas.	   Early	   de-­‐escalation	   policies	   and	   short	   duration	   of	   antibiotic	  treatments	  in	  addition	  to	  restriction	  of	  antibiotic	  prophylaxis	  to	  only	  those	  at	  the	  highest	  risk	  of	  infection	  should	  be	  implemented	  to	  minimize	  the	  development	  of	  antibiotic	   resistance.	   Fernandez	   et	   al	   discuss	   the	   benefits	   and	   drawbacks	   of	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prophylactic	  antibiotics	  in	  cirrhosis	  in	  a	  recent	  review	  and	  conclude	  that	  further	  development	   of	   non-­‐antibiotic	   strategies	   based	   on	   mechanisms	   of	   infection	   is	  urgently	  needed	  [105].	  
1.4.6 Systemic	   inflammatory	   response	   syndrome	   and	   compensatory	   anti-­‐
inflammatory	  response	  syndrome	  The	  concept	  of	  a	  systemic	  inflammatory	  response	  syndrome	  (SIRS)	  came	  from	  a	  1991	  consensus	  conference	  charged	  with	  the	  task	  of	  developing	  a	  set	  of	  clinical	  parameters	  to	  aid	  in	  the	  early	  identification	  of	  potential	  candidates	  to	  enter	  into	  clinical	   trials	   to	   evaluate	   new	   treatments	   for	   sepsis.	   SIRS	   was	   defined	   as	   the	  presence	  of	  at	  least	  2	  of	  the	  following	  criteria:	  (a)	  a	  core	  temperature	  of	  >38	  °C	  or	   <36	   °C;	   (b)	   a	   heart	   rate	   of	   ≥90	   beats/minute;	   (c)	   a	   respiratory	   rate	   of	   ≥20	  breaths/minute;	   or	   (d)	   a	   white	   blood	   cell	   (WBC)	   count	   of	   ≥12,000/mm3	   or	  ≤4000/mm3,	   or	   a	   differential	   count	   showing	   ≥10%	   immature	  polymorphonuclear	  neutrophil	  cells	  (PMNC)	  [106].	  	  The	   compensatory	   anti-­‐inflammatory	   response	   syndrome	   (CARS)	   describes	  prolonged	  elevations	  in	  anti-­‐inﬂammatory	  mediators	  and	  immune	  dysregulation	  with	  defects	  in	  both	  the	  innate	  and	  adaptive	  immune	  responses	  [107].	  CARS	  has	  been	  described	  as	  a	  harmful	  sequel	  to	  severe	  sepsis;	   patients	   can	   enter	   into	   this	   phase	   of	   immunoparesis	   (Figure	   1.10)	   and	  studies	  in	  patients	  without	  cirrhosis	  have	  shown	  that	  the	  severity	  of	  this	  phase	  determines	   outcome	   beyond	   the	   initial	   ‘cytokine	   storm’	   associated	   with	   SIRS	  [108,	  109].	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Figure	   1.10	   Systemic	   Inflammatory	   Response	   Syndrome	   (SIRS)	   and	   Compensatory	   Anti-­‐




Figure	  1.11	  Cirrhosis-­‐associated	  immune	  dysfunction	  (CAID)	  Progressive	  liver	  disease	  is	  associated	  with	  pathogen-­‐associated	  molecular	  patterns	  (PAMPs)	  and	  damage-­‐associated	  molecular	  patterns	  (DAMPs)-­‐driven	  stimulation.	  In	  compensated	  cirrhosis	  DAMPs	  released	  from	  damaged	  hepatocytes	  may	   initiate	  activation	  of	   the	   immune	  system	  and	  sterile	   systemic	   inflammation.	   In	  decompensated	  cirrhosis	   the	   increased	  translocation	  of	  bacterial	  products	  drives	   further	  activation	  of	   the	  immune	  system	   involving	   increased	  serum	   levels	  of	  pro-­‐inflammatory	  cytokines.	  The	  predominantly	  pro-­‐inflammatory	  CAID	  phenotype	  occurs	  in	  response	  to	  continuous	  PAMPs	  signalling	  and	  down-­‐regulation	  of	  anti-­‐inflammatory	   cytokines	   and	   negative	   feedback	   mechanisms.	   At	   end-­‐stage	   cirrhosis	   the	   immune	  response	  is	  exhausted	  and	  the	  CAID	  phenotype	  switches	  to	  a	  predominantly	   ‘immunodeficient’	  phenotype	  of	  impaired	  innate	  and	  adaptive	  protective	  immune	  responses	  [111].	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1.5 Neutrophils	  Neutrophils	   are	   a	  major	   innate	   immune	   cell	   subset	   involved	   in	   the	   first	   line	  of	  defense	   against	   infection.	   Conditions	   associated	   with	   neutropenia	   reveal	   that	  these	   cells	   are	   indispensible	   when	   it	   comes	   to	   control	   of	   bacterial	   and	   fungal	  infection.	   Rapidly	   recruited	   to	   sites	   of	   infection	   and	   inflammation,	   neutrophils	  engulf	   invading	   microbes	   via	   phagocytosis,	   then	   proceed	   to	   kill	   them	   by	  generating	   superoxide	   anions	   and	   hydrogen	   peroxide	   along	   with	   other	   ROS	  through	   activation	   of	   NADPH-­‐oxidase,	   a	   process	   known	   as	   respiratory	   or	  oxidative	  burst.	  	  Neutrophils	  were	  discovered	  more	   than	  100	  years	   ago,	   however	  knowledge	  of	  their	   function	   and,	   in	   particular,	   interaction	   with	   other	   cells	   of	   the	   immune	  system	   has	   expanded	   over	   the	   last	   few	   years.	   An	   overview	   of	   the	   role	   and	  function	   of	   this	   cell	   follows,	   including	   a	   summary	   of	   the	   current	   knowledge	   of	  their	  role	  in	  liver	  disease.	  	  
1.5.1 Neutrophils	  -­‐	  role	  and	  function	  
1.5.1.1 Neutrophil	  life	  cycle	  Neutrophils	  develop	  in	  the	  bone	  marrow	  from	  haematopoietic	  stem	  cells.	  Mature	  neutrophils	  are	  characterised	  by	  their	  segmented	  nucleus	  and	  granules	  that	  are	  filled	  with	  >700	  proteins	  [113].	  Granulocyte	  colony-­‐stimulating	  factor	  (G-­‐CSF)	  is	  a	  key	  factor	  regulating	  the	  neutrophil’s	  life	  cycle	  by	  increasing	  cell	  proliferation,	  survival,	   differentiation,	   and	   trafficking/mobilization	   [114].	   Neutrophils	  succumb	  via	  a	  number	  of	  possible	  death	  pathways	  (Figure	  1.12).	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Figure	  1.12	  Possible	   death	  pathways	   for	  neutrophils	   and	   impact	   on	   resolution	  or	  perpetuation	  of	  
inflammation	  [115].	  Based	  on	  signaling	  for	  recognition	  by	  macrophages	  and	  the	  stage	  at	  which	  they	  are	  removed,	  inflammatory	  sequelae	  will	  vary	  from	  anti-­‐inflammatory	  and	  immunosuppressive	  to	  pro-­‐inflammatory	  and	  immunogenic.	  	  	  Maintenance	   of	   neutrophil	   numbers	   is	   further	   regulated	   by	   clearance	   of	  apoptotic	   neutrophils	   by	   macrophages,	   a	   process	   termed	   “efferocytosis.”	  Efferocytosis	   reduces	   the	   production	   of	   interleukin	   (IL)-­‐23	   and	   IL-­‐17	   and	   also	  dampens	  G-­‐CSF	  production	  [116].	  	  The	   lifespan	   of	   a	   neutrophil	   is	   generally	  measured	   in	   hours.	   The	   paradigm	   of	  neutrophils	  as	  short-­‐lived	  immune	  cells	  has	  been	  challenged	  in	  recent	  years	  by	  
in-­‐vivo	   labelling	   studies,	   demonstrating	   a	   life	   span	   of	   up	   to	   5	   days	   for	   human	  neutrophils	   [117].	   The	   methodology	   identifying	   this	   increased	   lifespan	   has,	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however,	   been	   questioned	   as	   the	   technique	   almost	   certainly	   labelled	   bone	  marrow	   neutrophils.	   Nevertheless,	   during	   inflammation	   neutrophils	   become	  activated	  and	  their	  longevity	  is	  thought	  to	  increase	  by	  several	  fold	  [118].	  	  This	  is	  clearly	  an	  important	  concept	  for	  studies	  examining	  neutrophil	  function	  in	  certain	  conditions;	   there	   is	   the	   possibility	   of	   skewing	   the	   analyses	   towards	   the	   active	  cells	  and	  excluding	   ‘inactive’	  cells	  which	  may	  still	  have	  a	  role.	  As	   techniques	  of	  cell-­‐labelling	  improve,	  knowledge	  on	  the	  differing	  age	  of	  circulating	  neutrophils	  and	  the	  potential	  clinical	  relevance	  of	  this	  will	  come	  to	  light.	  	  In	  2016	  Potts	  et	  al	  conducted	  a	  pilot	  study	  examining	  intravascular	  granulocyte	  lifespan	  and	  showed	  that	  this	  was	  suppressed	  in	  compensated	  ARC	  compared	  to	  controls,	  this	  proved	  difficult	  to	  do	  in	  a	  small	  number	  of	  patients	  with	  AH	  and	  the	  authors	  state	  that	  with	  more	  refined	  techniques	  and	  increased	  patient	  numbers	  may	  enable	  measurement	  of	  granulocyte	  lifespan	  in	  other	  forms	  of	  chronic	  liver	  disease,	  including	  acute	  and	  acute-­‐on-­‐chronic	  liver	  failure	  [119].	  The	  processes	  of	  neutrophil	  death	  and	   ‘clear-­‐up’	  are	   less	  well	  understood	   than	  recruitment.	   Enhanced	   understanding	   of	   neutrophil	   removal	   or	   its	   failure	  may	  allow	   opportunities	   to	   intervene	   to	   improve	   host	   defense	   or	   indeed	   prevent	  inappropriate	  injury.	  
1.5.1.2 The	  neutrophil	  recruitment	  cascade	  The	   neutrophil	   recruitment	   cascade	   involves	   the	   following	   steps:	   tethering,	  rolling,	   adhesion,	   crawling	   and	   transmigration.	   The	   process	   is	   illustrated	   in	  figure	   1.13	   from	   Kolaczkowska	   and	   Kube’s	   review	   in	   Nature	   Reviews	  Immunology	  [120].	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Figure	  1.13	  The	  updated	  neutrophil	  recruitment	  cascade	  from	  the	  vasculature	  to	  the	  tissue.	  	  Two	  possible	  methods	  of	  transmigration	  are	  acknowledged:	  paracellular	  (between	  endothelial	  cells)	  a)	  and	  transcellular	  (through	  endothelial	  cells)	  b).	  Rolling	  is	  predominantly	  selectin-­‐dependent,	  adhesion,	  crawling	  and	   transmigration	  depend	  on	   integrin	   interactions.	  The	  chemokine	  gradient	  guides	  crawling	  neutrophils	  along	  the	  endothelium.	  The	  intravital	  microscopy	  image	  shows	  a	  skin	  post-­‐capillary	  venule	  with	  neutrophils	  (LY6G+	   cells)	   labelled	   in	   red	   (phycoerythrin	   antibody	   conjugate),	   mouse	   skin	   was	   infected	   with	  
Staphylococcus	  aureus	  and	  the	  image	  was	  taken	  2	  hours	  later.	  It	  captured	  neutrophils	  at	  different	  stages	  of	  migration	  [120].	  	  Neutrophil	  recruitment	  is	  initiated	  by	  changes	  on	  the	  endothelium	  including	  up-­‐regulation	  of	  selectins	  such	  as	  P-­‐selectin	  and	  E-­‐selectin	  which	  bind	  and	  activate	  receptors	  such	  as	  P-­‐selectin	  glycoprotein	  ligand	  1	  (PSGL1)	  on	  the	  neutrophil	  cell	  surface	  [121].	  Neutrophil	  receptors	  are	  discussed	  in	  1.5.1.4.	  
1.5.1.3 Microbicidal	  mechanisms	  of	  neutrophils	  Phagocytosis	   is	   the	   process	   by	   which	   certain	   cells	   engulf	   and	   destroy	  microorganisms	  and	  cellular	  debris.	  Generally	  these	  substances	  are	  coated	  with	  opsonins	  (antibodies	  and	  complement)	  to	  initiate	  binding	  with	  cell	  receptors	  on	  phagocytes	  –	   the	   first	   stage	  of	  phagocytosis.	   In	   the	   second	  stage	   the	  particle	   is	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engulfed	   and	   enclosed	   forming	   a	   phagosome.	   The	   third	   stage	   involves	   the	  merging	   of	   phagosomes	   and	   lysosomes	   with	   the	   formation	   of	   oxygen	   radicals	  (respiratory	   or	   oxidative	   burst)	   which	   ultimately	   results	   in	   the	   killing	   of	   the	  engulfed	  bacteria.	  	  In	   the	   1950s	   myeloperoxidase,	   known	   to	   be	   released	   from	   granules	   during	  phagocytosis,	  was	   found	   to	   be	   involved	   in	   generating	   hydrogen	  peroxide,	   then	  further	   experimentation	   clarified	   that	   another	   oxidase,	   NADPH	   oxidase,	   also	  played	  an	  important	  role	  in	  the	  generation	  of	  hydrogen	  peroxide	  and	  ROS	  [122].	  It	   is	  now	  known	   that	  neutrophils	  have	  other	  microbicidal	  mechanisms	   such	  as	  defensins	  and	  broadly	  acting	  proteases,	  however	  phagocytosis	  with	  generation	  of	  ROS	  and	  hypochlorous	  acid	  is	  still	  regarded	  as	  the	  critical	  killing	  mechanism	  for	  most	  invading	  pathogens	  [123,	  124].	  Neutrophil	  granules	  are	  reservoirs	  of	  proteins	  that	  can	  kill	  microbes	  and	  digest	  tissue.	   They	   are	   classified	   into	   three	   distinct	   subsets	   based	   on	   the	   presence	   of	  characteristic	  granule	  proteins:	  primary	  (azurophil)	  granules	  (myeloperoxidase,	  MPO),	   secondary	   (specific)	   granules	   (lactoferrin),	   and	   tertiary	   (gelatinase	  granules)	  [125].	  	  Lactoferrin	   can	   bind	   and	   transport	   iron	   but	   is	   thought	   to	   have	   not	   only	  antibacterial	   but	   antiviral	   and	   antiparasitic	   properties	   [126].	   Lactoferrin	  possesses	   a	   high	   affinity	   binding	  motif	   to	   the	   lipid	  A	   portion	   of	   LPS	   [127].	   It’s	  direct	  antimicrobial	  activity	  in	  animal	  models	  provided	  a	  basis	  for	  exploring	  it’s	  role	   in	   humans	   as	   a	   treatment;	   orally	   administered	   human	   recombinant	  lactoferrin	  was	  investigated	  in	  a	  phase	  2	  trial	  in	  adult	  patients	  with	  severe	  sepsis,	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the	  initial	  positive	  results	  however	  were	  not	  borne	  out	  in	  a	  follow	  up	  phase	  2/3	  trial	  [127,	  128].	  
1.5.1.4 Neutrophil	  cell	  surface	  receptors	  The	  function	  of	  the	  neutrophil	  is	  mediated	  by	  a	  number	  of	  cell	  surface	  receptors.	  Intracellular	  signal	  transduction	  pathways	  are	  then	  activated,	  which	  are	  complex	  and	  not	  completely	  understood.	  There	  are	  several	  classes	  of	  receptors	  expressed	  on	   the	   surface	   of	   neutrophils,	   including	   G-­‐protein-­‐coupled	   seven-­‐transmembrane	   receptors,	   Fc-­‐receptors,	   adhesion	   molecules	   like	  selectins/selectin	   ligands	   and	   integrins,	   various	   cytokine	   receptors,	   as	   well	   as	  innate	  immune	  receptors	  including	  Toll-­‐like	  receptors	  (TLRs)	  and	  C-­‐type	  lectins	  (Table	  1.1)	  [129].	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A	  number	  of	  these	  neutrophil	  receptors	  will	  be	  discussed	  in	  more	  detail.	  	  
1.	  G-­‐protein	  coupled	  receptors	  G-­‐protein	   coupled	   receptors	   include	   formyl-­‐peptide	   receptors	   which	   sense	  bacterial	   products	   and	   tissue	   injury,	   receptors	   for	   a	   range	  of	   chemoattractants	  and	  chemokine	  receptors.	  These	  receptors	  activate	  the	  chemotactic	  migration	  of	  neutrophils,	  binding	  of	  these	  receptors	  also	  triggers	  ROS	  production	  and	  ‘primes’	  the	   cell	   resulting	   in	   an	   augmented	   response	   to	   subsequent	   stimulation	   from	  other	  agonists.	  
2.	  Fc-­‐receptors	  Neutrophils	  express	  Fc-­‐receptors,	  these	  are	  primarily	  involved	  in	  recognition	  of	  Ig-­‐opsonised	   pathogens	   but	   also	   play	   a	   role	   in	   immune-­‐complex	   mediated	  inflammatory	  processes.	  The	  most	  important	  Fc-­‐receptors	  in	  neutrophils	  are	  the	  low	  affinity	  Fcγ-­‐receptors	   [130].	  Human	  neutrophils	  express	  FcγRIIA	  (CD32),	  a	  single-­‐chain	   transmembrane	   receptor	   which	   carries	   an	   immunoreceptor	  tyrosine-­‐based	  activation	  (ITAM)	  in	  its	  cytoplasmic	  tail	  and	  FcγRIIIB	  (CD16b),	  an	  extracellular	  molecule	  anchored	  to	  the	  plasma	  membrane	  by	  a	  GPI	  moiety	  [129].	  Low	   affinity,	   particularly	   FcγRIIIB,	   play	   important	   roles	   in	   immune-­‐complex	  mediated	  activation	  of	  neutrophils	  [131].	  
3.	  Adhesion	  receptors	  The	   two	  main	   groups	   of	   adhesion	   receptors	   are	   the	   selectins/selectin	   ligands	  and	   integrins.	   Selectins	   are	   transmembrane	   glycoproteins	   and	   mediate	  interactions	   between	   leukocytes	   and	   the	   vessel	   wall.	   The	   most	   important	  integrins	  expressed	  on	  leukocytes	  belong	  to	  the	  β2	  integrin	  family	  [132].	  
4.	  Cytokine	  receptors	  The	  cytokine	  receptors	  are	  divided	  into	  4	  main	  subsets	  as	  outlined	  in	  table	  1.1.	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5.	  Innate	  immune	  receptors	  Toll-­‐like	   receptors	   are	   innate	   immune	   receptors	   involved	   in	   the	   direct	  recognition	   of	   pathogens	   or	   tissue	   damage	   (Figure	   1.14).	   Neutrophil	   TLRs	  	  recognise	   various	   microbial	   structures	   leading	   to	   increased	   cytokine	   and	  chemokine	  production,	  priming	  and	  delayed	  apoptosis	  of	  the	  cells	  [129].	  
	  
Figure	  1.14	  Toll	  like	  receptors	  [133]	  	  Neutrophils	   express	   all	   TLRs	   except	   TLR3.	   The	   TLRs	   have	   multiple	   ligands,	   however	   TLR4	   has	   been	  predominantly	   associated	   with	   the	   recognition	   of	   LPS,	   a	   component	   of	   the	   outer	   membrane	   of	   gram-­‐negative	  bacteria	  and	  TLR2	  the	  peptidoglycans	  of	  gram-­‐positive	  bacteria.	  	  TLR4	   forms	   a	   complex	   with	   other	   proteins	   for	   ligand	   recognition.	   CD14	   is	   a	  glycosylphosphatidylinositol-­‐anchored	  membrane	   protein	   (and	   also	   exists	   in	   a	  soluble	  form)	  which	  binds	  LPS	  attached	  to	  LPS	  binding	  protein	  (LBP),	  this	  then	  associates	  with	  TLR4	  to	  form	  a	  functional	  LPS	  receptor	  complex	  [134].	  Binding	  of	  LPS	  is	  also	  thought	  to	  require	  the	  MD2	  protein	  [135].	  Further	  study	  suggests	  that	  CD14	  and	  LBP	  only	   enhance	  TLR4-­‐LPS	  binding	  and	   signalling	   and	  are	  not	  absolutely	  required	  for	  this	  process	  [136].	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1.5.1.5 Neutrophil	  extracellular	  traps	  Neutrophil	   extracellular	   traps	   (NETs),	   first	  described	   in	  2004,	  are	  extracellular	  strands	  of	  DNA	  bound	  to	  antimicrobial	  neutrophil-­‐derived	  peptides	  and	  proteins	  [137].	   NETs	   are	   web-­‐like	   structures	   thought	   to	   trap	   pathogens	   and	   their	  formation	  is	  also	  thought	  to	  be	  an	  alternative	  to	  death	  by	  apoptosis	  or	  necrosis	  [125].	   NET	   proteins	   are	   primarily	   the	   cationic	   bactericidal	   proteins:	   histones,	  defensins,	   elastase,	   proteinase	   3,	   heparin	   binding	   protein,	   cathepsin	   G,	  lactoferrin	  and	  MPO	  [138].	  NETs	  seem	  to	  contribute	  to	  autoimmune	  diseases,	  in	  which	  the	   target	  antigens	  are	   frequently	   the	  constituents	  of	  NETs	  (for	  example	  MPO/proteinase	   3)	   and	   intravascular	   NETs	   may	   damage	   the	   endothelium	  further	  exacerbating	  capillary	  leak	  in	  sepsis	  and	  acute	  lung	  injury	  [139].	  The	  full	  contribution	   of	   NETs	   to	   overall	   antimicrobial	   defense	   has	   not	   yet	   been	  established	   and	   strategies	   for	   the	   elimination	   of	   NETs	   in	   non-­‐infectious	  conditions	   may	   be	   beneficial.	   Recently	   there	   has	   been	   some	   interest	   in	   NET	  formation	  and	  potential	  contribution	  in	  liver	  disease.	  
1.5.2 Neutrophils	  -­‐	  role	  in	  liver	  disease	  As	   outlined	   above,	   neutrophils	   are	   vital	   for	   host	   defense	   and	   removal	   of	   cell	  debris	  but	  can	  also	  cause	  associated,	  bystander	  tissue	  damage.	  Neutrophils	  play	  a	  critical	  role	  in	  liver	  disease	  and	  evidence	  has	  accumulated	  in	  relation	  to	  several	  liver	   diseases	   including	   hepatic	   ischaemia/reperfusion	   injury,	   viral	   hepatitis,	  non-­‐alcoholic	  fatty	  liver	  disease,	  ALD,	  cirrhosis,	  liver	  failure	  and	  HCC	  [140].	  Neutrophil-­‐mediated	   parenchymal	   cell	   damage	   in	   the	   liver	   is	   thought	   to	   be	  initiated	   by	   the	   priming	   and	   subsequent	   accumulation	   of	   neutrophils	   in	   the	  hepatic	  sinusoids	  (Figure	  1.15)	  [141].	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The	  initial	  step	  is	  triggered	  by	  pro-­‐inflammatory	  mediators,	  and	  after	  receiving	  a	  chemotactic	   signal	   neutrophils	   can	   extravasate	   and	   attack	   the	   target	   cell,	   the	  hepatocyte.	  Generation	  of	  ROS,	  especially	  hypochlorous	  acid,	  as	  described	  above	  triggers	   an	   intracellular	   oxidant	   stress	   in	   the	   target	   cell	   and	   causes	   cell	   death	  [142].	  
	  
Figure	   1.15	   Proposed	   mechanisms	   of	   neutrophil	   mediated	   liver	   injury	   from	   Jaeschke	   and	  
Hasegawa’s	  review	  [141]	  	  The	   migration	   of	   neutrophils	   through	   the	   endothelium	   and	   into	   the	   liver	  parenchyma	   is	   essential	   for	   alcohol-­‐induced	   hepatic	   inflammation	   [140].	   This	  process	   is	   dependent	   on	   neutrophil	   integrin	   receptors	   and	   the	   endothelial	  surface.	   The	   expression	   of	   hepatic	   E-­‐selectin	   has	   been	   found	   to	   be	   very	  important	  for	  neutrophil	  infiltration	  into	  the	  liver	  and	  in	  the	  pathogenesis	  of	  the	  early	   stages	  of	  ALD	   [87].	  The	   initial	   innate	   response	   that	   leads	   to	  AAH	  may	  be	  triggered	   by	   alcohol	   in	   the	   liver	   and	   the	   increased	   translocation	   of	   LPS	  which	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activates	  Kupffer	   cells.	   As	   discussed	   in	   1.3	   it	   is	   believed	   that	   activated	  Kupffer	  cells	  produce	  a	  variety	  of	  cytokines	  and	  chemokines,	  including	  IL-­‐8,	  RANTES,	  IL-­‐17	  that	  subsequently	  recruit	  neutrophils	  to	  the	  liver	  [68].	  Serum	  levels	  and	  liver	  expression	  of	  CCL2	  are	  increased	  in	  AAH	  and	  were	  found	  to	  be	  associated	  with	  disease	  severity;	  CCL2	  liver	  expression	  correlated	  with	  neutrophil	  infiltrate	  and	  IL-­‐8	  expression	  [143].	  Recently	   there	  has	  been	   interest	   in	  NETs	  (described	  above)	  and	  whether	   these	  may	  mediate	  bacterial	   induced	   liver	  damage.	  Kolaczkowska	  et	  al	  demonstrated	  that	   after	  MRSA	   infection,	   bacteria	   accumulated	   in	   the	   liver	  more	   readily	   than	  any	  other	  organ	  as	  they	  were	  captured	  by	  Kupffer	  cells	  in	  the	  liver.	  Subsequently	  recruited	  neutrophils	  released	  NETs	  and	  these	  were	  found	  to	  cause	  the	  majority	  of	   liver	   injury	  seen,	   rather	   than	   the	  bacteria	   itself	   [144].	  This	  may	   in	   fact	  be	  of	  relevance	  in	  the	  development	  of	  AAH	  and	  warrants	  further	  exploration.	  	  
1.5.3 Neutrophils	  –	  defects	  in	  liver	  disease	  Neutrophil	   dysfunction	   both	   in	   acute	   and	   chronic	   liver	   disease	   has	   long	   been	  recognised	   [145].	   The	   most	   commonly	   reported	   defect	   in	   cirrhosis	   is	   the	  impaired	   phagocytosis	   of	   opsonized	   bacteria	   [93,	   146-­‐148].	   There	   is	   also	  defective	  oxidative	  burst,	  myeloperoxidase	  activity	  and	  a	  lower	  response	  to	  the	  peptidoglycan	  recognition	  protein	  with	  resultant	   impaired	  microbicidal	  activity	  [93,	   149,	   150].	   Impaired	   chemotaxis	   is	   seen,	   through	   reduced	   adhesion	   to	  endothelial	  cells	  and	  decreased	  transendothelial	  migration	  [147,	  151].	  In	  Taylor	  
et	   al’s	   study	   of	   neutrophil	   function	   in	   cirrhosis	   across	   all	   aetiology,	   baseline	  circulating	  neutrophil	  dysfunction	  was	   found	   to	  be	  a	  predictor	  of	  outcome	  and	  90-­‐day	   and	   1-­‐year	   survival	   [152].	   Cirrhotic	   patients	   who	   had	   increased	   basal	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production	  of	  ROS	  appeared	  to	  be	  at	  the	  highest	  risk	  of	  developing	  complications	  and	   multi-­‐organ	   dysfunction.	   Neutrophil	   dysfunction	   has	   been	   linked	   to	  persistent	  in	  vivo	  stimulation,	  especially	  observed	  in	  patients	  with	  higher	  serum	  levels	  of	  pro-­‐inflammatory	  cytokines	  [147]	  and	  ammonia	  [153].	  It	  is	  perhaps	  this	  persistent	   in	   vivo	  stimulation,	   resulting	   in	   increased	   basal	   ROS,	  which	   renders	  the	  cells	  unable	  to	  appropriately	  phagocytose	  with	  reduced	  stimulated	  burst	  on	  pathogen	  exposure,	  this	  is	  discussed	  further	  in	  1.8.	  In	   severe	   AAH	   blood	   neutrophils	   are	   activated	   as	   shown	   by	   increased	   H2O2	  production	   and	   decreased	   L-­‐selectin	   expression,	   TNF-­‐α	   and	   IL-­‐8	   plasma	   and	  tissue	   levels	   were	   found	   to	   be	   markedly	   increased	   and	   IL-­‐10	   reduced,	   during	  steroid	   therapy	   a	   normalization	   of	   these	   parameters	   was	   observed	   [61].	   A	  control	  group	  of	  AAH	  patients	  without	  corticosteroid	  therapy	  were	  not	  evaluated	  in	  this	  study.	  	  
	  
Figure	   1.16	   Figure	   demonstrating	   transmission	   electron	   microscopy	   (x4800)	   pictures	   of	   a	  
healthy	   control	   neutrophil	   (left)	   and	   a	   neutrophil	   from	   a	   patient	  with	   severe	   acute	   alcoholic	  
hepatitis	  which	  shows	  enlarged	  nuclei	  and	  dense	  cytoplasm.	  	  	  	  	  	  	  	  	  	  	  Manakkat	  Vijay,	  Ryan	  and	  Shawcross	  (unpublished	  data).	  
	  Mookerjee	   et	   al	   found	   that	   a	   resting	   burst	   ≥	   55%	   and	   a	   reduced	   phagocytic	  capacity	  ≤	  42%	  was	  associated	  with	  significantly	  greater	  risk	  of	  infection,	  organ	  failure	   and	   mortality	   [154].	   The	   ex	   vivo	   removal	   of	   endotoxin	   in	   this	   study	  resulted	  in	  improved	  neutrophil	  function.	  Stadlbauer	  et	  al	  went	  on	  to	  investigate	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neutrophil	  TLRs	  in	  mediating	  neutrophil	  dysfunction	  in	  AAH	  [155].	  Neutrophils	  from	  healthy	  volunteers	  were	  incubated	  with	  alcoholic	  hepatitis	  patients’	  plasma	  (n=12)	   with	   and	   without	   TLR2,	   4	   and	   9	   antagonists	   and	   with	   and	   without	  albumin.	   Patients’	   plasma	   increased	   oxidative	   burst,	   decreased	   CXCR1	   and	   2	  expression,	   decreased	   phagocytosis	   of	   normal	   neutrophils	   and	   increased	  expression	  of	  TLR2,	  4,	  and	  9.	  Inhibition	  of	  TLRs	  prevented	  the	  increase	  in	  burst	  and	   decrease	   in	   CXCR1	   and	   2	   expression	   but	   did	   not	   prevent	   phagocytic	  dysfunction.	  Incubation	  with	  albumin	  prevented	  the	  plasma	  induced	  neutrophil	  dysfunction	  [155].	  
1.5.4 HL-­‐60	  cell	  line	  Neutrophils	  are	  considered	  to	  have	  a	  short	  life	  span	  (6-­‐12	  hours)	  and	  this	  has	  to	  be	   taken	   into	   consideration	   when	   performing	   experiments.	   It	   is	   possible	   to	  isolate	   neutrophils	   from	   whole	   blood	   using	   commercial	   gradients	  (Polymorphprep,	   AxisShield).	   There	   are,	   however,	   some	   concerns	   when	   using	  primary	  cells	  for	  certain	  experiments.	  There	  is	  natural	  heterogeneity	  even	  within	  one	   person	   [156].	   Neutrophils	   are	   easily	   activated,	   experiments	   need	   to	   be	  performed	  quickly	   after	   blood	   is	   drawn	   and	   they	   can,	   therefore,	   be	   difficult	   to	  use	  in	  culture.	  	  HL-­‐60	   cells	   were	   first	   isolated	   in	   1977	   from	   a	   36-­‐year	   old	  woman	  with	   acute	  promyelocytic	   leukaemia	   [157].	   The	   cells	  were	   kept	   in	   continuous	   culture	   and	  deposited	  after	  8	  passages	  at	  the	  American	  Tissue	  Culture	  Central	  (ATCC),	  they	  are	  distributed	  at	  passage	  21.	  The	  original	  reason	   for	  studying	   these	  and	  other	  myeloid	  cells	  was	  to	  improve	  understanding	  and	  treatment	  for	  leukaemia	  [158].	  It	   was	   then	   discovered	   that	   these	   cells,	   under	   certain	   conditions,	   differentiate	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toward	  a	  neutrophil-­‐like	   state	   and	   the	   study	  of	   these	   cells	  has	  provided	  useful	  insight	  into	  neutrophil	  biology.	  	  HL-­‐60	   cells	   can	   be	   induced	   towards	  monocytes,	   eosinophil	   or	   granulocyte-­‐like	  cells	   (for	   a	   review	   see	   Collins	   [159]).	   The	  most	   common	  ways	   to	   differentiate	  cells	  towards	  a	  granulocytic	  lineage	  is	  with	  either	  dimethylsulphoxide	  (DMSO)	  or	  all-­‐trans-­‐retinoic	   acid	   (ATRA)	   [159].	   Upon	   differentiation	   the	   cells	   become	  smaller	  and	  there	  is	  induction	  of	  cell	  surface	  markers	  [160],	  however	  they	  fail	  to	  develop	  specific	  granules	   [161].	  These	  cells	  have	  been	  used	   to	   further	  examine	  phagocytosis	  and	  microbicidal	  activity	  of	  neutrophils	  [162-­‐164].	  
1.6 Interferons	  Interferon	   (IFN)	   was	   first	   described	   in	   1957	   as	   a	   cell	   product	   capable	   of	  interfering	   with	   viral	   replication	   in	   cells	   infected	   with	   homologous	   or	  heterologous	   viruses	   [165].	   IFNs	   are	   now	   recognized	   as	   central	   regulatory	  mediators	   of	   the	   immune	   response	   with	   three	   major	   biological	   activities:	  antiviral,	  anti-­‐tumour	  and	  immunoregulatory	  activity	  [166].	  	  	  IFNs	  have	  been	  classified	  into	  three	  types.	  Type	  I	  IFNs	  include	  13	  forms	  of	  IFN-­‐α,	  one	  form	  of	  IFN-­‐β,	  one	  form	  of	  IFN-­‐ω,	  one	  form	  of	  IFN-­‐ε,	  and	  one	  form	  of	  IFN-­‐κ	  [167].	   These	   molecules	   signal	   through	   a	   ubiquitously	   expressed	   receptor	  composed	  of	   two	   chains:	   IFN-­‐αR1	  and	   IFN-­‐αR2.	  Only	  one	   type	   II	   IFN	  has	  been	  identified:	   IFN-­‐γ,	   this	   was	   originally	   described	   in	   1965	   as	   a	   virus	   inhibitory	  protein	   [168].	   IFN-­‐γ	   signals	   through	   a	   ubiquitously	   expressed	   receptor	  composed	  of	  the	  IFN-­‐γR1	  and	  IFN-­‐γR2	  subunits	  [167].	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The	  type	  III	   interferons,	  IFN-­‐λ1,	  -­‐λ2	  and	  -­‐λ3	  (or	  IL-­‐29,	  IL-­‐28A	  and	  IL28B),	  were	  discovered	  in	  2003	  [169,	  170].	  Type	  III	  IFNs	  act	  through	  a	  receptor	  composed	  of	  two	   chains,	   an	   IFN-­‐λ-­‐specific	   IFN-­‐λR1	   expressed	   on	   certain	   cell	   types	   and	   a	  ubiquitously	  expressed	  IL-­‐10Rβ,	  which	  also	  forms	  part	  of	  the	  receptors	  for	  IL-­‐10,	  IL-­‐22	   and	   IL-­‐26	   [171].	   In	   addition	   to	   the	   antiviral	   properties	   of	   IFN-­‐λ	   there	   is	  increasing	  evidence	  that	  this	  class	  of	  cytokine	  also	  plays	  a	  significant	  role	  in	  the	  modulation	  of	  adaptive	  immunity,	  autoimmunity	  and	  tumour	  progression	  [172].	  	  
1.6.1 Interferons	  –	  role	  in	  alcohol-­‐related	  liver	  disease	  The	  most	   studied	   type	   of	   IFN	   in	   this	   area	   has	   been	   IFN-­‐α	   in	   individuals	   with	  hepatitis	   C	   virus	   (HCV)	   and	   excess	   alcohol	   consumption.	   Ethanol	   metabolites	  impair	  IFN-­‐α	  signalling	  through	  various	  pathways	  providing	  the	  mechanism	  for	  enhanced	  HCV-­‐infection	  severity	  by	  excess	  alcohol	  consumption	  in	  HCV-­‐infected	  individuals	  [173].	  	  Serum	   levels	  of	   IFN-­‐γ	  have	  been	  shown	  to	  be	  elevated	   in	  chronic	   liver	  disease.	  When	  compared	   to	   levels	  of	   IL-­‐1β,	  TNF-­‐α	  and	   IL-­‐6,	   serum	   levels	  of	   IFN-­‐γ	  were	  however	   increased	   in	   a	   smaller	   proportion	   of	   patients	   and	   did	   not	   further	  increase	  with	   progression	   to	   cirrhosis	   [174].	   In	   ALD	   the	   number	   of	   CD8+	   and	  CD4+	  T	  lymphocytes	  in	  the	  liver	  increases	  [72].	  Steatohepatitis	  is	  associated	  with	  a	  T	  helper	  (Th)	  1	  cytokine	  response	  characterised	  by	  IFN-­‐γ	  and	  TNF-­‐α	  elevation	  [175].	  When	  T	  cells	  were	  further	  examined	  in	  AAH	  the	  IL-­‐17	  pathway	  was	  found	  to	  be	  activated,	  IFN-­‐γ	  was	  found	  to	  be	  of	  less	  significance	  in	  this	  study	  [176].	  The	  role	  of	  IFN-­‐λ	  in	  ALD	  has	  not	  been	  examined.	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1.6.2 Interferon	  lambda	  IFN-­‐λ	   has	   a	   restricted	   cell-­‐response	   pattern	   and	   is	   thought	   to	   be	   of	   specific	  importance	  in	  antiviral	  protection	  [177,	  178].	  There	  has	  been	  particular	  interest	  in	   the	   role	   of	   IFN-­‐λ	   in	   HCV	   and	   hepatitis	   B	   infections,	   and	   genome-­‐wide	  association	   studies	   have	   identified	   IFN-­‐λ	   polymorphisms	   that	   are	   associated	  with	  improved	  outcome	  both	  in	  terms	  of	  spontaneous	  clearance	  and	  response	  to	  treatment	  [178,	  179].	  The	  role	  of	  IFN-­‐λ	  in	  bacterial	  infection	  is	  not	  known.	  IFN-­‐λ	  is	  thought	  to	  be	  of	  particular	   importance	  at	  epithelial	  surfaces	  (Figure	  1.17),	  as	  above,	   the	  most	   studied	   biological	   role	   of	   this	   class	   of	   cytokine	   has	   been	   their	  antiviral	  activity.	  Epithelial	  surfaces	  experience	  constant	  microbial	  exposure	  and	  it	   is	   thought	   that	   IFN-­‐λ	   signaling	   could	   control	   low-­‐level	   infections	   without	  broadly	  activating	  a	  systemic	  pro-­‐inflammatory	  response	  [172].	  Given	  the	  role	  of	  bacterial	  translocation	  in	  the	  pathogenesis	  of	  ALD,	  this	  may	  be	  of	  significance.	  	  Whilst	  a	  number	  of	  different	  cell	   types	  have	  been	  reported	  to	  produce	  IFN-­‐λ	  in	  response	   to	   viral	   infection,	   including	   monocytes,	   monocyte-­‐derived	   dendritic	  cells	   [180,	   181]	   and	   plasmacytoid	   dendritic	   cells	   [182]	   little	   is	   understood	  regarding	   the	   production	   and	   source	   of	   IFN-­‐λ	   in	   bacterial	   infection	   and	   in	  inflammatory	  conditions	  such	  as	  ALD.	  Recently,	  Blazek	  et	  al.	  have	  demonstrated	  that	   IFN-­‐λ2	   targets	   neutrophil	   chemotaxis	   in	   a	   mouse	   model	   of	   inflammatory	  arthritis	   [183]	   suggesting	   a	   relationship	   between	   IFN-­‐λ	   and	   neutrophils.	   The	  interplay	  between	  IFN-­‐λ	  and	  neutrophils	  in	  healthy	  and	  other	  disease	  states	  has	  not	  been	  explored	  and	  the	  question	  as	  to	  whether	  neutrophils	  produce	  IFN-­‐λ	  is	  unanswered.	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Figure	  1.17	  Antiviral	  effects	  of	  IFN-­‐λ	  at	  barrier	  surfaces	  [172]	  	  Hepatocytes	   express	   the	   IFN-­‐λ	   receptor	   and	   are	   highly	   responsive	   to	   IFN-­‐λ	   (B).	   Immunity	   in	   the	  gastrointestinal	   tract	   is	  shaped	  by	  the	  microbiome.	  The	   interactions	  between	  the	  virome	  and	  microbiome	  remain	  unclear	   and	   it	   is	   thought	   the	   ability	   of	   gut	  microbes	   to	   promote	   viral	   persistence	   requires	   IFN-­‐λ-­‐signalling	  (C).	  IFN-­‐λ-­‐signalling	  is	  also	  of	  importance	  within	  the	  respiratory	  tract,	  brain	  and	  skin	  (A,	  D,	  E).	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1.7 Management	  of	  alcohol-­‐related	  liver	  disease	  
1.7.1 Supportive	  measures	  The	  management	   of	   ARC	   focuses	   on	   alcohol	   abstinence,	   aggressive	   nutritional	  therapy	   and	   prophylaxis	   of	   cirrhosis	   complications	   [10].	   The	   importance	   of	  sepsis	  has	  been	  discussed	  in	  1.4.	  	  Referral	  to	  alcohol	  misuse	  specialists	  should	  be	  made	  at	  the	  earliest	  opportunity	  and	   the	   involvement	  of	  addiction	  specialists	  should	  be	  sought.	  Ongoing	  alcohol	  use	   after	   diagnosis	   is	   the	   most	   important	   factor	   increasing	   the	   risk	   of	  complications	   and	   death	   [46,	   47,	   184].	   Monitoring	   and	   treatment	   for	   alcohol	  withdrawal	   in	   the	   acute	   setting	   is	   required.	   Figure	   1.18	   outlines	   the	   broad	  recommendations	  in	  the	  management	  of	  ARC.	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Figure	  1.18	  Recommendations	  on	  the	  management	  of	  ARC	  from	  the	  EASL	  clinical	  practice	  guidelines	  
[10]	  Onset	   of	   decompensation	   in	   ALD	   should	   prompt	   clinicians	   to	   suspect	  superimposed	  AAH.	  	  
1.7.2 Liver	  transplantation	  Most	   liver	   transplant	  programmes	  recommend	  a	  6-­‐month	  period	  of	  abstinence	  prior	   to	   liver	   transplantation	   assessment.	   This	   is	   presumed	   to	   serve	   two	  purposes,	   first,	   to	   allow	   some	   individuals	   to	   recompensate	   and	   avoid	   the	  need	  for	  liver	  transplant	  and	  second,	  to	  identify	  patients	  likely	  to	  maintain	  abstinence.	  The	   latter	   point	   has	   come	   under	   scrutiny	   particularly	   in	   recent	   years	   and	   the	  data	  pertaining	   to	   the	  6-­‐month	   rule	  as	  a	  predictor	  of	   long-­‐term	  abstinence	  are	  controversial	   [185,	   186].	   Liver	   transplantation	   confers	   a	   survival	   benefit	   in	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patients	   with	   ARC	   classified	   as	   Child-­‐Pugh	   C	   or	   MELD≥15	   [10].	   ALD	   does	   not	  influence	  liver	  transplant	  survival	  benefit	  [187].	  A	  significant	  proportion	  of	  patients	  with	  AAH	  fail	  to	  respond	  to	  medical	  therapy	  and	  abstinence.	   In	  2011	  Mathurin	  et	  al.	   [100]	  published	  a	  prospective	  study	  of	  liver	   transplantation	   in	   26	   patients	   who	   failed	   to	   respond	   to	   1	   week	   of	  prednisolone	  therapy.	  Of	  those	  transplanted	  77%	  survived	  for	  6	  months,	  similar	  to	  a	  matched	  group	  of	  patients	  who	  responded	  to	  prednisolone	  and	  significantly	  better	  than	  a	  matched	  group	  of	  patients	  with	  AAH	  and	  a	  Lille	  score	  greater	  than	  0.45	   who	   did	   not	   undergo	   liver	   transplantation.	   Two-­‐year	   survival	   in	   the	  transplanted	  group	  was	  71%.	  Less	  than	  2%	  of	  patients	  with	  AAH	  received	  a	  liver	  transplant	  and	  a	  minor	  proportion	  of	   livers	  were	  used	   for	   transplantation	   into	  patients	  with	  AAH.	  A	  larger	  study	  is	  underway	  in	  France.	  The	  UK	  pilot	  study	  to	  permit	  transplantation	  for	  highly	  select	  patients	  with	  AAH	  ran	  for	  several	  years,	  but	  there	  were	  no	  patients	  transplanted	  and	  the	  study	  is	  currently	  suspended.	  
1.7.3 Specific	  therapies	  in	  severe	  alcoholic	  hepatitis	  Recent	   onset	   jaundice	   helps	   to	   distinguish	   patients	  with	  AAH	   from	   those	  with	  decompensated	   cirrhosis.	  Diagnosis	   and	   scoring	   systems	  used	  are	  described	   in	  1.1	  and	  1.2.	  A	  management	  algorithm	  for	  AAH	  is	  outlined	  in	  figure	  1.19.	  	  
56	  	  
	  
Figure	  1.19 Therapeutic	  algorithm	  for	  suspected	  AAH.	  	  	  A	  Lille	  score	  at	  seven	  days	  of	  ≥0.45	  indicates	  non-­‐response	  to	  steroids	  and	  increased	  risk	  of	   infection	  and	  death.	   Figure	   adapted	   from	   EASL	   Clinical	   Practical	   Guidelines:	   Management	   of	   Alcoholic	   Liver	   Disease.	  Blackmore,	  Ryan,	  Kings	  College	  Hospital	  Alcoholic	  Hepatitis	  Management	  Guidelines	  	  
Corticosteroids	  From	  1971	   to	  2014	   there	  were	  13	   randomised	   trials	   and	  4	  meta-­‐analyses	   that	  investigated	   the	   use	   of	   corticosteroids	   in	   AAH	   [188-­‐191].	   There	   have	   been	  disparate	  results	  and	  their	  role	  in	  this	  condition	  remains	  contentious.	  Concerns	  regarding	  their	  use	  have	  centered	  around	  the	  risk	  of	  sepsis	  and	  gastrointestinal	  haemorrhage.	   The	   largest	   placebo	   controlled	   study	   of	   steroids	   in	   AAH	   was	  performed	   in	   90	   patients	   and	   found	   prednisolone	   to	   provide	   no	   benefit	  compared	   to	   placebo	   [38].	   In	   studies	   where	   histological	   confirmation	   of	   the	  diagnosis	  was	  required	  prednisolone	  was	  associated	  with	  a	  short-­‐term	  reduction	  in	   mortality	   [192,	   193].	   The	   Cochrane	   meta-­‐analysis	   reported	   only	   a	   trend	  towards	  increase	  in	  survival	  [189].	  A	  re-­‐analysis	  of	  the	  3	  largest	  trials	  indicated	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that	  steroids	  significantly	  increased	  the	  short-­‐term	  survival	  of	  patients	  with	  AAH	  [190].	  The	  Steroids	  or	  Pentoxifylline	  for	  Alcoholic	  Hepatitis	  [STOPAH]	  trial	  was	  conducted	  between	  2011	  and	  2014	  (during	  the	  time	  that	  much	  of	  my	  laboratory-­‐based	   research	   was	   conducted)	   in	   an	   attempt	   to	   resolve	   the	   controversy	  regarding	   the	  use	  of	   steroids	  or	  pentoxifylline.	  The	   trial	   is	   the	   largest	   study	   to	  date	  in	  AAH.	  This	  was	  a	  double-­‐blind,	  factorial	  2	  x	  2,	  multicentre	  trial	  conducted	  in	  the	  UK	  between	  2011	  and	  2014	  [98].	  1103	  patients	  with	  a	  clinical	  diagnosis	  of	  AAH	  were	  randomly	  assigned	  to	  one	  of	  four	  groups;	  one	  receiving	  pentoxifylline-­‐matched	  placebo	  and	  prednisolone-­‐matched	  placebo,	   a	   second	  group	   receiving	  40mg	   of	   prednisolone	   daily	   and	   a	   pentoxifylline-­‐matched	   placebo,	   the	   third	  group	   receiving	   400mg	   of	   pentoxifylline	   three	   times	   daily	   and	   prednisolone-­‐matched	  placebo,	  and	  the	  fourth	  group	  receiving	  40mg	  of	  prednisolone	  daily	  and	  400mg	   of	   pentoxifylline	   three	   times	   daily.	   This	   study	   reported	   a	   reduction	   in	  mortality	   at	   28	   days	   for	   patients	   given	   prednisolone	   compared	   with	   control	  patients	  but	  this	  did	  not	  reach	  significance	  and	  survival	  curves	  converged	  after	  28	   days.	   Incident	   infections	   were	   more	   common	   among	   subjects	   given	  prednisolone	  than	  controls.	  	  
Nutrition	  Protein	   calorie	   malnutrition	   is	   common	   in	   severe	   AAH	   and	   is	   associated	   with	  impaired	   survival	   [194].	   Nasogastric	   feeding	   can	   be	   difficult	   to	   administer	  however,	   with	   impaired	   tolerance,	   particularly	   among	   patients	   with	   hepatic	  encephalopathy.	   A	   meta-­‐analysis	   of	   9	   trials	   of	   enteral	   feeding	   and	   4	   trials	   of	  parenteral	  nutrition	   found	   that	   these	  strategies	  produce	  a	  modest	   reduction	   in	  mortality	  [195].	  In	  a	  recent	  randomized	  trial	  of	  patients	  with	  severe	  AAH	  treated	  with	  steroids,	  intensive	  enteral	  nutrition	  was	  difficult	  to	  implement	  and	  did	  not	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increase	   survival	   [196].	  The	   authors	  did	   conclude	   that	   low	  daily	   energy	   intake	  was	  associated	  with	  greater	  mortality,	  so	  adequate	  nutritional	  intake	  should	  be	  a	  main	   goal	   of	   treatment.	   Although	   there	   is	   room	   for	   further	   high	   quality	   trials,	  assessment	  of	  nutritional	   status	   and	  provision	  of	   appropriate	   supplementation	  should	  form	  part	  of	  standard	  supportive	  care	  in	  all	  patients	  with	  AAH.	  
Pentoxifylline	  Pentoxifylline,	  a	  phosphodiesterase	  inhibitor,	  is	  thought	  to	  inhibit	  production	  of	  TNF.	   Akrividias	   et	   al.	   reported	   that	   24.5%	   (12/49)	   of	   AAH	   patients	   given	  pentoxifylline	  died	  within	  6	  months,	  compared	  to	  46.1%	  (24/52)	  given	  placebo,	  the	  authors	  state	  that	  the	  benefit	  appeared	  to	  be	  related	  to	  a	  significant	  decrease	  in	   the	   risk	   of	   developing	   hepatorenal	   syndrome	   [197].	   A	  meta-­‐analysis	   of	   five	  trials	   that	   compared	   pentoxifylline	   to	   placebo	   concluded	   that	   no	   conclusions	  could	   be	   drawn	   regarding	   whether	   pentoxifylline	   had	   a	   positive,	   negative	   or	  neutral	  effect	  on	  patients	  with	  AAH	  [198].	  Four	  of	  the	  five	  trials	  were	  deemed	  to	  have	  a	  high	   risk	  of	  bias.	   In	  a	   study	  of	  placebo	  vs	  pentoxifylline	   in	  335	  patients	  with	  Child	  Pugh	  C	  cirrhosis	   (255	  ALD,	  with	  133	  AAH),	   there	  was	  no	  significant	  difference	  in	  short-­‐term	  mortality	  between	  those	  given	  pentoxifylline	  vs	  placebo	  in	   the	  overall	   study	  and	   in	   those	  with	  AAH	   [199].	  Pentoxifylline	  was,	  however,	  shown	   to	   reduce	   the	   risk	   of	   complications	   including	   bacterial	   infection,	   renal	  insufficiency,	   hepatic	   encephalopathy	   and	   gastrointestinal	   haemorrhage.	   The	  combination	   of	   pentoxifylline	   and	   prednisolone	   was	   evaluated	   in	   4	   studies;	  results	   did	   not	   show	   that	   the	   combination	   was	   superior	   [15].	   Mathurin	   and	  colleague’s	   study	   that	   assigned	  270	  patients	   to	   a	   combination	  of	  pentoxifylline	  and	  prednisolone	  or	  prednisolone	  alone	  did	  not	  demonstrate	  any	  difference	   in	  survival.	   The	   study	   may	   have	   been	   underpowered	   to	   detect	   a	   significant	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difference	   in	  HRS	  which	  was	   lower	   in	   those	   receiving	  both	  drugs	   [200].	   In	   the	  STOPAH	   study,	   pentoxifylline	   did	   not	   improve	   outcomes,	   and	   there	   was	   no	  statistically	   significant	   difference	   in	   acute	   kidney	   injury	   between	   those	   that	  received	  pentoxifylline	  and	  those	  who	  did	  not	  [98].	  
Inhibitors	  of	  TNF	  Animal	   work	   and	   two	   small	   pilot	   studies	   indicated	   that	   there	   might	   be	  therapeutic	   potential	   of	   utilising	   monoclonal	   antibodies	   against	   TNF	   in	   AAH	  [201].	  Naveau	   et	   al.	   went	   on	   to	   conduct	   a	   double-­‐blind,	   randomized	   study	   of	  prednisolone	   vs	   the	   combination	   of	   prednisolone	   and	   infliximab	   (10mg/kg	   at	  week	  0,	  week	  2,	   and	  week	  4)	   in	  36	  patients	  with	   severe	  AAH	   [202].	   Increased	  infection	   and	   mortality	   was	   seen	   in	   the	   infliximab	   arm	   and	   the	   study	   was	  therefore	   stopped	   early.	   Similar	   problems	  were	   found	   in	   a	   trial	   of	   etanercept;	  infection	   rates	   and	   6-­‐month	   mortality	   was	   higher	   in	   the	   etanercept	   group	  compared	  to	  the	  placebo	  group	  [203].	  
N-­‐Acetylcysteine	  	  Oxidative	  stress	  is	  thought	  to	  be	  one	  of	  the	  key	  mediators	  in	  liver	  injury	  in	  AAH.	  The	   levels	   of	   antioxidants	   are	   decreased	   in	   liver	   disease	   and	   several	   studies,	  therefore,	  have	  tested	  the	  safety	  and	  efficacy	  of	  N-­‐acetylcysteine	  (NAC)	  alone	  or	  in	  combination	  with	  other	  antioxidants	  (Figure	  1.20).	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Figure	  1.20	  One-­‐month	  mortality	  of	  patients	  with	  alcoholic	  hepatitis	  given	  N-­‐acetylcysteine	  and/or	  
antioxidants	  alone	  or	  in	  combination	  with	  standard	  of	  care	  [15]	  The	  study	  with	  the	  most	  promising	  results	  was	  reported	  by	  Nguyen-­‐Khac	  et	  al.;	  the	  combination	  of	  NAC	  and	  prednisolone	   increased	  1-­‐month	  survival,	   reduced	  infections	   and	   HRS	   compared	   with	   prednisolone	   alone	   [204].	   Mortality	   was	  lower	   at	   6-­‐months	   (the	   primary	   outcome)	   but	   this	   was	   not	   significant.	   This	  strategy	  warrants	  further	  investigation.	  
Granulocyte	  Colony-­‐Stimulating	  Factor	  In	   2014	   Singh	   et	  al.	   published	   their	   study	   on	   the	   effects	   of	   pentoxifylline	   vs	   a	  combination	  of	  pentoxifylline	  and	  granulocyte	  colony-­‐stimulating	  factor	  (G-­‐CSF)	  in	  AAH	  [205].	  The	  aim	  of	  the	  study	  was	  to	  test	  the	  hypothesis	  that	  G-­‐CSF	  might	  mobilise	  bone	  marrow	  derived	  stem	  cells	  and	  promote	  hepatic	  regeneration	  and	  survival.	  A	  significantly	  larger	  proportion	  of	  patients	  who	  received	  pentoxifylline	  with	   G-­‐CSF	   survived	   for	   90	   days	   (18/23)	   than	   those	   who	   received	   only	  pentoxifylline	   (5/23).	   Fewer	   patients	   receiving	   combination	   therapy	   died	   of	  infection	  and	  liver	  failure.	  G-­‐CSF	  is	  a	  potent	  stimulus	  of	  neutrophil	  function	  and	  it	  is	   not	   clear	   whether	   this	   is	   the	   main	   mechanism	   by	   which	   therapy	   improved	  survival	   or	   whether	   this	   relates	   to	   improved	   liver	   regeneration	   as	   was	  hypothesized.	  Further	  studies	  are	  required,	   in	  particular	  evaluation	  of	  G-­‐CSF	   in	  combination	  with	  prednisolone.	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A	  recent	  network	  meta-­‐analysis	  compared	  outcomes	  among	  multiple	  treatments,	  based	  on	  22	   studies	  deemed	  high	  quality	   comprising	  more	   than	  2500	  patients	  with	  AAH	  [191].	  The	  authors	  concluded	  that	  pentoxifylline	  alone,	  corticosteroid	  alone,	   corticosteroid	   +	  NAC	   and	   corticosteroid	   +	   pentoxifylline	   are	   superior	   to	  placebo	   in	  decreasing	   short-­‐term	  mortality.	  These	   interventions	  were	   found	   to	  be	   generally	   comparable	   to	   each	   other,	   though	   the	   addition	   of	   NAC	   to	  corticosteroid	   may	   infer	   additional	   benefit.	   This	   was	   a	   well-­‐performed	   meta-­‐analysis	   however	   several	   points	   should	   be	   kept	   in	   mind;	   40%	   of	   the	   patients	  included	   were	   supplied	   by	   the	   STOPAH	   study.	   There	   were	   also	   considerable	  differences	   in	  one-­‐month	  survival	  among	   trials	  and	  only	  1	   study	  has	  examined	  the	   effect	   of	   the	   addition	   of	   NAC	   to	   prednisolone	   compared	   to	   prednisolone	  alone.	   In	   future	   it	  may	  be	  possible	   to	   carefully	   tailor	   treatments	   to	   individuals,	  including	   true	   discernment	   at	   presentation	   of	   those	   who	   are	   likely	   to	   benefit	  from	  certain	  agents	  pre-­‐exposure.	  A	  finding	  that	  was	  reinforced	  in	  the	  network	  meta-­‐analysis	  was	  that	  there	  are	  no	  agents	   that	   decrease	   medium	   or	   long-­‐term	   mortality	   in	   patients	   with	   severe	  AAH.	   Importantly,	   the	   report	   concludes	   that	   a	   combined	   pharmacological	   and	  psychotherapeutic	  approach	  to	   treating	   these	  patients	   is	  warranted	   in	  order	   to	  improve	  long-­‐term	  mortality.	  
1.7.4 Potential	  new	  treatments	  Figure	  1.21	  outlines	  potential	  therapeutic	  targets	  and	  strategies.	  Antibiotics	  and	  probiotics	   to	   alter	   the	   gut	  microbiome	   are	   being	   evaluated	   as	   are	   LPS-­‐binding	  antibodies.	  There	  is	  a	  careful	  balance	  to	  be	  struck,	  as	  evidenced	  by	  the	  anti-­‐TNF	  trials,	  in	  obtaining	  control	  of	  inflammation	  yet	  avoiding	  life-­‐threatening	  immune	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suppression.	   A	   meta-­‐analysis	   of	   placebo	   controlled	   trials	   did	   not	   confirm	   the	  difference	  seen	  in	  infection	  rates	  between	  those	  exposed	  to	  steroid	  therapy	  and	  those	  not.	  Nevertheless	   the	   concern	  of	  heightened	  susceptibility	   to	   infection	   in	  this	   condition	  whilst	   on	   steroid	   therapy	   has	   formed	   the	   basis	   for	   several	   new	  studies	  combining	  steroid	  and	  prophylactic	  antibiotics	  [15].	  	  	  
	  	  	  	  	  





























Figure	  1.21	  Future	  therapeutic	  targets	  and	  strategies	  in	  alcoholic	  hepatitis	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1.8 Synopsis	  and	  aims	  of	  study	  There	  has	  been	  an	  exponential	   rise	   in	   the	   incidence	  of	  ALD,	  particularly	   in	   the	  UK.	  AAH	   is	   the	  most	   florid	   form	  of	  ALD	  with	  a	  mortality	   rate	  of	  approximately	  30%	   in	   the	   first	   28	  days.	  Treatment	   for	  patients	  with	  AAH	  has	  not	   changed	   in	  decades.	  One	  of	   the	  reasons	   for	  this	   is	   the	  relative	   lack	  of	  understanding	  of	   the	  pathophysiology	   and	   drivers	   of	   this	   condition.	   No	   study	   has	   longitudinally	  investigated	  changes	  in	  immune	  function	  in	  this	  condition	  and	  the	  impact,	  at	  this	  level,	  of	  current	  treatments	  used.	  	  Sepsis	   is	   a	   significant	  problem	  and	  a	  major	   contributor	   to	  mortality	  across	   the	  spectrum	   of	   liver	   disease.	   The	   rise	   of	   multi-­‐drug	   antimicrobial	   resistance	   is	  further	  reason	  to	  develop	  non-­‐antibiotic	  strategies	  based	  upon	  an	  understanding	  of	  the	  defects	  leading	  to	  increased	  susceptibility	  to	  infection.	  	  Neutrophils	  are	  a	  major	  immune	  cell	  subset	  involved	  in	  the	  first	  line	  of	  defense	  against	  infection;	  the	  patient	  with	  chronic	  granulomatous	  disease	  highlights	  the	  importance	   of	   this	   cell	   in	   combating	   infection.	   Neutrophil	   dysfunction,	  characterised	   by	   an	   inability	   to	   phagocytose	   bacteria,	   has	   been	   described	   in	  cirrhosis,	  there	  is	  however	  a	  paucity	  of	  understanding	  regarding	  the	  mechanisms	  involved	  in	  the	  neutrophil	  dysfunction	  that	  exists	  and	  how	  this	  relates	  to	  alcohol-­‐induced	   liver	   toxicity.	   In	   addition,	   whether	   other	   derangements	   in	   neutrophil	  function	  contribute	  to	  the	  state	  of	  immunoparesis	  in	  ALD	  is	  not	  well	  understood.	  	  My	  preliminary	  data	  suggested	  a	   ‘tolerance’	  or	   impaired	  response	  to	  endotoxin	  stimulation	   on	   the	   one	   hand	   and	   a	   ‘hyper-­‐responsiveness’	   on	   the	   other	  which	  may	  exacerbate	  the	  systemic	  inflammatory	  response	  in	  AAH	  contributing	  to	  poor	  outcome.	  The	   risk	   of	   exacerbating	   the	  underlying	   inflammatory	   state	   has	   been	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one	  of	  the	  main	  concerns	  in	  the	  development	  of	  immunotherapeutic	  approaches	  in	   AAH.	   Likewise,	   anti-­‐inflammatory	   therapies	   may	   render	   individuals	  progressively	  immunosuppressed	  and	  this	  difficult	  dynamic	  remains	  a	  challenge.	  Figure	   1.22	   illustrates	   my	   hypothesis;	   neutrophils	   are	   activated	   by	  LPS/cytokines/ethanol	   with	   subsequent	   ROS	   and	   lactoferrin	   secretion	   which	  may	   contribute	   to	   hepatic	   inflammation.	   A	   cycle	   of	   inflammation	   ensues,	   the	  neutrophils	  become	  exhausted	  and	  fail	  to	  appropriately	  respond	  to	  pathogens	  if	  encountered.	  This,	  of	  course,	  is	  dynamic	  and	  the	  management	  of	  the	  individual	  is	  dependent	   on	   where	   they	   are	   in	   the	   disease	   course.	   The	   impact	   of	   current	  therapies	  and	  interplay	  with	  the	  adaptive	  immune	  system	  are	  also	  of	  importance	  and	  the	  topic	  of	  study	  in	  my	  work.	  	  
	  
Figure	  1.22	  Hypothesis	  of	  neutrophil	  dysfunction	  in	  alcoholic	  hepatitis	  and	  how	  this	  may	  contribute	  
to	  hepatic	  inflammation,	  SIRS	  and	  CARS	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My	  broad	   intention	   is	   to	   strengthen	  our	  knowledge	  of	   the	   immunopathological	  processes	   involved	   in	  AAH	  and	  ARC	  and	  potentially	   improve	  treatment	  options	  and	  care	  for	  this	  population	  of	  patients.	  The	  use	  of	  the	  HL-­‐60	  cell	  line,	  which	  was	  originally	   intended	   to	   create	   part	   of	   a	   co-­‐culture	  model	  with	   a	   hepatocyte-­‐like	  cell	   line,	   led	  to	  further	  questions	  regarding	  neutrophil	  biology	  and	  the	  work	  on	  the	  neutrophil-­‐interferon-­‐λ	  relationship	  both	  in	  health	  and	  disease	  states	  which	  has,	   until	   now,	   been	   largely	   unexplored.	   As	   discussed,	   interferon-­‐λ	   is	   of	  importance	   at	   epithelial	   surfaces	   and	   viral	   liver	   disease,	   and	   given	   the	  significance	   of	   the	   gut-­‐liver	   axis	   in	   ALD	   merited	   further	   investigation	   in	   this	  condition.	  Aims	  and	  objectives:	  1. To	  characterize	  neutrophil	  phenotype	  and	  responses	  ex	  vivo	   to	  bacterial	  and	  LPS	  challenge	  in	  patients	  with	  AAH	  compared	  with	  patients	  with	  ARC	  and	  healthy	  controls	  (HC).	  2. To	   evaluate	   peripherally	   circulating	   neutrophils	   as	   contributors	   to	  hepatic	  damage	  and	  multi-­‐organ	   failure	   in	  AAH	  compared	  with	  patients	  with	  ARC	  and	  HC.	  3. To	   prospectively	   examine	   neutrophil	   function	   and	   the	   effect	   of	   current	  AAH	   therapies	   on	   innate	   immune	   function	   by	   sequential	   analyses	   of	  patients	  enrolled	  in	  the	  STOPAH	  trial.	  4. To	  examine	   the	   interplay	  between	  neutrophils,	   ethanol	   and	   the	   liver	  by	  using	  the	  HL-­‐60	  cell	  line	  and	  an	  in	  vitro	  model.	  5. To	   identify	   novel	   targets	   which	  may	   propagate	   immunoparesis	   in	   ALD,	  specifically	   examining	   the	   relationship	   of	   neutrophils	   and	   IFN-­‐λ	   in	   anti-­‐bacterial	  immune	  defenses	  in	  health	  and	  ARC.	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2 	  Materials	  and	  Methods	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2.1 Materials	  
2.1.1 General	  consumables	  Rosewell	   Park	   Memorial	   Institute	   (RPMI)	   medium	   [Sigma-­‐Aldrich,	   United	  Kingdom	   (UK)];	   Flow	   cytometer	   tubes	   –	   5mL	   [Becton	   Dickinson	   (BD),	   UK];	  Falcon	  tubes	  /	  Cellstar	  tubes	  -­‐	  15	  and	  50	  mL	  [Starlabs,	  UK];	  Lysing	  solution	  [BD];	  PolymorphprepTM	  solution	   [Axis	  Shield,	  Norway];	  DNAse-­‐I	   [Sigma-­‐Aldrich,	  UK];	  Phosphate	  buffered	  saline	  (PBS)	  [Sigma-­‐Aldrich,	  UK];	  Cytofix/cytoperm	  solution	  [BD];	  Permwash	  buffer	  [BD];	  RNAprotect	  Cell	  Reagent	  [Qiagen,	  UK]	  Flow	  cytometry	  antibodies:	  Information	  given	  in	  appendix.	  	  Stimulants:	   Lipopolysaccharide	   (LPS)	   [Sigma-­‐Aldrich,	   UK];	   fixed	   E.	   coli	   (strain	  DH5α);	  Recombinant	  interferon-­‐λ1,	  interferon-­‐λ2,	  interferon-­‐	  λ3	  [R&D	  Systems,	  UK];	  Pansorbin	  [Sigma-­‐Aldrich,	  UK];	  Poly	  I:C	  [Invivogen].	  Kits:	  Neutrophil	   function	  kit	  –	  PhagotestTM	  and	  Burst	  TestTM	   [Orpegen	  Pharma,	  Germany];	   Cytometric	   bead	   array	   (CBA)	   [BD,	   UK]	   –	   Human	   Soluble	   Protein	  Master	  Buffer	  Kit	  [BD,	  UK];	  Human	  Soluble	  Protein	  Flex	  Sets	  –	  IL-­‐6,	   IL-­‐8,	   IL-­‐10,	  TNF-­‐α,	   GCSF,	   VCAM-­‐1,	   ICAM-­‐1,	   E-­‐selectin,	   L-­‐selectin,	   VEGF	   [BD,	   UK];	   Limulus-­‐ameboctye-­‐lysate	  assay	  [LAL,	  Pierce/ThermoFisher	  Scientific,	  UK];	  MACSxpress	  Neutrophil	  Isolation	  Kit	  [Miltenyi	  Biotec,	  UK];	  Qiagen	  RNEasy	  Kit	  [74104,	  Qiagen,	  UK];	  QIAamp	  RNA	  Blood	  Mini	  Kit	  [52304,	  Qiagen,	  UK];	  RNeasy	  MinElute	  Cleanup	  Kit	   [Qiagen,	   UK];	   QuantiTect	   Reverse	   Transciption	   Kit	   [Qiagen,	   UK];	   Taqman	  Universal	   Master	   Mix	   II	   [Applied	   Biosystems,	   ThermoFisher	   Scientific,	   UK];	  Primers	  and	  probes	  for	  interferon-­‐λ1,	  interferon-­‐λ2/3,	  interferon-­‐λ	  receptor	  and	  RPLP0	   as	   endogenous	   control	   [Applied	   Biosystems,	   ThermoFisher	   Scientific,	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UK];	   Lactoferrin	   ELISA	   kit	   (Merck	   Millipore,	   Germany);	   Interferon-­‐λ	   ELISA	   kit	  (R&D	  Systems,	  UK].	  Instruments:	   Flow	   cytometer	   –	   BD	   Fluorescence	   activated	   cell	   sorting	   (FACS)	  machine	   Canto	   II	   and	   LSRII	   [BD,	   San	   Jose,	   California,	   USA];	   Centrifuge	   [Rotina,	  Germany];	   Water	   bath	   [Grant,	   UK];	   Nanodrop	   spectrophotometer	   [Thermo	  Scientific,	  UK];	  ABI	  7500	  TaqMan	  [Applied	  Biosystems,	  ThermoFisher	  Scientific,	  UK]. Analysis	  softwares:	  BD	  FACS	  DIVA	  software	  V6.0	  [BD,	  San	  Jose,	  California,	  USA];	  FCAP	   array	   software	   V1.0.1	   [BD,	   San	   Jose,	   California,	   USA];	   SPSS	   20.0	   [IBM	  statistics,	  UK];	  GraphPad	  Prism	  V6.0	  [UK].	  
2.2 Study	  design	  A	  prospective	  cohort	  study	  was	  performed	  on	  patients	  presenting	  with	  AAH.	  A	  histological	   diagnosis	  was	   not	   required,	   this	   is	   discussed	   further	   in	   3.5.	   Blood	  samples	   were	   collected	   within	   48	   hours	   of	   hospital	   admission,	   prior	   to	  administration	   of	   any	   immunosuppressant	   therapy.	   Antibiotic	   use	   was	   not	   a	  contraindication	   but	   patients	   were	   not	   recruited	   with	   untreated	   sepsis.	  Neutrophil	  phenotype	  and	  function	  were	  characterised	  at	  baseline	  and	  at	  day	  7,	  14,	   28,	   90	   and	   180;	   follow-­‐up	   samples	   depended	   on	   disease-­‐course.	   Patients	  with	  ARC	  were	  also	  sampled,	  alongside	  HC.	  
2.3 Study	  population	  Patients	  over	  18	  years	  of	  age	  with	  severe	  AAH	  defined	  as	  a	  bilirubin	  >80	  μmol/L	  and	   a	  Maddrey’s	   Discriminant	   Factor	   >32	   [36]	   and	   a	   history	   of	   excess	   alcohol	  (>80g/day	  male,	  >60g/day	  for	  female),	  as	  per	  the	  STOPAH	  study,	  were	  recruited.	  Patients	  were	  excluded	   if	   there	  was	  a	  history	  of	   abstinence	   from	  alcohol	  of	  >6	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weeks,	   duration	   of	   jaundice	   >3	   months,	   the	   presence	   of	   other	   causes	   of	   liver	  disease,	   evidence	   of	   current	   malignancy,	   pregnancy,	   the	   concomitant	   use	   of	  antioxidants	   or	   other	   immunomodulatory	   therapies	   within	   the	   last	   6	   months,	  aspartate	   aminotransferase	  >500	   IU/L	  or	   alanine	   aminotransferase	  >300	   IU/L,	  patients	  with	   a	   serum	   creatinine	   >500	   μmol/L	   or	   requiring	   renal	   replacement	  therapy,	   patients	   requiring	   inotropic	   support,	   active	   gastrointestinal	  haemorrhage	  and	  untreated	  sepsis.	  Patients	  with	  ARC	  both	  actively	  drinking	  and	  abstinent	   from	  alcohol	   for	  greater	   than	  6	  months	  were	  recruited.	  ARC	  patients	  ranged	   from	   Child	   Pugh	   A	   to	   C,	   the	  majority	   had	   decompensated	   disease	   and	  were	  hospitalised,	   patients	  with	  untreated	   sepsis,	  malignancy	  or	  HIV	  were	  not	  recruited.	   Healthy	   subjects	   were	   also	   analysed.	   The	   HC	   alcohol	   intake	   was	  <20g/day	   and	   they	   had	   not	   drunk	   alcohol	   or	   exercised	   excessively	   72-­‐hours	  prior	  to	  blood	  being	  drawn.	  
2.4 Consent	  and	  data	  collection	  The	   study	   was	   performed	   in	   accordance	   with	   the	   declaration	   of	   Helsinki	   and	  ethical	   permission	   was	   granted	   from	   the	   North	   East	   London	   Research	   Ethics	  Committee	  (reference	  number	  08/H0702/52)	  and	   the	  Steroid	  or	  Pentoxifylline	  for	  Alcoholic	  Hepatitis	  (STOPAH)	  study	  (09/MRE09/	  59).	  
After	   obtaining	   fully	   informed	   consent	   or	   assent;	   clinical,	   biochemical	   and	  physiological	   data	   were	   collected.	   Specifically	   alcohol	   use,	   liver	   biochemistry,	  synthetic	   function	   and	   the	   use	   of	   antibiotic	   and	   immunomodulatory	   therapies	  were	   recorded.	   Data	   on	   the	   occurrence	   of	   bacterial,	   fungal	   and	   viral	   infection	  were	   collected	   along	   with	   the	   incidence	   of	   organ	   failure	   and	   outcome.	   An	  application	  for	  information	  on	  the	  treatment	  arms	  for	  those	  patients	  enrolled	  in	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STOPAH	  was	  made	  after	  trial	  completion.	  	  
2.5 Sample	  collection	  and	  storage	  Venous	   blood	   was	   collected	   into	   heparinised	   pyrogen-­‐free	   tubes.	   Neutrophil	  phenotype	   and	   function	   tests	   were	   performed	   within	   2	   hours	   of	   blood	   being	  drawn	  in	  all	  subjects.	  Plasma	  was	  obtained	  by	  centrifugation	  of	  whole	  blood	  at	  4500	   rpm	   for	   10	  minutes	   at	   4°C	   and	   stored	   at	   -­‐80°C	   for	   subsequent	   analyses	  including	  cytokine	  determination	  by	  cytometric	  bead	  array	  (CBA).	  
2.6 Flow	  cytometry	  The	   expression	   [mean	   fluorescence	   intensity	   (MFI)	   and	   frequency]	   of	   various	  surface	   and	   intracellular	   receptors	   present	   on	   the	   white	   blood	   cells	   were	  analysed	   using	   a	   flow	   cytometer.	   Flow	   cytometry	   measures	   optical	   and	  fluorescence	  characteristics	  of	  single	  cells,	  these	  pass	  through	  a	  single	  apparatus	  in	  a	   fluid	   stream	  [206].	  The	  size	  and	   internal	   complexity	  of	   cells	  are	  measured	  using	   the	   light	   scattered	   by	   forward	   angle	   and	   right	   angle	   respectively.	  Additionally,	  antibodies	  conjugated	  to	  fluorescent	  dyes	  can	  bind	  specific	  proteins	  on	  the	  cell	  surface	  or	  inside	  the	  cell.	  Samples	  were	  acquired	  on	  a	  BD	  FACSCanto	  II	  TM. 
2.7 Isolation	  of	  white	  blood	  cells	  after	  lysis	  of	  red	  cells	  One	   hundred	   μL	   of	   whole	   blood	   was	   placed	   in	   5	   mL	   tubes	   and	   1	   mL	   of	   lysis	  solution	   [<15%	   formaldehyde	   and	   <50%	   di-­‐ethylene	   glycol]	   was	   added.	   The	  lysate	  was	  mixed	  gently	  and	  left	  at	  room	  temperature	  (RT)	  for	  15	  minutes.	  The	  reaction	  was	   stopped	  by	   adding	  2	  mL	  of	   phosphate-­‐buffered	   saline	   (PBS).	   The	  solution	   was	   centrifuged	   at	   600g	   for	   5	   minutes	   at	   18°C	   and	   the	   supernatant	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discarded	  leaving	  the	  cell	  pellet	  at	  the	  bottom	  of	  the	  tube.	  The	  cells	  were	  then	  re-­‐suspended	  in	  100	  μL	  of	  PBS	  before	  staining	  for	  flow	  cytometry.	  
2.8 Isolation	  of	  white	  blood	  cells	  using	  PolymorphprepTM	  solution	  PolymorphprepTM	   solution	   separates	   white	   blood	   cells	   and	   other	   blood	  components	   based	   on	   their	   density.	   To	   isolate	   the	   white	   blood	   cells	   using	  PolymorphprepTM	   solution,	   20	   mL	   of	   heparinised	   blood	   was	   collected	   and	  processed	   under	   aseptic	   conditions	   in	   a	   bio-­‐safety	   cabinet.	   Whole	   blood	   was	  layered	   over	   15	  mL	   of	   PolymorphprepTM	   solution	   in	   a	   50	  mL	   falcon	   tube.	   The	  tubes	  were	  balanced	  and	  centrifuged	  at	  800g	  for	  35	  minutes	  at	  18°C,	  with	  least	  acceleration	   and	   zero	   brakes.	   The	   separated	   blood	   contains	   peripheral	   blood	  mononuclear	  cells	  (PBMC)	  on	  top,	  granulocytes	  in	  the	  middle	  and	  red	  blood	  cells	  at	  the	  bottom	  (Figure	  2.1).	  PBMC	  and	  granulocytes	  were	  isolated	  in	  two	  different	  sterile	   50	   mL	   falcon	   tubes.	   Granulocytes	   were	   washed	   twice	   with	   PBS	   and	  centrifuged	  at	  800g	  for	  10	  minutes	  at	  18°C	  with	  brakes.	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Figure	  2.1	  Separation	  of	  PBMCs	  and	  PMNs	  on	  PolymorphprepTM	  
2.9 Isolation	  of	  neutrophils	  using	  the	  MACSxpress	  Neutrophil	  Isolation	  Kit	  	  The	  MACSxpress	  neutrophil	  isolation	  kit	  isolates	  untouched	  neutrophils	  directly	  from	  whole	   blood	  without	   density	   gradient	   centrifugation.	   Red	   blood	   cells	   are	  aggregated	   and	   sedimented,	   while	   non-­‐target	   cells	   are	   removed	   by	  immunomagnetic	  depletion	  with	  MACSxpress	  Beads.	  	  The	   MACSxpress	   Neutrophil	   Isolation	   Cocktails	   is	   delivered	   as	   a	   lyophilized	  pellet.	   The	   pellet	  was	   reconstituted	   by	   adding	   2	  mL	   of	   Buffer	   A	   to	   one	   vial	   of	  lyophilized	   MACSxpress	   Cell	   Isolation	   Cocktail	   and	   mixed	   gently	   immediately	  before	  use.	  The	  final	  cocktail	  was	  prepared	  by	  mixing	  the	  appropriate	  volumes	  of	  reconstituted	   pellet	   and	   Buffer	   B.	   For	   8	   mL	   of	   blood,	   the	   final	   cocktail	   was	  prepared	  by	  adding	  2	  mL	  of	  reconstituted	  pellet	  to	  2	  mL	  of	  Buffer	  B	  and	  mixed	  gently.	  The	  4	  mL	  cocktail	  was	  added	  to	  the	  8	  mL	  of	  blood	  in	  a	  15	  mL	  tube.	  The	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tube	   was	   closed	   tightly	   and	   inverted	   gently	   three	   times.	   The	   sample	   was	  incubated	  for	  5	  minutes	  at	  room	  temperature	  on	  a	  tube	  rotator	  on	  run	  speed	  of	  12	   rpm.	   The	   tube	   was	   removed	   from	   the	   tube	   rotator	   and	   the	   cap	   carefully	  opened.	   The	   open	   tube	   was	   placed	   in	   the	   magnetic	   field	   of	   the	   MACSxpress	  Separator	  for	  15	  minutes	  (Figure	  2.2).	  	  Whilst	   the	   tube	   was	   inside	   the	   MACSxpress	   Separator,	   the	   supernatant	   was	  carefully	  collected	  into	  a	  new	  15	  mL	  tube.	  The	  supernatant	  contained	  the	  target	  cell	  fraction.	  An	  aliquot	  of	  the	  supernatant	  was	  taken	  for	  cell	  counting.	  	  
	  
Figure	  2.2	  The	  MACSxpress	  Separator.	  	  The	   magnetically	   labeled	   cells	   will	   adhere	   to	   the	   wall	   of	   the	   tube	   while	   the	   aggregated	   erythrocytes	  sediment	  to	  the	  bottom.	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2.10 Cell	  count	  The	   cells	   were	   suspended	   with	   PBS	   and	   diluted	   (1/10)	   with	   Trypan	   Blue	  solution.	   Cells	   were	   counted	   using	   a	   Neubauer	   haemocytometer	   and	   up	   to	   1	  million	   (1x106)	   viable	   cells	  were	   re-­‐suspended	  with	   100	   μL	   of	   PBS	   in	   a	   single	  tube	  for	  flow	  cytometry	  staining.	  
The	   total	   number	   (no.)	   of	   cells	   in	   the	  PBS	   (isolated	   from	  a	   single	   sample)	  was	  calculated	  as	  follows:	  
Total	  no.	  of	  cells	  =	  Cells	  counted	  x	  dilution	  factor	  x	  depth	  factor	  x	  103	  x	  volume	  of	  PBS	  /	  Area	  counted	  
=	  Cells	  counted	  x	  10	  x	  10	  x	  103	  x	  volume	  of	  PBS	  /	  4	  
Cells	  counted	  –	  number	  of	  cells	  counted	  in	  the	  haemocytometer.	  
Dilution	   factor	   –	   the	  dilution	  of	   cells	  with	   trypan	  blue	   (1	   in	  10	  dilution	  –	  5	  μL	  cells	  with	  45	  μL	  of	  trypan	  blue).	  
Depth	  factor	  –	  the	  distance	  between	  the	  cytometer	  and	  cover	  slip	  (0.1	  mm	  -­‐	  10)	  103	  –	  for	  the	  conversion	  of	  per	  mL.	  
Volume	  of	  PBS	  –	  5	  mL	  of	  PBS	  in	  which	  the	  cells	  were	  suspended.	  
Area	   counted	   –	   four,	   the	   16	   small	   squares	   in	   the	   areas	   1,	   2,	   3	   and	   4	   of	   the	  haemocytometer	  were	  counted	  as	  shown	  below	  in	  figure	  2.3.	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Figure	  2.3	  Image	  of	  the	  areas	  used	  for	  counting	  white	  blood	  cells	  in	  a	  haemocytometer	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2.11 Cell	  surface	  and	  intracellular	  receptor	  analyses	  
2.11.1 Staining	  of	  cells	  for	  flow	  cytometry	  For	  flow	  cytometry,	  up	  to	  100,	  000	  white	  blood	  cells	  were	  re-­‐suspended	  in	  100	  μL	  of	  staining	  buffer	  and	  stained	  with	  fluorochrome	  conjugated	  antibodies	  in	  one	  tube.	   To	   stain	   for	   receptors	   present	   on	   cell	   surface,	   monoclonal	   antibodies	  conjugated	  with	  fluorochromes	  were	  added	  to	  the	  white	  blood	  cells,	  mixed	  and	  incubated	  at	  RT	  in	  darkness	  for	  30	  minutes.	  Following	  this	  the	  cells	  were	  washed	  with	   1	   mL	   of	   sterile	   PBS,	   centrifuged	   at	   600g	   for	   5	   minutes	   at	   18°C	   and	   the	  supernatant	  was	  discarded.	  	  
To	   prepare	   the	   cells	   for	   intracellular	   staining,	   100	   μL	   of	   cytofix/cytoperm	  solution	  was	  added	  to	  the	  cell	  pellet	  after	  surface	  stain,	  mixed	  gently	  and	  left	  at	  RT	   for	   20	  minutes.	   The	   cells	   were	   washed	   with	   1	  mL	   of	   BD	   permeabilisation	  wash	  buffer,	  centrifuged	  at	  600g	  for	  5	  minutes	  at	  18°C	  and	  the	  supernatant	  was	  discarded.	   The	   cells	   were	   then	   stained	   with	   intracellular	   or	   intranuclear	  antibodies	   and	   incubated	   at	   RT	   in	   darkness	   for	   30	   minutes.	   The	   cells	   were	  washed	   again	  with	   1	  mL	   of	   permeabilisation	   buffer,	   centrifuged	   at	   600g	   for	   5	  minutes	   at	   18°C	   and	   the	   supernatant	   was	   discarded.	   The	   cells	   were	   then	   re-­‐	  suspended	  in	  300	  μL	  of	  PBS	  and	  analysed	  using	  a	  flow	  cytometer.	  
All	  antibodies	  were	  titrated	  by	  staining	  them	  with	  blood	  samples	  collected	  from	  HC	  to	  determine	  the	  right	  concentration	  of	  antibody	  required	  to	  be	  added	  to	  the	  cells.	   The	   stock	   antibodies	   were	   diluted	   with	   PBS	   and	   those	   dilutions	   which	  expressed	   maximum	   mean	   fluorescence	   intensity	   (MFI)	   were	   chosen	   for	   the	  experiment.	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2.11.2 Identification	  of	  white	  blood	  cells	  and	  the	  different	  subsets	  The	  BD	  FACSCanto	   II	   TM	   instrument	  was	  used	  and	  operated	  using	   the	  BD	  FACS	  Diva	  Software	  6.1.2.	  A	  new	  experiment	  was	  created	  and	  compensation	  settings	  applied.	   In	  a	  new	  global	  worksheet,	   a	  dot	  plot	  was	  created	   to	  display	   the	  cells.	  Cells	  were	  identified	  in	  the	  forward	  scatter	  channel	  area	  (FSC-­‐A)	  and	  side	  scatter	  channel	  area	  (SSC-­‐A)	  of	  the	  dot	  plot	  based	  on	  their	  size	  and	  complexity.	  As	  cells	  increase	   in	  size	  and	  complexity	   they	  move	  away	   from	  zero	   in	  FSC-­‐A	  and	  SSC-­‐A	  respectively.	   The	   FSC-­‐A	   and	   SSC-­‐A	   are	   measured	   on	   a	   linear	   scale	   and	   the	  fluorochrome	  expression	  was	  measured	  on	  a	  logarithmic	  scale.	  	  
	  
Figure	   2.4	   Flow	   cytometry	   image	   of	   human	   leukocytes	   showing	   the	   position	   of	   granulocytes,	  
monocytes	  and	  lymphocytes	  on	  a	  FSC-­‐A/SSC-­‐A	  dot	  plot. 	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Figure	  2.4	  demonstrates	   the	   leukocyte	  populations.	  The	   lymphocytes	  are	   small	  cells	   without	   granules	   hence	   their	   position	   on	   the	   dot	   plot.	   The	   population	  further	   along	   the	   X-­‐axis	   are	   considered	   as	  monocytes	   since	   they	   are	   the	   large	  cells	  amongst	  the	  white	  blood	  cells	  without	  granules.	  The	  large	  population	  above	  are	  considered	  as	  granulocytes,	  since	   they	  are	  present	   in	   the	  majority	  amongst	  the	  white	  blood	  cells	  and	  contain	  granules.	  The	  different	  populations,	  namely	  the	  granulocytes	   in	   my	   work,	   were	   further	   characterised	   by	   staining	   for	   the	   key	  receptors	  expressed	  on	  those	  cells	  using	  fluorochrome	  conjugated	  antibodies.	  
2.11.3 Identification	  and	  characterisation	  of	  neutrophils	  In	  humans,	  CD16,	  CD11b	  and	  CD62L	  have	  been	  shown	  to	  be	  useful	  markers	  for	  the	   identification	   of	   neutrophils.	   Depending	   on	   the	   experiment	   set-­‐up,	   these	  markers	   were	   used	   as	   an	   individual	  marker	   or	   in	   combination	   to	   identify	   the	  neutrophils.	   (CD16,	   an	   Fc-­‐gamma	   receptor,	   CD11b,	   a	   sub-­‐unit	   of	   the	   integrin	  receptor	   MAC-­‐1	   and	   CD62L	   or	   L-­‐selectin,	   another	   adhesion	   molecule	   are	  discussed	   in	   1.5.)	   Baseline	   neutrophil	   phenotype	   was	   characterised	   by	  determining	   the	   expression	   of	   CD16,	   CD11b,	   TLR2,	   TLR4	   and	   TLR9	   in	  granulocytes	  isolated	  from	  whole	  blood	  after	  erythrocyte	  lysis.	  	  
2.11.4 Identification	  and	  characterization	  of	  T	  cells	  	  T	  cells	  were	  identified	  using	  CD3	  an	  important	  receptor	  present	  on	  the	  surface	  of	  T	   cells	   that	   helps	   in	   its	   activation.	   Following	   that,	   CD4	   and	  CD8	  markers	  were	  used	  to	  characterize the	  different	  subsets	  of	  T	  cells.	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2.12 Neutrophil	  phagocytosis	  
2.12.1 Principle	  and	  assay	  procedure	  Phagocytosis	  was	  quantified	  using	  the	  PhagotestTM	  which	  allows	  the	  quantitative	  determination	   of	   leukocyte	   phagocytosis	   using	   fluorescein	   isothiocyanate	  (FITC)-­‐labelled	  opsonised	  E.	  coli	  bacteria	  on	  the	  flow	  cytometer.	  One	  hundred	  μL	  of	  whole	  blood	  was	  incubated	  in	  a	  water	  bath	  at	  37°C	  in	  darkness	  for	  20	  minutes	  with	  20	  μL	  of	  FITC	  labelled	  opsonised	  E.	  coli	  along	  with	  a	  control	  (PBS).	  Ice	  cold	  trypan	  blue	  was	  added	  to	  all	   the	  tubes	  and	  left	  at	  RT	  for	  20	  minutes	  to	  quench	  the	  fluorescence	  of	  bacteria	  attached	  to	  the	  cell	  surface.	  Cells	  were	  washed	  with	  2	  mL	  PBS	  by	  gently	  mixing	  with	  a	  pipette,	  centrifuged	  at	  600g	  for	  5	  minutes	  and	  the	  supernatant	  was	  discarded.	  Red	  cell	  lysis	  was	  performed	  by	  adding	  2	  mL	  of	  lysis	   solution	   with	   an	   incubation	   period	   of	   15	   minutes	   at	   room	   temperature. Cells	   were	   then	   washed	   with	   2	   mL	   PBS	   and	   centrifuged	   as	   above	   and	   the	  supernatant	  discarded.	  Four	  μL	  of	  fluorochrome	  conjugated	  antibody	  CD16	  (PE)	  was	  added	  to	  the	  tube	  containing	  FITC-­‐labelled	  E.	  coli	  and	  the	  control	  tube	  and	  incubated	  at	  RT	  in	  darkness	  for	  30	  minutes.	  Cells	  were	  washed	  with	  2	  mL	  of	  PBS,	  centrifuged	   at	   600g	   for	   5	   minutes	   and	   the	   supernatant	   was	   discarded.	   Three	  hundred	  μL	  of	  PBS	  was	  added	  to	  all	  the	  tubes	  and	  acquired	  in	  a	  flow	  cytometer.	  A	  negative	  control	  tube	  (100	  μL	  of	  whole	  blood)	  was	  treated	  in	  similar	  conditions	  without	  the	  addition	  of	  FITC-­‐labelled	  E.	  coli	  and	  CD16-­‐PE.	  
2.12.2 Flow	  cytometer	  set-­‐up	  for	  the	  neutrophil	  phagocytosis	  assay	  (NPA)	  A	   new	   experiment	   was	   created	   and	   the	   specimen	   tubes	   were	   labelled	   as	  negative,	  tube	  –	  1	  and	  tube	  –	  2.	  In	  the	  inspector,	  settings	  were	  adjusted	  to	  show	  FSC-­‐A,	  SSC-­‐A,	  FITC	  and	  PE	  in	  the	  panel.	  In	  the	  global	  worksheet,	  a	  dot	  plot	  with	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FSC-­‐A	   (X-­‐axis)	   and	  SSC-­‐A	   (Y-­‐axis)	  was	   created.	  Cells	   in	   the	  negative	   tube	  were	  acquired	   and	   the	   FSC/SSC	   voltages	   were	   adjusted	   between	   250	   -­‐	   400	   V	   to	  identify	  the	  white	  blood	  cells	  in	  the	  dot	  plot.	  The	  large	  population	  in	  the	  dot	  plot	  was	   identified	  as	  granulocytes	   [Figure	  2.5].	  Another	  dot	  plot	  with	  CD16-­‐PE	   (X-­‐axis)	  and	  SSC-­‐A	  (Y-­‐axis)	  were	  created	  showing	  the	  granulocytes.	  While	  cells	  from	  tube	   –	   1	   (without	   FITC	  E.	   coli)	  were	   acquired,	   granulocytes	   expressing	   CD16+	  were	  gated	  and	  identified	  as	  CD16+	  neutrophils.	  A	  plot	  with	  FITC	  E.	  coli	  showing	  CD16+	   neutrophils	   was	   created.	   An	   interval	   gate	   was	   fixed	   using	   the	   FITC-­‐negative/control	   population	   (tube	   1)	   [Figure	   2.6].	   Cells	   from	   tube	   –	   2	   were	  acquired	  with	  the	  voltages	  adjusted	  based	  on	  tube	  –	  1	  to	  identify	  the	  neutrophils	  undergoing	  phagocytosis	  (%)	  [Figure	  2.7].	  




Figure	  2.5	  Image	  of	  dot	  plots	  from	  negative	  tube	  in	  NPA.	  	  
	  
Figure	  2.6	  Image	  of	  dot	  plots	  from	  tube	  1	  in	  NPA.	  
	  
Figure	  2.7	  Image	  of	  dot	  plot	  from	  tube	  2	  in	  NPA.	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2.13 Neutrophil	  oxidative	  burst	  
2.13.1 Principle	  and	  assay	  procedure	  Neutrophil	  oxidative	  burst	  (OB)	  was	  determined	  with	  a	  Burst	  kit	  using	  different	  stimulants	  and	  dihydrorhodamine	  as	  a	  fluorogenic	  substrate.	  The	  percentage	  of	  phagocytic	  cells	  which	  produce	  reactive	  oxygen	  species	  (ROS)	  (the	  conversion	  of	  dihydrorhodamine	  to	  rhodamine	  and	  the	  amount	  of	  rhodamine	  per	  cell)	  can	  be	  quantified	  using	  a	  flow	  cytometer. Neutrophil	  low	  burst	  (LB)	  was	  assessed	  by	  stimulating	  the	  whole	  blood	  with	  20	  μL	   of	   chemotactic	   synthetic	   peptide,	   formyl-­‐Met-­‐Leu-­‐Phe	   (fMLP)	   (0.2μM)	   and	  high	  burst	  (HB)	  was	  assessed	  by	  stimulating	  whole	  blood	  using	  20	  μL	  of	  protein	  kinase	   C	   ligand	   phorbol	   12-­‐myristate	   13-­‐acetate	   (PMA)	   (0.2μM).	   Neutrophil	  phagoburst	   (PB)	  was	  assessed	  by	  stimulating	   the	  whole	  blood	  with	  20	  μL	  of	  E.	  
coli	  (2x107).	  Resting	  oxidative	  burst	  (OB)	  was	  assessed	  by	  adding	  20	  μL	  of	  PBS	  to	  the	  whole	  blood.	  To	  measure	  the	  ROS	  production,	  20	  μL	  of	  dihydrorhodamine	  was	  added	  to	  all	  the	  tubes	  and	  incubated	  in	  a	  water	  bath	  at	  37°C	  in	  darkness	  for	  20	   minutes.	   Dihydrorhodamine-­‐123	   is	   oxidised	   to	   rhodamine-­‐123	   in	   the	  presence	   of	   ROS	   and	   gives	   green	   fluorescence.	   Whole	   blood	   without	  dihydrorhodamine	   was	   added	   to	   a	   tube	   separately	   as	   a	   control.	   Cells	   were	  washed	  with	  1	  mL	  of	  PBS	  by	  gently	  mixing	  with	  a	  pipette,	  centrifuged	  at	  600g	  for	  5	  minutes	  and	  the	  supernatant	  was	  discarded.	  Red	  blood	  cells	  were	  lysed	  using	  a	  lysis	  solution	  as	  described	  above.	  Four	  μL	  of	  fluorochrome	  conjugated	  antibody	  CD16	   (PE)	  was	   added	   to	   all	   the	   tubes	   and	   incubated	   at	   RT	   in	   darkness	   for	   30	  minutes.	  Cells	  were	  washed	  with	  2	  mL	  of	  PBS,	  centrifuged	  at	  600g	  for	  5	  minutes	  and	  the	  supernatant	  was	  discarded.	  Three	  hundred	  μL	  of	  PBS	  was	  added	  to	  the	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tubes	   and	   acquired	   in	   a	   flow	   cytometer.	   A	   negative	   control	   (100	   μL	   of	   whole	  blood)	   was	   treated	   in	   similar	   conditions	   without	   the	   addition	   of	  dihydrorhodamine	  and	  CD16-­‐PE.	  
2.13.2 Flow	  cytometer	  set-­‐up	  for	  the	  neutrophil	  oxidative	  burst	  experiment	  The	   experiment	   was	   set-­‐up	   using	   the	   methods	   described	   for	   the	   NPA	   -­‐	   the	  rhodamine	  positive	  population	  was	  set	  using	  the	  negative	  control.	  
2.14 Lipopolysaccharide	  stimulation	  Whole	   blood	   was	   incubated	   at	   37°C	   with	   Roswell	   Park	   Memorial	   Institute	  (RPMI)-­‐1640	   media	   and	   stimulated	   with	   either	   LPS	   (E.	   coli	   0111:B4)	  (200ng/mL)	  or	  with	  PBS	  in	  controls	  for	  2	  hours	  (unstimulated).	  The	  stimulated	  cells	  were	  then	  stained	  and	  analysed	  by	  flow	  cytometry	  as	  previously	  described.	  The	  supernatant	  of	   the	  stimulated	  cells	  were	  carefully	  collected	  and	  stored	  at	  -­‐80°C	   for	   subsequent	   cytokine	   analysis.	   The	   conditions	   used	   for	   the	   ex-­‐vivo	  studies,	  including	  the	  concentration	  of	  LPS	  had	  previously	  been	  optimised	  using	  sequential	  assays	  of	  different	  concentrations	  of	  stimuli	  with	  healthy	  blood.	  
2.15 Endotoxin	  measurement	  The	   Toxisensor	   Chromogenic	   Limulus	   Amoebic	   Lysate	   (LAL)	   Endotoxin	   Assay	  (Genscript,	  UK)	  was	  used	  to	  measure	  the	  endotoxin	  levels	  in	  the	  plasma	  samples	  stored	   at	   -­‐80°C.	   This	   kit	   can	   measure	   from	   0.005	   to	   1	   endotoxin	   unit	   /	   mL	  (EU/mL)	  and	  detects	  endotoxin	  based	  on	  a	  chromogen	  using	  a	  modified	  LAL	  and	  a	   synthetic	   substrate.	   This	   assay	   was	   performed	   using	   the	   protocol	   booklet	  provided	  with	  the	  kit.	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2.16 Lactoferrin	  measurement	  Sandwich	   ELISA	  was	   performed	   as	   per	   protocol,	   using	   a	   Lactoferrin	   ELISA	   kit	  (Merck	  Millipore,	  Germany).	  
2.17 Analyses	  of	  cytokines	  and	  endothelial	  activation	  markers	  Pro-­‐	  and	  anti-­‐inflammatory	  cytokines	  [IL-­‐8,	  IL-­‐6,	  IL-­‐10,	  TNF-­‐α,	  GCSF]	  levels	  and	  endothelial	   activation	   markers	   [VCAM-­‐1,	   ICAM-­‐1,	   E-­‐selectin,	   L-­‐selectin,	   VEGF]	  were	   determined	   in	   previously	   stored	   plasma	   and	   supernatant	   samples	   using	  cytometric	  bead	  array	  (CBA).	  Cytokine	  levels	  were	  quantified	  using	  the	  capture	  and	   detection	   beads	   from	   different	   Human	   Soluble	   Protein	   Flex	   Sets	   and	   a	  Master	  Buffer	  Kit.	  
2.17.1 Preparation	  of	  standards	  A	  lyophilised	  standard	  from	  the	  flex	  set	  of	  each	  cytokine	  tested	  were	  pooled	  into	  one	   15	   mL	   polypropylene	   tube	   and	   reconstituted	   with	   assay	   diluent.	   The	  reconstituted	  standards	  were	  left	  to	  equilibrate	  for	  15	  minutes	  at	  RT	  followed	  by	  gentle	  mixing	   using	   a	   pipette.	   A	   serial	   dilution	  was	   performed	   by	   transferring	  500	  μL	  of	   top	   standard	  with	   equal	   volume	  of	   assay	  diluent	   to	  1:2	  dilution	   and	  then	  further	  up	  to	  1:256.	  Assay	  diluent	  was	  used	  as	  the	  0-­‐pg/mL.	  
2.17.2 Preparation	  of	  capture	  and	  detection	  beads	  Based	   on	   the	   instruction	   manual	   provided,	   equal	   volumes	   (50	   μL)	   of	   capture	  bead	  and	  detection	  bead	  were	  used	  for	  testing	  the	  plasma	  or	  supernatants	  and	  the	   beads	   were	   50x	   concentration.	   This	   experiment	   was	   optimised	   in	   our	  laboratory;	  it	  was	  found	  that	  the	  capture	  and	  detection	  beads	  yield	  a	  good	  result	  when	   diluted	   100x.	   All	   the	   beads	   were	   vortexed	   for	   15	   seconds	   immediately	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before	  use.	  
2.17.2.1 Capture	  beads	  As	   per	   protocol,	   capture	   bead	   preparation	   varied	   depending	   on	   whether	  supernatant	   samples	   or	   plasma	   samples	   were	   being	   analysed.	   The	   total	   bead	  volume	  was	   calculated	   based	   on	   the	   number	   of	   samples	   (including	   standards)	  and	  cytokines	  measured	  for	  each	  experiment.	  	  
For	  plasma	  samples: 
The	  appropriate	  amount	  of	  capture	  beads	  (as	  shown	  below)	  from	  the	  stock	  vials	  of	  each	  Human	  Soluble	  Protein	  Flex	  Set	  were	  pooled	  into	  a	  15-­‐mL	  polypropylene	  tube	   and	   0.5	   mL	   of	   wash	   buffer	   was	   added	   to	   them.	   The	   tube	   was	   then	  centrifuged	   at	   200	   g	   for	   5	   minutes	   and	   the	   supernatant	   was	   discarded	   by	  carefully	   aspirating	   it	   without	   disturbing	   the	   bead	   pellet.	   The	   bead	   pellet	   was	  then	   re-­‐suspended	   in	   capture	   bead	   diluent	   to	   a	   final	   concentration	   of	   50	   μL	   /	  test.	  
An	  example	  calculation:	  
No.	  of	  tests	  –	  50;	  Volume	  of	  capture	  beads	  from	  each	  flex	  set	  –	  25	  μL;	  No.	  of	  flex	  sets	  (cytokine	  beads)	  –	  4;	  final	  concentration	  –	  50	  μL	  	  
Therefore	  Total	  bead	  volume	  =	  50	  	  
No.	  of	  tests	  x	  50	  μL	  of	  final	  concentration	  =	  2500	  μL 
For	  supernatants: 
The	  appropriate	  amount	  of	  capture	  beads	  (as	  shown	  below)	  from	  the	  stock	  vials	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of	  each	  Human	  Soluble	  Protein	  Flex	  Set	  were	  pooled	  into	  a	  15-­‐mL	  polypropylene	  tube	   and	  mixed	  with	   capture	   bead	   diluent.	   The	   final	   concentration	   of	   capture	  bead	   volume	   was	   50	   μL	   /	   test.	   The	   volume	   of	   the	   capture	   bead	   diluent	   was	  calculated	   by	   subtracting	   the	   volume	   for	   each	   bead	   tested	   from	   the	   total	   bead	  volume	  required	  for	  the	  assay.	  An	  example	  calculation: No.	   of	   tests	   –	   50;	   volume	   of	   capture	   beads	   from	   each	   flex	   set	   –	   25	   μL;	   final	  concentration	  –	  50	  μL;	  No	  of	  flex	  sets	  (cytokine	  beads)	  –	  4	  Total	  bead	  volume	  =	  No.	  of	  tests	  –	  50	  x	  Final	  concentration	  –	  50	  μL	  =	  2500	  μL	  So	  when	  4	  cytokines	  were	  tested,	  diluent	  volume	  =	  2500	  μL	  –	  (25	  μL	  x	  4)	  =	  2400	  μL.	  
2.17.2.2 Detection	  beads	  The	   procedure	   for	   detection	   bead	   preparation	   was	   the	   same	   for	   supernatant	  samples	   and	  plasma.	  Therefore	   the	   appropriate	   amount	   of	   detection	  beads	   (as	  shown	  below)	  from	  the	  stock	  vials	  of	  each	  Human	  Soluble	  Protein	  Flex	  Set	  were	  pooled	  into	  a	  15-­‐mL	  polypropylene	  tube	  and	  mixed	  with	  detection	  bead	  diluent.	  The	  final	  concentration	  of	  detection	  bead	  volume	  was	  50	  μL/test.	  The	  volume	  of	  the	   detection	   bead	   diluent	   was	   calculated	   by	   subtracting	   the	   volume	   for	   each	  bead	  tested	  from	  the	  total	  bead	  volume	  required	  for	  the	  assay. An	  example	  calculation: No.	  of	  tests	  –	  50;	  Volume	  of	  detection	  beads	  from	  each	  flex	  set	  –	  25	  μL;	  No	  of	  flex	  sets	  (cytokine	  beads)	  –	  4;	  Final	  concentration	  –	  50	  μL	  Total	  bead	  volume	  =	  No.	  of	  tests	  –	  50	  x	  Final	  concentration	  –	  50	  μL	  =	  2500	  μL	  When	  4	  cytokines	  were	  tested,	  diluent	  volume	  =	  2500	  μL	  –	  (25	  μL	  x	  4)	  =	  2400	  μL	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2.17.3 Assay	  procedure	  The	  assay	  was	  performed	  on	  tubes	  and	  50	  μL	  of	  flex	  standards	  starting	  from	  0	  to	  2000	  pg/mL	  (top	  standard)	  and	  plasma	  and	  supernatant	  samples	  were	  placed	  in	  FACS	  tubes. The	  mixed	  capture	  beads	  were	  vortexed	  for	  at	   least	  5	  seconds	  and	  50	  μL	  was	  added	  to the	  standards	  and	  samples.	  The	  tubes	  were	  mixed	  gently	  and	  incubated	  at	  RT	  in	  darkness.	  After	  an	  hour,	  the	  mixed	  PE	  detection	  reagent	  was	  vortexed	  for	  at	  least	  5	  seconds	  and	  50	  μL	  was	  added	  to	  all	  the	  tubes.	  The	  tubes	  were	  mixed	   gently	   and	   left	   to	   incubate	   at	   RT	   in	   darkness.	   After	   two	   hours	   of	  incubation,	   1	  mL	  of	  wash	  buffer	  was	   added	   to	   all	   the	   tubes	   and	   centrifuged	   at	  200g	  for	  5	  minutes.	  The	  supernatant	  was	  discarded	  carefully	  and	  the	  beads	  were	  re-­‐suspended	  in	  300	  μL	  of	  wash	  buffer	  for	  flow	  cytometry	  analysis.	  
2.17.4 Sample	  acquisition	  and	  analyses	  All	  samples	  were	  acquired	  in	  the	  BD	  FACS	  CantoII	  flow	  cytometer	  using	  the	  BD	  FACS	  DIVA	  software.	  Compensation	  was	  performed	  using	   the	   instrument	  setup	  beads	   provided	   along	   with	   the	   Master	   Buffer	   Kit,	   to	   avoid	   spectral	   overlap.	  Standards	  were	  acquired	  starting	  from	  negative	  or	  0-­‐pg/mL	  to	  top	  standard	  or	  2000	  pg/mL	  followed	  by	  the	  plasma	  or	  supernatant	  samples.	  Files	  were	  saved	  as	  FCS	  3.0	  and	  the	  results	  were	  analysed	  using	  the	  FCAP	  array	  software.	  
2.18 HL-­‐60	  cell	  culture	  The	   HL-­‐60	   cells	   were	   sourced	   from	   the	   American	   Type	   Culture	   Collection	  (ATCC).	   HL-­‐60	   cells	   are	   distributed	   as	   frozen	   aliquots	   of	   low	   passage	   cells	   in	  RPMI-­‐1640	   with	   10%	   glycerol	   and	   are	   stored	   in	   liquid	   nitrogen.	   Cells	   were	  thawed	  and	  re-­‐suspended	  in	  culture	  medium.	  To	  make	  the	  culture	  medium	  11.5	  mL	   of	   1M	   HEPES	   buffer,	   3	   mL	   of	   1M	   sodium	   hydroxide,	   5	   mL	   of	   Penicillin	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Streptomycin	   and	   500	   μL	   of	   Glutamine	  were	   added	   to	   1000	  mL	   of	   RPMI.	   The	  RPMI	  was	   then	   supplemented	  with	   20%	   fetal	   bovine	   serum	   (FBS).	   Cells	   were	  maintained	   initially	   in	   20%	  FBS,	   then	   transferred	   to	   10%	  FBS	   and	  maintained	  between	  0.1-­‐1	  million	  cells/mL.	  
2.19 HL-­‐60	  differentiation	  and	  characterisation	  Different	  concentrations	  of	  DMSO	  were	  used	  to	  induce	  neutrophil	  differentiation.	  After	  characterisation	  and	  examination	  of	  function	  data,	  the	  decision	  was	  made	  to	  use	  1.5%	  DMSO	  and	  examine	  cells	  at	  day	  6	  of	  exposure.	  	  The	  expression	  of	  CD14,	  CD16,	  CD11b,	  TLR2,	  TLR4,	  TLR9,	  CD181	  and	  CD182	  on	  the	   differentiated	   and	   non-­‐differentiated	   cells	   were	   examined	   by	   FACS	   as	  outlined	  earlier.	  The	   Phagotest	   and	   Phagoburst	   experiments	   were	   adapted	   for	   use	   on	   the	  differentiated	  cells.	  The	   function	   of	   differentiated	   HL-­‐60	   cells	   was	   also	   assessed	   following	   culture	  with	  ethanol	  in	  concentrations	  of	  10mM,	  50mM,	  100mM,	  250mM	  and	  500mM.	  In	  these	   experiments,	   hepatocyte	   (VL17A)	   metabolized	   ethanol	   was	   also	   used	  (courtesy	  of	  Dr	  Elena	  Palma	  Institute	  of	  Hepatology).	  
2.20 Evaluation	  of	  interferon	  lambda	  	  
2.20.1 High	  sensitivity	  IFN-­‐λ1	  ELISA	  HC	  and	  patient	  plasma	  were	  examined	  for	  IFN-­‐λ1	  using	  a	  sandwich	  ELISA,	  performed	  as	  per	  protocol	  (High	  sensitivity	  IFN-­‐λ1	  ELISA	  kit,	  R&D	  Systems,	  UK).	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2.20.2 Staining	  for	  lambda	  receptor	  in	  healthy	  control	  leucocyte	  subsets	  Two	  hundred	  μL	  of	  blood	  from	  HCs	  was	  drawn	  and	  100	  μL	  incubated	  with	  CD14,	  CD16,	   CD11b,	   CD3,	   CD56,	   CD19	   plus	   IL28	   receptor	   isotype	   or	   IL28	   receptor.	  After	   15	   minutes,	   samples	   were	   lysed	   and	   washed	   as	   described	   above,	   then	  examined	  using	  FACS.	  	  
2.20.3 Interferon	  lambda	  and	  HL-­‐60	  cells	  Differentiated	  and	  non-­‐differentiated	  HL-­‐60	  cells	  were	  stained	  for	  IL28	  receptor	  and	   examined	   using	   FACS.	   Differentiated	   HL-­‐60	   cells	   were	   incubated	   with	  recombinant	  IL29	  (100	  ng/mL)	  and	  phagocytosis	  tested	  as	  described	  earlier.	  
2.20.4 Healthy	  control	  stimulant	  optimisation	  1.5	  mL	  of	  HC	  blood	  was	   cultured	   in	   duplicates	  with	   either	   15	  μL	   of	   Pansorbin	  (1:1000),	  150	  μL	  of	   fixed	  E.	   coli	   (10	  bacteria/cell),	   75	  μL	  of	  Poly	   I:C	  or	  PBS	  as	  control.	   After	   2	   hours,	   one	   set	   of	   the	   above	   samples	   underwent	   neutrophil	  extraction	   using	   the	   MACSxpress	   Neutrophil	   Isolation	   Kit	   (2.9)	   providing	   a	  neutrophil	   fraction	   for	   RNA	   extraction.	   RNA	   was	   extracted	   directly	   from	   the	  other	  4	  samples	  using	  the	  Qiagen	  Blood	  Mini	  RNA	  kit	  (the	  leukocyte	  fraction).	  	  As	  neutrophils	  have	  a	  low	  RNA	  content	  [207],	  volumes	  of	  blood	  (and	  accordingly	  stimulant)	  were	  increased	  to	  8	  mL	  to	  increase	  the	  yield	  of	  neutrophil	  RNA.	  The	  leukocyte	  cultures	  were	  kept	  at	  1.5	  mL.	  
2.20.5 RNA	  extraction	  To	  extract	  RNA	  from	  isolated	  neutrophils	  and	  the	  HL-­‐60	  cells	  the	  Qiagen	  RNEasy	  Kit	  (74104,	  Qiagen,	  UK)	  was	  used,	  and	  to	  extract	  RNA	  from	  whole	  blood	  cultures	  the	  QIAamp	  RNA	  Blood	  Mini	  Kit	   (52304,	  Qiagen,	  UK)	  was	  used.	  Extracted	  RNA	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samples	   were	   concentrated	   with	   the	   RNeasy	   MinElute	   Cleanup	   Kit	   (74204,	  Qiagen,	  UK)	  according	  to	  manufacturer’s	  instructions.	  
2.20.6 PCR	  RNA	  was	  transcribed	  into	  cDNA	  using	  the	  QuantiTect	  Reverse	  Transcription	  Kit	  (205311,	  Qiagen,	  UK).	  Quantitative	  PCR	  was	   carried	  out	  using	   specific	  primers	  and	  probes	  for	   interferon-­‐λ1,	   interferon-­‐λ2/3,	   interferon-­‐λ	  receptor	  and	  RPLP0	  as	  endogenous	  control	   (Applied	  Biosystems,	  ThermoFisher	  Scientific,	  UK).	  Fifty	  nanograms	   of	   cDNA	   were	   used	   per	   reaction.	   Reactions	   were	   performed	   in	  duplicate	   on	   an	   ABI	   7500	   TaqMan.	   Relative	   mRNA	   amounts	   were	   quantified	  using	  the	  ΔΔCt	  method	  with	  normalization	  to	  RPLP0	  gene	  expression.	  
2.20.7 Investigation	  of	  interferon	  lambda	  and	  neutrophil	  function	  in	  ALD	  	  Patients	   with	   ARC	   were	   recruited.	   Plasma	   was	   obtained	   by	   centrifugation	   at	  3000g	   for	   10	   minutes	   at	   4°C	   and	   stored	   at	   -­‐80°C	   for	   subsequent	   cytokine	  analyses	  by	  Cytokine	  Bead	  Array	  (CBA)	  or	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA).	  Whole	  blood	  was	   incubated	  with	   fixed	  E.	  coli	   (strain	  DH5α,	   grown	   in	  LB	  broth	  and	  fixed	  with	  1%	  paraformaldehyde	  in	  sterile	  phosphate	  buffered	  saline,	  PBS)	  at	  a	  concentration	  of	  10	  bacteria/cell	  or	  PBS	  (unstimulated)	  at	  37°C	  for	  2	  hours.	  Two	  parallel	   cultures	  were	   set	   up	   and	   after	   2	   hours	  neutrophils	  were	   isolated	  immediately	  as	  described	  previously	  for	  RNA	  extraction,	  supernatants	  collected	  and	  the	  whole	  blood	  fractions	  (both	  stimulated	  and	  unstimulated)	  were	  stored	  in	  RNAprotect	  Cell	  Reagent	   (Qiagen,	  UK)	  at	   -­‐80°C	   for	   subsequent	  RNA	  extraction.	  RNA	  extraction	  and	  PCR	  were	  performed	  as	  described	  above.	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Patient	  whole	  blood	  was	  incubated	  individually	  with	  recombinant	  interferon-­‐λ1,	  interferon-­‐λ2	   or	   interferon-­‐λ3	   at	   a	   concentration	   of	   100ng/mL	   (R&D	   Systems,	  UK)	   for	  2	  hours	   at	  37°C.	  PBS	  was	  used	  as	  negative	   control.	   Supernatants	  were	  collected	   by	   centrifugation	   and	   stored	   at	   -­‐80°C	   for	   subsequent	   cytokine	  quantification.	   Fluorochrome-­‐conjugated	   antibodies	   (anti-­‐human	  CD182,	   PSGL-­‐1,	  CD11b,	  TLR4,	  TLR2,	  CD16,	  CD14,	  CD62L;	  BD	  Biosciences,	  UK;	  eBioscience,	  UK)	  were	   used	   for	   staining	   and	   analysed	   by	   flow	   cytometry.	   Phagotest	   and	  Phagoburst	  kits	  were	  used	  to	  measure	  neutrophil	  phagocytosis	  and	  production	  of	  reactive	  oxygen	  species	  pre-­‐	  and	  post-­‐culture	  with	  interferon-­‐λ.	  High	  sensitivity	  IL29	  ELISA	  was	  performed	  on	  plasma	  and	  supernatant	  samples.	  
2.21 Statistical	  analyses	  Patient	  demographics	  are	  expressed	  as	  median	  (inter-­‐quartile	  range),	  frequency	  (percentage)	  as	  appropriate.	  Data	  were	  analysed	  using	  independent	  or	  paired	  t	  test,	  analysis	  of	  variance	  or	  non-­‐parametric	  tests	  where	  appropriate.	  Pearson	  or	  Spearman	  rank	  correlations	  were	  used	  as	  appropriate.	  Statistics	  were	  calculated	  using	  MS	  Excel	  2010,	  SPSS	  21	  or	  GraphPad	  Prism	  6.	  p	  value	   less	  than	  0.05	  was	  considered	  as	  statistically	  significant.	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3 	  Neutrophil	   phenotype,	   function	   and	   responses	   to	  
bacterial	  challenge	  in	  alcohol-­‐related	  liver	  disease	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3.1 Background	  As	  outlined	  in	  chapter	  1,	  neutrophil	  dysfunction	  has	  been	  recognized	  in	  AAH	  and	  ARC	  for	  some	  time.	  The	  risk	  of	  exacerbating	  the	  underlying	   inflammatory	  state	  has	   been	   one	   of	   the	  main	   concerns	   in	   the	   development	   of	   immunotherapeutic	  approaches	   in	   AAH.	   Likewise,	   anti-­‐inflammatory	   therapies	   may	   render	  individuals	  progressively	  immunosuppressed	  and	  this	  difficult	  dynamic	  remains	  a	   challenge.	   Neutrophil	   function	   was	   therefore	   examined	   alongside	   plasma	  cytokine	  determination	  with	  the	  aim	  of	  providing	  a	  comprehensive	  profile	  of	  the	  changes	  seen	  in	  AAH	  patients	  at	  admission.	  The	  comparative	  groups	  used	  were	  HCs,	  and	  patients	  with	  ARC.	  For	  some	  analyses	  the	  latter	  group	  were	  divided	  into	  those	  who	  were	  actively	  drinking	  and	  those	  who	  were	  abstinent	  from	  alcohol	  to	  provide	  further	  information	  on	  the	  impact	  of	  active	  alcohol	  consumption	  on	  the	  parameters	  examined.	  The	  neutrophil	   response	   to	  LPS	  was	  examined	   to	  mimic	  an	  infective	  insult	  or	   ‘second	  hit’	  frequently	  seen	  in	  these	  groups	  of	  patients.	  In	  addition,	   the	   inhibitory	   checkpoints	   PD1	   and	   TIM-­‐3,	   described	   in	   1.3.5,	   were	  examined	  on	  innate	  and	  adaptive	   immune	  compartments,	   the	  relationship	  with	  LPS	   and	   effect	   of	   blockade	   of	   these	   receptors	   on	   neutrophil	   function	  was	   also	  specifically	  evaluated.	  
3.2 Aim	  of	  the	  investigation	  To	  characterize	  neutrophil	  phenotype	  and	  responses	  ex	  vivo	  to	  bacterial	  and	  LPS	  challenge	   in	   patients	   with	   AAH	   compared	   with	   patients	   with	   ARC	   and	   HCs.	  Neutrophil	   phagocytosis,	   stimulated	   oxidative	   burst,	   plasma	   endotoxin	   levels,	  and	   neutrophil	   receptor	   response	   and	   cytokine	   production	   following	   LPS	  exposure	  were	  examined.	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To	   evaluate	   peripherally	   circulating	   neutrophils	   as	   contributors	   to	   hepatic	  damage	   and	  multi-­‐organ	   failure	   in	  AAH	   compared	  with	   patients	  with	  ARC	   and	  HCs.	  Neutrophil	  resting	  burst,	  cell	  surface	  receptor	  changes,	  plasma	  lactoferrin,	  cytokine	  and	  endothelial	  activation	  markers	  were	  examined.	  To	   evaluate	   whether	   any	   defects	   in	   neutrophil	   function	   had	   reversibility	  following	   the	   examination	   and	   blockade	   of	   the	   immune	   inhibitory	   checkpoints	  PD1	  and	  TIM-­‐3.	  
3.3 Methods	  
3.3.1 Patients	  and	  study	  design	  A	  prospective	   cohort	   study	  was	   performed	  on	  patients	   presenting	  with	   severe	  AAH	  as	  described	  in	  2.3.	  ARC	  patients	  and	  HCs	  were	  also	  recruited	  as	  described.	  	  
3.3.2 Neutrophil	  phenotype	  Baseline	  neutrophil	  phenotype	  was	  characterised	  by	  determining	  the	  expression	  of	   CD16,	   CD11b,	   TLR2,	   TLR4	   and	   TLR9	   in	   granulocytes	   isolated	   from	   whole	  blood	  after	  erythrocyte	  lysis	  as	  described	  in	  2.11.	  
3.3.3 Neutrophil	  function	  Baseline	   neutrophil	   phagocytosis	   and	   oxidative	   burst	   were	   characterised	   as	  described	  in	  2.12	  and	  2.13.	  
3.3.4 Endotoxin	  analyses	  The	   Toxisensor	   Chromogenic	   Limulus	   Amoebic	   Lysate	   (LAL)	   Endotoxin	   Assay	  (Genscript,	  UK)	  was	  used	  to	  measure	  the	  endotoxin	  levels	  in	  the	  plasma	  samples	  stored	  at	  -­‐80°C.	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3.3.5 Lipopolysaccharide	  stimulation	  As	   described	   in	   2.14,	   whole	   blood	   was	   incubated	   at	   37°C	   with	   Roswell	   Park	  Memorial	   Institute	   (RPMI)-­‐1640	  media	   and	   stimulated	  with	   either	   LPS	   (E.	   coli	  0111:B4)	   (200ng/mL)	  or	  with	  PBS	   in	   controls	   for	  2	  hours	   (unstimulated).	  The	  stimulated	   cells	   were	   then	   stained	   and	   analysed	   by	   flow	   cytometry.	   The	  supernatants	  of	  the	  stimulated	  cells	  were	  carefully	  collected	  and	  stored	  at	  -­‐80°C	  for	  subsequent	  cytokine	  analysis.	  	  
3.3.6 Lactoferrin	  quantification	  Sandwich	   ELISA	  was	   performed	   as	   per	   protocol,	   using	   a	   Lactoferrin	   ELISA	   kit	  (Merck	  Millipore,	  Germany).	  
3.3.7 Analyses	  of	  cytokines	  and	  endothelial	  markers	  Pro-­‐	  and	  anti-­‐inflammatory	  cytokines	  [IL-­‐8,	  IL-­‐6,	  IL-­‐10,	  TNF-­‐α,	  GCSF]	  levels	  and	  endothelial	   activation	   markers	   [VCAM-­‐1,	   ICAM-­‐1,	   E-­‐selectin,	   L-­‐selectin,	   VEGF]	  were	   determined	   in	   previously	   stored	   plasma	   and	   supernatant	   samples	   using	  CBA	  as	  described	  in	  2.17.	  
3.3.8 The	  effect	  of	  Programmed	  cell	  death	  1	  (PD1)	  and	  T-­‐cell	  immunoglobulin	  and	  
mucin	  domain-­‐containing	  protein	  3	  (TIM3)	  blockade	  on	  neutrophil	  function	  Expression	   of	   PD1/PDL1	   and	   TIM3/galectin-­‐9	   were	   assessed	   by	   FACS	   on	  immune	   cell	   subsets	   in	   whole	   blood	   and	   PBMCs.	   For	   blocking	   experiments,	  neutrophils	  were	  pre-­‐	  incubated	  with	  10	  mg/mL	  anti–TIM3	  and	  anti–PD1	  for	  4	  hours	   at	   370C/5%	   CO2	   and	   Phagotest	   and	   Phagoburst	   (Orpegen	   Pharma,	  Germany)	   were	   adapted	   for	   use	   in	   96-­‐well	   plates	   and	   analyzed	   by	   FACS	  according	   to	   previously	   described	   protocols.	   CBA	   was	   performed	   on	   PBMC	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culture	   supernatants	   for	   production	   of	   IL-­‐2,	   IL-­‐4,	   IL-­‐5,	   IL-­‐6,	   IL-­‐8,	   IL-­‐10,	   TNF-­‐α	  and	  interferon	  gamma	  as	  previously	  described.	  	  
3.4 Results	  
3.4.1 Study	  population	  Thirty-­‐one	   patients	   with	   severe	   AAH	  were	   recruited.	   Thirty-­‐one	   patients	   with	  ARC	  were	   recruited,	   sixteen	  were	   actively	   drinking	   (AA),	   fifteen	   patients	  were	  abstinent	  (ABA),	  defined	  as	  no	  consumption	  of	  alcohol	  for	  greater	  than	  6	  months.	  Ten	   HC	   were	   analysed	   (Figure	   3.1.)	   The	   HC	   were	   recruited	   from	   within	   the	  department,	  these	  subjects	  were	  not	  age-­‐matched	  to	  the	  disease	  groups	  and	  this	  is	  discussed	  further	  in	  3.5.	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Figure	  3.1	  Patient	  groups,	  analyses	  performed	  and	  time	  points	  of	  sequential	  analyses	  in	  the	  
alcoholic	  hepatitis	  cohort.	  	  9	  patients	  had	  ‘paired’	  analyses	  where	  both	  neutrophil	  function	  and	  TLRs	  were	  both	  assessed.	  	  
98	  	  
	  
Table	  3-­‐1	  Demographic	  and	  clinical	  data	  for	  patients	  studied	  
Parameters	  
Median	  (IQR)	   HC	  (n=10)	   AAH	  (n=31)	   AA	  (n=16)	   ABA	  (n=15)	  Age	   36	  (29-­‐44)	   49	  (34-­‐60)	   51	  (44-­‐54)	   56	  (48-­‐60)	  Female	  (%)	   4	  (40%)	   17	  (55%)	   5	  (31%)	   6	  (40%)	  Bilirubin	  (3-­‐20	  μmol/L)	   	   247	  (116-­‐401)	   34	  ****	  (20-­‐84)	   27	  ****	  (18-­‐33)	  Albumin	  	  (35-­‐50	  g/L)	   	   27	  (25-­‐29)	   28	  (25-­‐38)	   32	  **	  (28-­‐37)	  INR	  	  (0.9-­‐1.2	  ratio)	   	   1.9	  (1.7-­‐2.3)	   1.6	  *	  (1.2-­‐1.7)	   1.3	  ****	  (1.2-­‐1.6)	  Creatinine	  (45-­‐120	  μmol/L)	   	   63	  (50-­‐127)	   61	  (48-­‐72)	   64	  (52-­‐78)	  Sodium	  (135-­‐145	  mmol/L)	   	   135	  (132-­‐137)	   139	  *	  (135-­‐142)	   133	  (130-­‐139)	  Total	   white	   blood	  cell	  count	  	  (4.0-­‐11.0	  x	  109/L)	   	   9.7	  (6.7-­‐17.4)	   5.6	  **	  (3.9-­‐8.7)	   4.6	  ****	  (2.9-­‐7.3)	  Neutrophil	  count	  (2.2-­‐6.3	  x	  109/L)	   	   7.8	  (4.8-­‐16.3)	   3.5	  **	  (2.2-­‐6.3)	   3.3	  ***	  (2.2-­‐5.2)	  Lymphocyte	  count	  (1.3-­‐4	  x	  109/L)	   	   1.2	  (1.1-­‐1.9)	   1.2	  (0.9-­‐1.9)	   1.0	  (0.7-­‐1.7)	  Ascites	  	  (Median	  Child	  Pugh	  grade)	   	   20	  (65%)	  (2)	   12	  (75%)	  (2)	   9	  (60%)	  (3)	  Hepatic	  encephalopathy	  (Median	  Child	  Pugh	  grade)	   	   10	  (32%)	  	  (1)	   7	  (44%)	  	  (1)	   6	  (40%)	  	  (1)	  Child	  Pugh	  score	  (Grade	  A,	  B,	  C)	   	   11	  (0,	  8,	  23)	   9	  (3,	  6,	  7)	   8	  ***	  (4,	  8,	  3)	  DF	   	   53	  (40-­‐70)	   NA	   NA	  MELD	   	   25	  (22-­‐29)	   14	  ****	  (11-­‐18)	   12	  ****	  (9-­‐13)	  Positive	   bacterial	  culture	  	   	   6	  (19%)	   7	  (44%)	   3	  (20%)	  Positive	   fungal	  culture	  	   	   8	  (26%)	   3	  (19%)	   0	  1-­‐month	  mortality	   	   5/28	  (18%)	  (3	   patients	   excluded,	  data	  unknown)	   2/16	  (13%)	   0	  3-­‐month	  mortality	   	   6/26	  (23%)	  (5	   patients	   excluded,	  data	  unknown)	   2/11	  (18%)	  (5	   patients	   excluded,	  data	  unknown)	   0	  (3	   patients	   excluded,	  data	  unknown)	  6-­‐month	  mortality	   	   9/24	  (38%)	  (7	   patients	   excluded,	  data	  unknown)	   2/11	  (18%)	  (5	   patients	   excluded,	  data	  unknown)	   1/9	  (11%)	  (6	   patients	   excluded,	  data	  unknown)	  	  	  	  *-­‐	  compared	  to	  AAH,	  *	  -­‐	  p<0.05,	  **	  -­‐	  p<0.01,	  ***	  -­‐	  p<0.005,	  ****	  -­‐	  p<0.0001	  
	  -­‐	  1	  patient	  transplanted	  
	  -­‐	  up	  to	  6	  months	  post-­‐sampling	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  Abbreviations:	  Acute	  Alcoholic	  Hepatitis:	  AAH;	  Alcohol-­‐related	  cirrhosis	  active-­‐drinkers:	  AA;	  Alcohol-­‐related	   cirrhosis	   abstinent	   patients:	   ABA;	   International	   Normalised	  Ratio:	  INR;	  Discriminant	  function:	  DF;	  Model	  for	  End-­‐stage	  Liver	  Disease:	  MELD	  	  	  
Table	  3-­‐2	  Further	  clinical	  information	  on	  the	  ARC	  cohort	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Table	  3-­‐3	  Bacterial	  and	  fungal	  isolates	  from	  patient	  cohorts	  







3.4.2 CD16	  and	  CD11b	  expression	  Baseline	   neutrophil	   surface	   receptor	   expression	   of	   the	   FcγRIII	   molecule	   CD16	  and	   the	  β-­‐integrin	  CD11b	   (C3bi)	  were	  determined	   amongst	   the	  patient	   groups	  and	   HC.	   CD16	   expression	   was	   significantly	   reduced	   in	   AAH	   patients	   and	   ARC	  patients	  compared	  to	  HC	  (p<0.05)	  (Figure	  3.2	  and	  3.3).	  There	  was	  no	  difference	  in	  the	  CD11b	  expression	  in	  patients	  compared	  to	  HC	  (Figure	  3.4).	  




Figure	   3.2	   Decreased	   circulating	   neutrophil	   CD16	   expression	   in	   patients	   with	   AAH	   and	   ARC	  
compared	  to	  HC.	  	  CD16	  was	   significantly	   decreased	   in	  ARC	   and	  AAH	   compared	   to	  HC	   (*	   -­‐	   compared	   to	  HC;	   **	   -­‐	   p<0.01,	   *	   -­‐	  p<0.05).	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data.	  
	  	  
Figure	  3.3	  Decreased	  circulating	  neutrophil	  CD16	  expression	  in	  patients	  with	  AAH	  and	  ARC	  divided	  















































Figure	  3.4	  Circulating	  neutrophil	  CD11b	  receptor	  expression	  in	  AAH	  patients	  and	  ARC	  (divided	  into	  
those	  actively	  drinking	  and	  abstinent)	  compared	  to	  HC.	  	  There	   was	   no	   difference	   in	   the	   CD11b	   expression	   in	   patients	   compared	   to	   HC.	   Kruskal-­‐Wallis	   test	   with	  Dunn’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data.	  	  	  	   	  




























Figure	   3.5	   Decreased	   circulating	   neutrophil	   TLR2	   expression	   in	   patients	   with	   AAH	   and	   ARC	  
compared	  to	  HC.	  	  TLR2	  was	   significantly	   decreased	   in	  ARC	   and	  AAH	   compared	   to	  HC	   (*	   -­‐	   compared	   to	  HC;	   **	   -­‐	   p<0.01,	   *	   -­‐	  p<0.05).	  Ordinary	  one-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data	  (normal	  data).	  
	  
Figure	  3.6	  Decreased	  circulating	  neutrophil	  TLR2	  expression	  in	  patients	  with	  AAH	  and	  ARC	  divided	  



















































Figure	   3.7	   Decreased	   circulating	   neutrophil	   TLR4	   expression	   in	   patients	   with	   AAH	   and	   ARC	  
compared	  to	  HC.	  	  TLR4	   expression	  was	   significantly	   decreased	   in	  ARC	   and	  AAH	   compared	   to	  HC	   (*	   -­‐	   compared	   to	  HC;	   **	   -­‐	  p<0.01).	  Ordinary	  one-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data	  (normal	  data).	  	  	  	  
	  	  
Figure	  3.8	  Decreased	  circulating	  neutrophil	  TLR4	  expression	  in	  patients	  with	  AAH	  and	  ARC	  divided	  
















































Figure	   3.9	   Increased	   circulating	   neutrophil	   TLR9	   expression	   in	   patients	   with	   AAH	   and	   ARC	  
compared	  to	  HC.	  	  TLR9	   expression	  was	   significantly	   increased	   in	   ARC	   and	  AAH	   compared	   to	  HC	   (*	   -­‐	   compared	   to	  HC;	   **	   -­‐	  p<0.01,*	  -­‐	  p<0.05).	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data.	  	  	  
	  
Figure	  3.10	  Increased	  circulating	  neutrophil	  TLR9	  expression	  in	  patients	  with	  AAH	  compared	  to	  HC.	  When	   ARC	   patients	   were	   divided	   into	   actively	   drinking	   and	   abstinent	   groups	   there	   was	   no	   significant	  difference	   between	   TLR9	   expression	   in	   these	   groups	   compared	   to	   controls.	   TLR9	   expression	   was	  significantly	  increased	  in	  AAH	  compared	  to	  HC	  (*	  -­‐	  compared	  to	  HC;	  **	  -­‐	  p<0.01).	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data.	  	  	  	  
















































3.4.4 Neutrophil	  phagocytosis	  Phagocytic	   capacity	   was	   confirmed	   to	   be	   significantly	   reduced	   in	   the	   patient	  groups	   compared	   to	   HC	   (Figure	   3.11	   and	   3.12).	   There	   was	   no	   significant	  difference	  seen	  between	  the	  AAH	  patients	  and	  those	  with	  ARC.	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Figure	  3.11	  Impaired	  neutrophil	  phagocytic	  capacity	  in	  patients	  compared	  to	  HC.	  	  Neutrophil	   phagocytic	   capacity	   expressed	   as	   FITC	   (labeled	   E.	   coli)	   mean	   fluorescence	   intensity	   was	  significantly	  reduced	  in	  both	  groups	  of	  patients	  compared	  to	  HC	  (*	  -­‐	  compared	  to	  HC;	  *	  -­‐	  p<0.05).	  Ordinary	  one-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data	  (normal	  data).	  	  
	  
Figure	   3.12	   Impaired	   neutrophil	   phagocytic	   capacity	   in	   patients	   with	   AAH	   and	   ARC	   divided	   into	  












































3.4.5 Neutrophil	  oxidative	  burst	  Resting	  burst	  was	  found	  to	  be	  significantly	  elevated	  in	  the	  AAH	  group	  compared	  to	  HC.	  The	  difference	  observed	  between	  HC	  and	  ARC,	  and	  ARC	  and	  AAH	  did	  not	  reach	  significance	  (Figures	  3.13	  and	  3.14).	  There	  was	  significant	  variation	  within	  the	  groups	  and	  this	  is	  discussed	  further	  in	  the	  final	  chapter.	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Figure	   3.13	   Resting	   neutrophil	   oxidative	   burst	   expressed	   as	   Rhodamine	   mean	   fluorescence	  
intensity.	  	  Resting	  neutrophil	  ROS	  production	  was	  found	  to	  be	  significantly	  higher	  in	  AAH	  patients	  compared	  to	  HC.	  (*	  -­‐	  compared	  to	  HC;	  *	  -­‐	  p<0.05,	  HC	  vs	  ARC	  p=0.26.)	  If	  the	  outlier	  within	  the	  ARC	  group	  is	  removed	  this	  does	  not	   significantly	   alter	   the	   statistical	   findings.	   Kruskal-­‐Wallis	   test	   with	   Dunn’s	   multiple	   comparisons	   test	  were	  used	  to	  analyse	  the	  data.	  	  	  
	  
Figure	   3.14	   Resting	   neutrophil	   oxidative	   burst	   expressed	   as	   Rhodamine	   mean	   fluorescence	  
























































On	  examination	  of	   low	  burst	   (fMLP	   stimulation),	   high	  burst	   (PMA	  stimulation)	  and	   phagoburst	   (E	  coli	  stimulation)	   (Methods	   2.13.1),	   there	  was	   no	   significant	  difference	  seen	  between	  the	  groups.	  	  
3.4.6 Endotoxin	  One	   of	   the	   distinguishing	   factors	   between	   HC,	   ARC	   and	   AAH	   patients	   was	  increasing	   plasma	   endotoxin.	   Plasma	   endotoxin	   levels	   were	   significantly	  elevated	   in	  AAH	  compared	   to	  HC	   (p<0.001)	  and	   to	  ARC	   (p=0.024);	   levels	  were	  also	  significantly	  higher	  in	  ARC	  compared	  to	  HC	  (p=0.022).	  Levels	  were	  found	  to	  correlate	  with	   severity	  of	   disease	   as	  defined	  by	  MELD	   in	   all	   patients	   (r=0.520;	  p=0.018)	   and	   Maddrey’s	   discriminant	   function	   in	   the	   AAH	   cohort	   (r=0.571;	  p=0.021)	  (Figure	  3.15).	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Figure	  3.15	  Plasma	  endotoxin	  levels	  were	  significantly	  elevated	  in	  patient	  groups	  compared	  to	  HC.	  	  Endotoxin	   levels	   were	   found	   to	   correlate	   with	   disease	   severity	   as	   defined	   by	  MELD	   (r=0.520;	   p=0.018).	  Levels	   were	   significantly	   higher	   in	   AAH	   compared	   to	   ARC	   (p=0.024)	   and	   were	   found	   to	   correlate	   with	  disease	   severity	   as	   defined	   by	  Maddrey’s	   discriminant	   function	   (r=0.571;	   p=0.021).	   Spearman’s	   test	  was	  used	  to	  analyse	  the	  data.	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3.4.7 LPS	  stimulation	  Neutrophils	   from	   HC	   significantly	   up-­‐regulated	   TLR-­‐4	   receptor	   expression	   in	  response	  to	  challenge	  with	  LPS	  but	  the	  cirrhotic	  and	  AAH	  patients	  failed	  to	  do	  so	  (Figure	  3.16).	  
	  
Figure	  3.16	  Neutrophil	  TLR4	  expression	  pre-­‐	  and	  post-­‐LPS	  stimulation.	  	  HC	   significantly	   up-­‐regulated	   TLR4	   in	   response	   to	   LPS	   stimulation	   (p=0.02);	   the	   patient	   groups	   did	   not	  significantly	  up-­‐regulate	  TLR4	  following	  LPS	  culture.	  Paired	  t-­‐test	  was	  used	  to	  analyse	  the	  pre	  and	  post-­‐LPS	  data	  (normal	  data).	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3.4.8 Cytokine	  profiles	  The	  most	  notable	  findings	  from	  the	  baseline	  plasma	  cytokine	  profiling	  were	  the	  differences	   seen	   in	   IL-­‐6	   and	   IL-­‐8	   levels.	   Plasma	   IL-­‐8	   levels	   were	   significantly	  higher	  in	  ARC	  compared	  to	  HC	  (p=0.01)	  and	  found	  to	  be	  of	  a	  significantly	  higher	  level	   in	   AAH	   compared	   to	  HC	   (p<0.0001).	   A	   significant	   difference	  was	   seen	   in	  AAH	   compared	   to	   ARC	   (p<0.0001)	   (Figure	   3.17	   and	   3.18).	   Plasma	   IL-­‐6	   levels	  were	  significantly	  higher	  in	  ARC	  compared	  to	  HC	  (p=0.0003).	  Plasma	  IL-­‐6	  levels	  were	  significantly	  higher	  in	  AAH	  compared	  to	  HC	  (p<0.0001).	  Unlike	  circulating	  plasma	   IL-­‐8	   levels	   there	  was	  no	  difference	   in	   IL-­‐6	  when	  ARC	   and	  AAH	  patient	  groups	  were	  compared	  (Figure	  3.19	  and	  3.20).	  G-­‐CSF,	  IL-­‐10	  and	  TNF-­‐α	  were	  not	  detected	  in	  the	  baseline	  plasma	  AAH	  samples.	  	  Following	  2	  hour	  stimulation	  with	  LPS,	  plasma	  supernatant	  IL-­‐8	  and	  IL-­‐6	  levels	  were	  found	  to	  significantly	  increase	  (in	  order	  of	  100-­‐fold	  or	  greater)	  in	  the	  HCs.	  In	   the	   AAH	   cohort	   although	   basal	   levels	   of	   IL-­‐8	   and	   IL-­‐6	   were	   significantly	  higher,	   no	   such	   increase	  was	   seen.	  High	   levels	   appear	   to	   be	   observed	   at	   basal	  state	   perhaps	   relating	   to	   circulating	   endotoxin	   in	   this	   group,	   with	   subsequent	  lack	  of	  response	  on	  additional	  LPS	  challenge.	  	  Figures	  3.21	  and	  3.22	  represent	  the	  fold-­‐change	  in	  IL-­‐8	  and	  IL-­‐6	  pre-­‐	  and	  post-­‐culture	  with	  LPS.	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Figure	  3.17	  Increased	  circulating	  IL-­‐8	  levels	  in	  patients	  with	  AAH	  and	  ARC	  compared	  to	  HC.	  	  Plasma	  IL-­‐8	  (pg/mL)	  measured	  using	  CBA	  was	  significantly	  increased	  in	  ARC	  compared	  to	  HC	  (p=0.01).	  IL-­‐8	  levels	   were	   found	   to	   be	   significantly	   elevated	   in	   AAH	   compared	   to	   HC	   (p<0.0001)	   and	   ARC	   (p<0.0001).	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data.	  	  
	  
Figure	  3.18	  Increased	  circulating	  IL-­‐8	  levels	  in	  patients	  with	  AAH	  and	  actively	  drinking	  ARC	  patients	  





































Figure	  3.19	  Increased	  circulating	  IL-­‐6	  levels	  in	  patients	  with	  AAH	  and	  ARC	  compared	  to	  HC.	  	  Plasma	  IL-­‐6	  (pg/mL)	  measured	  using	  CBA	  was	  significantly	  increased	  in	  ARC	  compared	  to	  HC	  (p=0.0003).	  IL-­‐8	  levels	  were	  found	  to	  be	  significantly	  elevated	  in	  AAH	  compared	  to	  HC	  (p<0.0001).	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data.	  	  
	  
Figure	   3.20	   Increased	   circulating	   IL-­‐6	   levels	   in	   patients	   with	   AAH	   and	   actively	   drinking	   and	  



































Figure	   3.21	   IL-­‐8	   fold	   change	   pre-­‐	   and	   post-­‐LPS	   stimulation	   in	   patient	   groups	   (left)	   and	   patient	  
groups	  and	  HC	  (right).	  	  The	  fold	  change	  was	  significantly	  lower	  in	  the	  AAH	  group	  compared	  to	  actively	  drinking	  cirrhotic	  patients	  (p<0.05)	  and	   compared	   to	   abstinent	   cirrhotic	  patients	   (p<0.01).	  Kruskal-­‐Wallis	   test	  with	  Dunn’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data.	  	  	  	  
	  
Figure	   3.22	   IL-­‐6	   fold	   change	   pre-­‐	   and	   post-­‐LPS	   stimulation	   in	   patient	   groups	   (left)	   and	   patient	  
groups	  and	  HC	  (right).	  	  The	  fold	  change	  was	  significantly	  lower	  in	  the	  AAH	  group	  compared	  to	  actively	  drinking	  cirrhotic	  patients	  (p<0.05).	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  multiple	  comparisons	  test	  were	  used	  to	  analyse	  the	  data.	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3.4.9 Lactoferrin	  Plasma	   lactoferrin,	   released	   from	   secondary	   granules	   in	   neutrophils,	   was	  significantly	  increased	  in	  the	  AAH	  patients	  compared	  to	  cirrhotics	  without	  AAH	  (p<0.005)	   and	   HC	   (p<0.0001)	   (Figure	   3.23).	   There	   was	   a	   positive	   correlation	  between	   plasma	   lactoferrin	   and	   plasma	   IL-­‐8	   in	   AAH	   patients	   (r=0.74)	   (Figure	  3.24).	  	  
	  
































































































































3.4.11 Effect	  of	  PD1/TIM3	  blockade	  on	  neutrophil	  function	  This	  work	  was	  done	   in	   collaboration	  with	  Lee	  Markwick	  at	   the	  Foundation	   for	  Liver	  Research	  [78].	  A	  marked	  increase	  in	  the	  expression	  of	  PD1	  (p=0.036)	  and	  galectin-­‐9	   (p=0.36)	   was	   found	   on	   CD4	   T	   cells	   in	   AAH	   compared	   with	   healthy	  controls.	   On	   CD8	   T	   cells,	   increased	   expression	   of	   PDL1	   (p=0.041),	   TIM3	  (p=0.042),	   and	   galectin-­‐9	   (p=0.037)	  were	   also	   observed.	   This	  was	   not	   seen	   in	  ARC.	   In	   AAH,	   but	   not	   in	   ARC,	   an	   increase	   in	   the	   frequency	   of	   LPS-­‐challenged	  PBMC	   producing	   IL-­‐10	   (p=0.020)	  was	   found	   compared	  with	  HC.	   Conversely,	   a	  marked	   decrease	   in	   the	   frequency	   of	   LPS-­‐challenged	   PBMC	   producing	   IFN	  gamma	  (p=0.001)	  was	  found.	  Expressed	  as	  a	  ratio	  (IFN	  gamma/IL-­‐10),	  there	  was	  a	   skew	   in	   the	  LPS-­‐mediated	   immune	   response	   in	  AAH	  compared	  with	  patients	  with	   ARC	   (p=0.026)	   and	   HC	   (p=0.004),	   demonstrating	   that	   the	   antibacterial	  immunity	   of	   PBMCs	   is	   skewed	   in	   AAH	   toward	   an	   immunosuppressive	   IL-­‐10-­‐dominated	   response,	   perhaps	   reflective	   of	   a	   CARS	   predominant	   phase.	  Concentrations	   of	   endotoxin	   observed	   in	   AAH	   were	   found	   to	   induce	  hyperexpression	   of	   PD1	   and	   TIM3	   on	   HC	   Tregs,	   CD4	   and	   CD8	   cells.	   	   In	   AAH,	  inhibition	  of	  PD1/TIM3	  increased	  the	  frequency	  of	  bacterially	  challenged	  PBMC	  producing	   IFN	   gamma	   (p=0.048)	   and	   reduced	   IL-­‐10-­‐producing	   PBMCs	  (p=0.002).	   In	   AAH,	   ex	   vivo	   treatment	   of	   whole	   blood	  with	   anti–PD1	   and	   anti–TIM3	  blocking	  antibodies	  enhanced	  neutrophil	  phagocytosis/ingestion	  capacity	  (p=0.005)	  (Figure	  3.30).	  Spontaneous	  oxidative	  burst	  remained	  unchanged	  and	  the	  production	  of	  IL-­‐1β,	  IL-­‐6,	  IL-­‐8	  and	  TNF-­‐α	  was	  not	  provoked	  by	  treatment.	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Figure	  3.30	  Neutrophil	  phagocytosis	  pre-­‐	  and	  post-­‐	  blockade	  of	  PD-­‐1	  and	  TIM-­‐3.	  	  Ingestion	   capacity	  was	   significantly	   increased	   following	   treatment	  with	   anti-­‐PD1	   and	   anti-­‐TIM3	   blocking	  antibodies.	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3.5 Discussion	  	  In	  this	  study	  neutrophils	  from	  AAH	  patients	  were	  confirmed	  to	  be	  activated	  with	  evidence	   of	   increased	  production	   of	  ROS	   and	   lactoferrin	   release.	   Resting	   burst	  was	  only	  found	  to	  be	  significantly	  elevated	  in	  the	  AAH	  group;	  this	  is	   in	  keeping	  with	  previously	  published	  data	  [154].	   Interestingly,	  a	  significant	  difference	  was	  observed	   in	   circulating	   lactoferrin	   levels	   between	   the	   AAH	   and	   ARC	   groups.	  Plasma	   IL-­‐8,	   a	   potent	   neutrophil-­‐attracting	   chemokine,	   was	   significantly	  increased	   in	  AAH	  patients	  compared	  to	  HC	  and	  cirrhotics	  as	  previously	  seen	   in	  multiple	   studies	   [208].	   IL-­‐8	   was	   found	   to	   directly	   correlate	   with	   plasma	  lactoferrin.	  Lactoferrin	  levels	  did	  not	  correlate	  with	  disease	  severity,	  as	  defined	  by	  Maddrey’s	  discriminant	   function;	   sequential	   analyses	   and	  outcome	  data	   are	  discussed	  further	  in	  chapter	  4.	  	  	  Liver	   biopsies	   were	   not	   routinely	   performed	   to	   confirm	   the	   diagnosis	   of	   AAH	  and,	   accepting	   that	   the	   issue	   of	   biopsy	   in	   clinical	   practice	   in	   AAH	   remains	  contentious,	   the	   benefits	   of	   doing	   this	   within	   this	   study	   would	   have	   been	  numerous.	   It	   is	   possible	   that	   some	   patients	   with	   ARC	   did	   have	   superimposed	  AAH	   and	   histological	   specimens	   would	   have	   provided	   additional	   important	  research	   material.	   The	   patients	   were,	   however,	   screened	   carefully	   and	   the	  clinical	  inclusion	  and	  exclusion	  criteria	  for	  the	  STOPAH	  study	  were	  applied.	  	  	  	  It	  would	  be	  interesting	  to	  study	  neutrophils	  that	  hone	  to	  the	  liver	  in	  AAH	  and	  we	  do	   not	   know	   if	   the	   findings	   on	   the	   peripherally	   circulating	   neutrophils	   are	  replicated	  on	  those	  within	  the	  liver.	  This	  would	  be	  valuable	  to	  explore	  but	  would	  require	  fresh	  liver	  tissue	  samples;	  portal	  vein	  neutrophil	  analyses	  could	  also	  be	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compared	  to	  peripheral	  samples	  and	  cross-­‐liver	  sampling	  during	  hepatic	  venous	  pressure	  gradient	  studies	  could	  be	  performed.	  In	  addition,	  further	  work	  into	  NET	  formation	  in	  AAH	  may	  be	  of	  value.	  In	  recent	  work	  in	  mice	  it	  has	  been	  shown	  that	  after	  MRSA	  infection,	  bacteria	  are	  captured	  by	  Kupffer	  cells	  residing	  in	  the	  liver,	  subsequently	   recruited	   neutrophils	   release	   NETs	   into	   the	   vasculature	   in	   an	  attempt	   to	   eradicate	   the	   pathogen.	   It	   was	   found	   that	   the	  majority	   of	   the	   liver	  injury	  was	  induced	  by	  the	  NETs	  and	  when	  NET	  production	  was	  blocked,	  damage	  was	  ameliorated	  [144].	  Interestingly,	  lactoferrin	  is	  also	  believed	  to	  be	  one	  of	  the	  components	  of	  NETs	  and	  is	  thought	  to	  inhibit	  NET	  formation	  [209].	  Perhaps	  the	  release	   of	   lactoferrin	   from	  peripherally	   circulating	  neutrophils,	   responsible	   for	  the	   high	   plasma	   levels	   observed	   in	   my	   work,	   allows	   the	   persistence	   of	   NETs	  within	  the	  liver	  in	  AAH	  as	  honing	  neutrophils	  may	  be	  functionally	  deplete	  in	  this	  protein.	  We	  have	  shown	  that	  neutrophil	  granule	  release	  is	  dysregulated	  in	  ARC	  [210],	   this	   may	   be	   of	   even	   greater	   importance	   in	   AAH.	   Further	   work	   on	   liver	  tissue,	   including	   neutrophil	   elastase	   and	   myeloperoxidase	   assessment,	   may	  allow	   this	   to	   be	   elaborated	   upon.	   Strategies	   that	   inhibit	   NET	   production	   or	  induce	  the	  shedding	  of	  anchor	  molecules,	  such	  as	  von	  Willebrand	  Factor,	  might	  prevent	  the	  ongoing	  tissue	  damage	  seen	  in	  AAH	  and	  other	  liver	  conditions.	  The	  trigger	   of	   AAH,	   and	   particularly	   whether	   there	   is	   an	   infective	   trigger	   that	  precipitates	   the	   cascade	   of	   damage	   also	   warrants	   further	   exploration.	   This	  concept,	  I	  believe,	  is	  further	  supported	  by	  the	  finding	  that	  >90%	  of	  AAH	  patients	  in	   Vergis	   et	  al’s	  study	   had	   detectable	   bacterial	   DNA	   levels,	   a	   rate	   substantially	  higher	  than	  seen	  in	  HCs,	  patients	  with	  bloodstream	  infections,	  and	  patients	  with	  other	  forms	  of	  decompensated	  liver	  disease	  [97].	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High	  circulating	  endotoxin	  levels	  were	  confirmed	  in	  the	  patient	  groups	  studied;	  these	  were	  of	   a	   greater	   level	   in	  AAH	  and	  were	   found	   to	   correlate	  with	  disease	  severity.	  Neutrophil	   antibacterial	   activities	   and	   key	   detecting	   receptors	   (TLRs)	  were	  found	  to	  be	  dysfunctional	  in	  the	  patient	  groups.	  Across	  the	  entire	  spectrum	  of	   patients	   there	   appeared	   to	   be	   a	   blunted	   response	   to	   LPS.	   A	   possible	  explanation	  for	  this	  may	  be	  chronic	  sub-­‐clinical	  exposure	  to	  pathogen	  secondary	  to	  gut	  bacterial	   translocation	   in	  cirrhosis,	  which	   leads	  to	  a	  dampened	  response	  when	   a	   significant	   bacterial	   insult	   ensues.	   This	   finding	   does	   not	   appear	   to	   be	  specific	  to	  AAH	  and	  may	  have	  wider	  implications	  for	  cirrhosis	  of	  all	  causes.	  Gut	  modulation	  remains	  a	  key	  focus	  of	  investigation	  and	  our	  laboratory	  have	  further	  studies	  underway	  examining	  the	  effect	  of	  the	  non-­‐absorbable	  antibiotic	  rifaximin	  on	   neutrophil	   parameters.	   Unfortunately,	   it	   was	   not	   possible	   to	   meaningfully	  correlate	   endotoxin	  with	  neutrophil	   TLR4	   results	   due	   to	   the	   small	   numbers	   of	  patients	  with	  matched	  analyses	  and	  this	  would	  have	  been	  interesting	  to	  evaluate	  along	  with	  sequential	  endotoxin	  analyses	  in	  the	  entire	  group	  of	  patients.	  	  Only	  patients	  with	  ALD	  were	  studied	  and	  this	  was	  because	  the	  group	  of	  interest	  were	   those	  with	   AAH	   and	   the	   ARC	   /	  HCs	  were	   used	   as	   comparators.	   It	  would	  have	   added	   to	   the	   study	   to	   have	   included	   patients	   with	   cirrhosis	   of	   other	  aetiology.	   In	   Taylor’s	   study	   aetiology	   of	   liver	   disease	   did	   not	   impact	   on	  neutrophil	   stimulated	   burst	   or	   phagocytosis,	   which	   was	   seen	   to	   decline	   with	  worsening	   severity	   of	   liver	   disease;	   alcohol	   was	   the	   most	   common	   cause	   of	  cirrhosis	   in	   these	   patients	   [152],	   mimicking	   a	   ‘real	   world’	   cohort	   of	   cirrhotic	  patients.	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The	   influence	   of	   active	   alcohol	   use	   did	   not	   appear	   to	   impact	   on	   neutrophil	  phenotype.	   Phagocytosis	   however	   was	   not	   as	   severely	   dampened	   in	   the	   ABA	  group.	  This	  may,	  in	  fact,	  be	  explained	  by	  the	  difference	  in	  Child-­‐Pugh	  scores	  and	  severity	  of	  liver	  disease	  as	  this	  was	  lower	  in	  the	  ABA	  compared	  to	  the	  AA	  group.	  It	   is	   difficult	   to	   comprehensively	   examine	   the	   impact	   of	   active	   alcohol	   use	   in	  these	   studies	   as	   there	   are	  many	   confounding	   factors,	   and	   patients	   need	   to	   be	  matched	   as	   closely	   as	   possible	   to	   draw	   any	   accurate	   conclusions.	   One	   of	   the	  drawbacks	  of	   the	   study	   is	   the	  heterogeneity	  of	   the	  patient	   cohorts	   and	   this,	   to	  some	  extent,	   is	  unavoidable	  in	  observational	  human	  studies	  such	  as	  mine.	  With	  increased	  patient	  numbers	   it	  would	  have	  been	  of	  use	  to	   further	  divide	  the	  ARC	  groups,	  again	  it	  has	  to	  be	  noted	  that	  these	  were	  a	  heterogeneous	  group.	  The	  HC	  also	  tended	  to	  be	  younger,	  it	  would	  have	  added	  to	  the	  work	  if	  these	  subjects	  had	  been	   more	   closely	   matched.	   In	   addition,	   the	   study	   of	   excess	   alcohol	   drinkers	  without	   evidence	   of	   liver	   disease	   or	   early	   fatty	   change	   would	   have	   provided	  further	  information	  on	  the	  direct	  impact	  of	  alcohol.	  In	  fact,	  future	  studies	  should	  include	   this	   group	   with	   large	   numbers	   so	   that	   the	   precipitants	   and	   disease	  triggers	  can	  be	  understood,	  this	  is	  discussed	  further	  in	  my	  final	  chapter.	  	  	  In	   contrast	   to	   neutrophil	   TLR2	   and	   TLR4	   expression,	   TLR9	   was	   found	   to	   be	  significantly	  increased	  in	  the	  AAH	  group.	  This	  is	  out	  of	  keeping	  with	  Stadlbauer’s	  data	  where	  TLR2,	  TLR4	  and	  TLR9	  were	  all	  found	  to	  be	  elevated	  [155].	  This	  may,	  in	   part,	   be	   explained	   by	   the	   different	   experimental	   techniques	   used;	   in	  Stadlbauer’s	   study	   normal	   neutrophils	   were	   incubated	   with	   plasma	   from	  patients	  with	  AAH.	  The	  reduced	  TLR2	  and	  TLR4	  expression	  is	  likely	  to	  culminate	  in	   reduced	   antibacterial	   surveillance,	   but	   why	   the	   neutrophils	   have	   reduced	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expression	  is	  not	  explained.	  The	  elevated	  intracellular	  TLR9	  expression	  may,	  on	  the	   other	   hand,	   be	   induced	   by	   high	   circulating	   DAMPS	   secondary	   to	  hepatocellular	   damage	   in	   AAH.	   In	   paracetamol-­‐induced	   acute	   liver	   failure	  neutrophil	   TLR9	   has	   been	   found	   to	   correlate	   with	   ammonia	   levels	   [211].	  Ammonia	   levels	   were	   not	   routinely	   checked	   on	   the	   patients	   I	   studied	   and,	   in	  retrospect,	  the	  relationship	  between	  ammonia	  and	  neutrophil	  TLR9	  would	  have	  been	   interesting	   to	   confirm	   in	   my	   patient	   cohorts,	   as	   would	   the	   effect	   on	  neutrophil	   TLR9	   following	   plasma	   exposure	   to	   various	   stimulants	   including	  ammonia.	   To	   some	   extent,	   time	   constraints	   limited	   further	   evaluation	   of	   TLR9	  and	   this,	  within	   the	   paradigm	  of	   sterile	   inflammation,	  would	   be	   an	   interesting	  area	  of	  study.	  
	  When	   soluble	   endothelial	  markers	  were	   examined,	   E-­‐selectin	  was	   found	   to	   be	  elevated	  across	  the	  spectrum	  of	  patients	  recruited,	  although	  levels	  tended	  to	  be	  higher	   in	   AAH	   there	   was	   no	   significant	   difference	   between	   the	   AAH	   and	   ARC	  groups.	   L-­‐selectin	   was	   only	   found	   to	   be	   increased	   in	   the	   ARC	   group.	   Perhaps	  surprisingly,	   VCAM1	   and	   ICAM1	  were	   reduced	   in	   AAH	   compared	   to	   ARC,	   it	   is	  important	   to	   highlight	   that	   tissue	   levels	   or	   expression	  were	   not	   examined	   and	  the	  temporal	  relationship	  of	  when	  patients	  present	  to	  hospital	  may,	  as	  with	  any	  interpretation,	  be	  of	   relevance	  here.	   It	  would	  have	  been	  of	   interest	   to	  examine	  the	  AAH	  neutrophils	  for	  chemokine	  receptors	  and	  cell-­‐adhesion	  molecules	  such	  a	  CD181	  and	  P-­‐selectin	  glycoprotein	  ligand-­‐1	  (PSGL-­‐1),	  and	  future	  studies	  should	  focus	   on	  neutrophil-­‐endothelial	   interaction	   to	   strengthen	   the	   understanding	   of	  the	  process	  of	  migration	  of	  neutrophils	  to	  the	  liver	  parenchyma.	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One	   of	   the	  most	   important	   findings	   demonstrated	   is	   the	   potential	   for	   immune	  dysfunction	   reversibility	   in	   this	   condition.	   The	   indirect	   improvement	   of	  PD1/TIM3	   blockade	   on	   neutrophil	   antibacterial	   responses	   in	   AAH	   through	  improved	  interferon	  gamma/IL-­‐10	  responses	  is	  of	  particular	  interest	  and	  reveals	  a	  previously	  unknown	  potential	  therapeutic	  target.	  Importantly	  this	  strategy	  did	  not	   aggravate	   factors	   associated	   with	   the	   inflammatory	   state	   in	   AAH.	   The	  immunosuppression	   rather	   than	   the	   initial	   cytokine	   storm	   may	   be	   the	  predominant	   driver	   of	   mortality	   in	   this	   group	   of	   patients	   and	   greater	  understanding	  of	  why	  certain	  patients	  appear	  to	  enter	  a	  harmful	  compensatory	  anti-­‐inflammatory	   response	   syndrome	   [107]	   is	   needed.	   The	   evolution	   of	   the	  disease	  state	  of	  AAH	  and	  impact	  of	  current	  therapies	  in	  use	  forms	  the	  basis	  of	  the	  next	  chapter.	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4 	  Longitudinal	   analyses	   of	   neutrophil	   function	   and	  
effect	   of	   current	   therapies	   on	   innate	   immune	  
function	  in	  acute	  alcoholic	  hepatitis	  
136	  	  
4.1 Background	  It	   is	   increasingly	   recognised	   that	   patients	   with	   AAH	   have	   a	   dynamic	   disease	  course;	   better	   understanding	   of	   this	   may	   help	   tailor	   specific	   therapies	   to	  individual	  patients	  with	  reduction	  in	  morbidity	  and	  mortality.	  	  
No	   study	   has	   longitudinally	   investigated	   changes	   in	   immune	   function	   in	   this	  condition	  and	  the	  impact,	  at	  this	  level,	  of	  current	  treatments	  used.	   	  A	  particular	  question	  of	  interest	  is	  why	  certain	  individuals	  with	  AAH	  enter	  a	  state	  of	  immune	  exhaustion;	  increased	  examination	  of	  this	  aspect	  with	  longitudinal	  studies	  would	  add	  to	  our	  understanding	  of	  this	  potentially	  harmful	  phase	  of	  illness.	  
4.2 Aim	  of	  investigation	  To	  prospectively	  examine	  neutrophil	  and	  plasma	  cytokine	  profiles	  (as	  described	  in	   chapter	   3)	   in	   the	   AAH	   cohort	   through	   sequential	   analyses.	   The	  majority	   of	  patients	   were	   enrolled	   in	   the	   STOPAH	   trial	   which	   enabled	   observation	   of	   the	  natural	   disease	   course	   in	   addition	   to	   the	   effect	   of	   current	   AAH	   therapies	   on	  innate	   immune	   function.	  The	  STOPAH	  study,	  previously	  described,	   randomised	  patients	   with	   a	   clinical	   diagnosis	   of	   AAH	   to	   one	   of	   four	   groups;	   one	   receiving	  pentoxifylline-­‐matched	   placebo	   and	   prednisolone-­‐matched	   placebo,	   a	   second	  group	   receiving	   40mg	   of	   prednisolone	   daily	   and	   a	   pentoxifylline-­‐matched	  placebo,	  the	  third	  group	  receiving	  400mg	  of	  pentoxifylline	  three	  times	  daily	  and	  prednisolone-­‐matched	   placebo,	   and	   the	   fourth	   group	   receiving	   40mg	   of	  prednisolone	  daily	  and	  400mg	  of	  pentoxifylline	  three	  times	  daily.	  Pentoxifylline	  was	   not	   found	   to	   improve	   survival	   in	   patients	   with	   alcoholic	   hepatitis.	  Prednisolone	  was	   associated	  with	   a	   reduction	   in	  28-­‐day	  mortality	   that	  did	  not	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reach	  significance,	  with	  no	  improvement	  in	  outcomes	  at	  90	  days	  or	  1	  year	  [98].	  For	  the	  purposes	  of	  my	  analyses	  my	  patient	  cohort	  were	  divided	  into	  those	  who	  received	  prednisolone	  and	  those	  who	  did	  not.	  
4.3 Methods	  
4.3.1 Patients	  and	  study	  design	  A	  prospective	   cohort	   study	  was	   performed	  on	  patients	   presenting	  with	   severe	  AAH	   as	   previously	   defined.	   Blood	   samples	   were	   collected	   within	   48	   hours	   of	  hospital	  admission,	  prior	  to	  administration	  of	  any	  immunosuppressant	  therapy.	  Follow-­‐up	  analyses	  were	  performed	  on	  day	  7	  and	  day	  28	  when	  possible	  (day	  1	  pertains	  to	  the	  day	  of	  sampling).	  Eight	  patients	  had	  analyses	  at	  later	  time	  points.	  	  
4.3.2 Experiments	  Neutrophil	   phenotype,	   function,	   characterization	   post-­‐LPS	   stimulation,	   plasma	  lactoferrin,	   cytokine	   and	   endothelial	   marker	   analyses	   were	   performed	   as	  previously	  described.	  
4.4 Results	  
4.4.1 Clinical	  data	  Table	  3.1	  outlines	  the	  clinical	  demographics	  of	  the	  cohorts	  studied.	  The	  median	  age	  of	   the	  AAH	  group	  was	  49	   (IQR	  34-­‐60),	   the	  median	  DF	  was	  53	   (IQR	  40-­‐70)	  and	   the	  median	  MELD	  was	  25	   (IQR	  22-­‐29).	  Table	  4.1	  details	   the	  mortality	  and	  incidence	   of	   infection,	   defined	   as	   a	   positive	   culture	   over	   a	   6-­‐month	   follow-­‐up	  period.	   Given	   the	   STOPAH	   study	   findings,	   for	   my	   analyses	   patients	   were	  reviewed	   as	   a	   cohort	   and	   subsequently	   divided	   into	   two	   groups	   –	   those	   who	  received	  prednisolone	  and	  those	  who	  did	  not.	  Twenty-­‐eight	  day	  mortality	  for	  the	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group	   of	   patients	   studied	   was	   18%.	   Ten	   out	   of	   28	   (36%)	   developed	   culture	  positive	  infection	  over	  the	  6-­‐month	  follow-­‐up.	  Eleven	  out	  of	  26	  patients	  received	  prednisolone	  therapy	  (treatment	  data	  not	  available	  in	  5	  patients).	  There	  was	  no	  significant	   difference	   in	   DF	   or	   MELD	   between	   the	   patients	   who	   received	  prednisolone	  and	  those	  who	  did	  not.	  Twenty-­‐eight	  day	  mortality	  (taken	  from	  the	  time	  of	  sampling)	  in	  the	  prednisolone-­‐treated	  group	  and	  the	  non-­‐prednisolone-­‐treated	   group	   was	   18%	   and	   20%,	   respectively.	   A	   higher	   proportion	   of	  prednisolone-­‐treated	  patients	  developed	  culture-­‐positive	  infection	  (2	  patients	  in	  this	   arm	  were	   removed	   from	   results	   due	   to	   unavailable	   data	   over	   the	   defined	  follow-­‐up	  period).	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Table	  4-­‐1	  Mortality	  at	  28	  days,	  three-­‐	  and	  six-­‐months	  and	  culture	  positive	  infection	  incidence	  in	  the	  
AAH	  patients	  studied	  	   Whole	  group	   Prednisolone-­‐treated	   Non-­‐prednisolone	  treated	  	  28	  day	  mortality	   5/28	  18%	  
(3	   patients	   excluded,	  data	  unknown)	  
2/11	  18%	   3/15	  20%	  
3-­‐month	  mortality	   6/26	  23%	  
(5	   patients	   excluded,	  data	  unknown)	  	  
3/9	  33%	  
(2	   patients	   excluded,	  data	  unknown)	  
3/15	  20%	  
6-­‐month	  mortality	   9/24	  38%	  
(7	   patients	   excluded,	  data	  unknown)	  	  
6/7	  	  86%	  
(4	   patients	   excluded,	  data	  unknown)	  
3/15	  20%	  
Culture	   positive;	  6-­‐month	   follow-­‐up	  
10/28	  36%	  
(3	   patients	   excluded,	  data	  unknown)	  
6/9	  67%	  








Figure	  4.1	  Phagocytic	  capacity	  in	  the	  culture-­‐negative	  and	  culture-­‐positive	  AAH	  patients.	  	  No	   significant	   difference	   was	   seen	   between	   the	   2	   groups.	   Unpaired	   t-­‐test	   was	   used	   to	   analyse	   the	   data	  (normal	  data).	  
	  
Figure	   4.2	   Phagocytic	   capacity	   in	   the	   culture-­‐negative	   and	   culture-­‐positive	   AAH	   sub-­‐group	   of	  











































































































Figure	   4.4	   TLR4	   fold	   change	   post-­‐LPS	   challenge	   in	   the	   culture-­‐positive	   and	   culture-­‐negative	   AAH	  































































Figure	  4.6	  Baseline	  plasma	  IL-­‐8	  levels	  in	  the	  AAH	  patients	  who	  developed	  culture-­‐positive	  infection	  



























4.4.4 Neutrophil	  function	  –	  longitudinal	  analyses	  There	   was	   no	   significant	   difference	   in	   day	   1	   phagocytosis	   compared	   to	   day	   7	  when	  the	  whole	  group	  was	  examined.	  Phagocytic	  capacity	  in	  the	  group	  who	  did	  not	  receive	  prednisolone	  showed	  a	  trend	  to	  improve	  at	  day	  7	  compared	  to	  day	  1	  (p=0.06)	  (Figure	  4.7).	  An	  improvement	  was	  not	  seen	  in	  the	  prednisolone-­‐treated	  group	  of	  patients	   (Figure	  4.8).	  Day	  7:	  day	  1	   fold	   change	   in	  phagocytic	   capacity	  was	   significantly	   higher	   in	   the	   group	   of	   patients	   not	   exposed	   to	   prednisolone	  compared	   to	   the	   group	   treated	  with	   prednisolone	   (p=0.01)	   (Figure	   4.9).	   Eight	  patients	  had	  neutrophil	  function	  studies	  performed	  at	  day	  30,	  in	  addition	  to	  day	  1	  and	  day	  7.	  Three	  of	   these	  patients	  were	   in	   the	  prednisolone-­‐arm,	  5	  were	  not	  treated	  with	  prednisolone.	  Figures	  4.10	  and	  4.11	  demonstrate	  the	  trends	  seen	  in	  these	  individuals.	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Figure	  4.9	  Day	  7:	  day	  1	  fold	  change	  in	  phagocytic	  capacity	  in	  the	  prednisolone-­‐treated	  AAH	  patients	  







































Figure	  4.10	  Phagocytic	  capacity	  in	  the	  AAH	  patients	  not	  exposed	  to	  prednisolone	  on	  day	  1,	  day	  7	  and	  
































Figure	  4.11	  Phagocytic	  capacity	  in	  the	  AAH	  patients	  treated	  with	  prednisolone	  on	  day	  1,	  day	  7	  and	  






























There	  was	  no	  difference	  in	  resting	  burst	  between	  day	  1	  and	  day	  7	  in	  either	  the	  prednisolone-­‐treated	   or	   non-­‐prednisolone	   treated	   groups.	   When	   day	   7:	   day	   1	  fold	   change	   in	   resting	   burst	   was	   compared	   between	   the	   two	   groups	   no	  significant	   difference	   was	   observed.	   Figure	   4.12	   demonstrates	   the	   changes	  observed	  in	  the	  small	  number	  of	  patients	  who	  had	  sequential	  analyses	  –	  day	  1,	  day	   7	   and	   day	   30.	   These	   patients	   were	   not	   enrolled	   into	   the	   prednisolone	  arm/treated	  with	  prednisolone.	  
	  
Figure	  4.12	  Resting	  burst	  in	  the	  AAH	  patients	  not	  exposed	  to	  prednisolone	  on	  day	  1,	  day	  7	  and	  day	  
































4.4.5 Plasma	  IL-­‐8,	  IL-­‐6,	  lactoferrin	  –	  longitudinal	  analyses	  Plasma	   IL-­‐8	   at	   day	   7	  was	   significantly	   lower	   than	   day	   1	  when	   the	  whole	   AAH	  group	  were	  examined	  (Figure	  4.13).	  On	  sub-­‐group	  analyses,	  IL-­‐8	  significantly	  fell	  in	   the	   group	   that	   were	   not	   treated	   with	   prednisolone	   (Figure	   4.14).	   The	  difference	   between	   day	   1	   and	   day	   7	   levels	   was	   not	   significant	   in	   the	  prednisolone-­‐treated	  patients.	  On	  removal	  of	  the	  outlier,	  the	  only	  patient	  found	  to	  have	  an	  increase	  in	  IL-­‐8	  at	  day	  7,	  there	  was	  a	  trend	  of	  IL-­‐8	  reduction	  at	  day	  7	  compared	  to	  day	  1	   in	  the	  prednisolone-­‐treated	  patients	  (p=0.06)	  (Figure	  4.15).	  The	   day	   1	   plasma	   IL-­‐8	   levels	   tended	   to	   be	   higher	   in	   the	   group	   treated	   with	  prednisolone	   than	   the	   group	  who	  were	   not	   exposed	   to	   prednisolone	   (p=0.06).	  There	  was	  no	  significant	  difference	  in	  the	  fold	  change	  in	  IL-­‐8	  levels	  in	  day	  1	  and	  day	  7	  between	  the	  two	  groups.	  	  Figure	  4.16	  demonstrates	  the	  changes	  observed	  in	  the	  small	  number	  of	  patients	  who	  had	  sequential	  analyses	  –	  day	  1,	  day	  7	  and	  day	  30.	  These	  patients	  were	  not	  enrolled	   into	   the	   prednisolone	   arm/treated	   with	   prednisolone.	   (Prednisolone-­‐treated	  patients	  not	  shown	  as	  only	  2	  had	  day	  1,	  day	  7,	  day	  30	  IL-­‐8	  analyses).	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Figure	  4.16	  Plasma	  IL-­‐8	  levels	  on	  day	  1,	  day	  7	  and	  day	  30	  in	  the	  AAH	  patients,	  these	  patients	  were	  



















IL-­‐6	  at	  day	  7	  was	  significantly	  lower	  than	  day	  1	  when	  the	  whole	  AAH	  group	  were	  examined	   (Figure	  4.17).	  There	  was	  a	   trend	   in	   reduction	   in	   IL-­‐6	   levels	   at	  day	  7	  compared	  to	  day	  1	  in	  the	  group	  treated	  with	  prednisolone	  (Figure	  4.18).	  There	  was	  no	  significant	  difference	   in	   IL-­‐6	   levels	  at	  day	  1	  and	  day	  7	   in	   the	  group	  not	  exposed	  to	  prednisolone	  (Figure	  4.19).	  There	  was	  no	  significant	  difference	  in	  the	  day	  1	  IL-­‐6	  levels	  between	  the	  group	  treated	  with	  prednisolone	  and	  the	  group	  not	  exposed	  to	  prednisolone.	  	  Figure	  4.20	  demonstrates	  the	  changes	  observed	  in	  the	  small	  number	  of	  patients	  who	  had	  sequential	  analyses	  –	  day	  1,	  day	  7	  and	  day	  30.	  These	  patients	  were	  not	  enrolled	  into	  the	  prednisolone	  arm/treated	  with	  prednisolone.	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Figure	  4.17	  Plasma	  IL-­‐6	  levels	  in	  the	  AAH	  patients	  on	  day	  1	  and	  day	  7.	  	  IL-­‐6	  was	  significantly	  lower	  across	  the	  whole	  group	  on	  day	  7	  compared	  to	  day	  1	  (p=0.01).	  This	  remained	  the	  case	  when	  the	  outlier	  (with	  a	  very	  high	  plasma	  day	  1	  IL-­‐6	  level)	  was	  removed	  (p=0.026).	  Wilcoxon	  matched-­‐pairs	  sign	  rank	  test	  was	  used	  to	  analyse	  the	  data.	  	  
	  




















































Figure	  4.20	  IL-­‐6	  levels	  at	  day	  1,	  day	  7	  and	  day	  30	  in	  the	  AAH	  patients,	  these	  patients	  were	  not	  in	  the	  





















Although	  there	  was	  a	  trend	  to	  reduction	  in	  plasma	  lactoferrin	  at	  day	  7	  compared	  to	  day	  1	  no	  significant	  difference	  was	  seen	  when	  the	  whole	  group	  was	  examined	  and	  there	  was	  no	  difference	  seen	  on	  sub-­‐group	  analyses.	  	  
4.5 Discussion	  One-­‐month	   mortality	   rates	   were	   perhaps	   lower	   than	   expected,	   this	   may	   have	  been	  impacted	  by	  the	  patients	  lost	  to	  follow-­‐up,	  but	  is	  in	  line	  with	  results	  of	  the	  STOPAH	   study	   [98].	   It	   was	   not	   possible	   to	   perform	   sequential	   analyses	   on	   all	  patients	   for	   similar	   reasons.	   In	   the	   small	   number	   of	   patients	   studied	   infection	  rates	  were	  not	  insignificant,	  patients	  were	  not	  recruited	  if	  there	  was	  evidence	  of	  untreated	  sepsis.	  The	  rate	  of	  infection	  may	  have	  also	  been	  under-­‐represented	  as	  I	   chose	   to	  define	   infection	  as	   a	  positive	   culture	  over	  a	   time	   frame	  of	  6	  months	  post-­‐sampling;	  this	  removed	  clinical	  bias	  and	  provided	  a	  robust	  definition	  for	  the	  follow-­‐up	   period.	   The	   data	   could	   also	   have	   been	   analysed	   with	   definition	   of	  infection	   as	   positive	   urinalysis,	   chest	   X-­‐ray	   or	   decision	   to	   initiate	   antibiotics;	  when	  the	  patients	  were	  divided	  in	  this	  way	  in	  my	  cohort	  the	  numbers	  were	  too	  small	   to	   run	  meaningful	   statistical	  analyses.	  The	  positive	  cultures	  were	  usually	  detected	  during	  the	  hospital	  admission	  or	  within	  3	  months	  of	  patient	  sampling.	  	  	  Longer	   follow-­‐up	   with	   sequential	   analyses	   to	   determine	   the	   most	   susceptible	  time	  point	  for	  infection	  would	  be	  of	  interest,	  as	  would	  correlation	  with	  response	  to	   steroids	   and	   liver	   recovery/regeneration.	   A	   recent	   publication	   using	   the	  STOPAH	  cohort	  suggests	  that	  infections	  may	  be	  predicted	  in	  AAH	  by	  measuring	  levels	   of	   circulating	   bacterial	   DNA	   [97].	   The	   authors	   state	   that	   infections	   are	  common	   in	   AAH	   but	   are	   only	   independently	   associated	   with	   mortality	   when	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patients	  receive	  prednisolone,	  and	  suggest	  that	  infection	  and	  mortality	  could	  be	  avoided	  by	  bacterial	  DNA	  stratified	  prednisolone-­‐prescribing.	  The	  bacterial	  DNA	  data	  would	  be	  useful	  to	  study	  relative	  to	  the	  neutrophil	  analyses	  performed,	  and	  in	   particular	   in	   relation	   to	   the	   reduction	   in	   neutrophil	   function	   seen	   in	   the	  prednisolone	  group.	  	  The	  numbers	  I	  studied	  were	  too	  small	  to	  provide	  clear-­‐cut	  outcome	  correlations,	  but	   it	   appears	   that	   the	   neutrophil-­‐TLR4	   fold	   change	   post-­‐LPS	   stimulation	  was	  significantly	   lower	   amongst	   the	   6-­‐month	   non-­‐survivors	   compared	   to	   the	   6-­‐month	   survivors.	   Endotoxin-­‐tolerance	   is	   now	   well	   recognized	   in	   cirrhotic	  patients	  [111]	  and	  these	  data	  point	  towards	  this	  as	  a	  poor	  prognostic	  feature	  in	  AAH.	  More	   than	  90%	  of	   the	  AAH	  patients	  analysed	   in	  Vergis’	   recent	   study	  had	  detectable	   bacterial	   DNA	   levels	   [97].	   As	   above,	   it	   would	   be	   interesting	   to	  correlate	  neutrophil	  function	  and	  TLR	  responses	  with	  bacterial	  DNA	  levels.	  	  Taylor	   et	   al	   have	   previously	   shown	   that	   neutrophil	   phagocytic	   capacity	   and	  resting	  burst	  differentiates	  survivors	  from	  non-­‐survivors	  in	  cirrhosis	  of	  all	  cause	  [152],	  the	  number	  of	  patients	  in	  this	  study	  was	  higher	  than	  the	  number	  of	  AAH	  patients	   included	   in	  my	   analyses	  which	  may,	   in	   part,	   explain	   the	   difference	   in	  findings.	  Of	  course,	  return	  to	  alcohol	  consumption	  is	  a	  key	  determinant	  when	  it	  comes	   to	  6-­‐month	  and	   longer-­‐term	  survival	   in	  AAH	  and	   this	  would	  need	   to	  be	  kept	   in	   consideration	  with	   further	   study	   design.	   Of	   the	   25	   patients	  within	  my	  cohort	   who	   were	   not	   confirmed	   to	   have	   died	   at	   3	   months,	   5	   had	   definitely	  returned	  to	  alcohol	  use.	  This	  information	  was	  unknown	  in	  10	  patients	  who	  may	  have	   additionally	   returned	   to	   alcohol	   consumption	   by	   this	   early	   time-­‐point.	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Clearly,	   in	   further	   studies,	   when	   examining	   outcome	   after	   3	   months,	   patients	  would	  need	  to	  be	  stratified	  for	  return	  to	  alcohol	  use.	  	  	  Perhaps	   the	  most	   notable	   finding	   is	   the	   impact	   of	   prednisolone	   on	   phagocytic	  capacity.	  Phagocytosis	  in	  the	  group	  who	  did	  not	  receive	  prednisolone	  showed	  a	  trend	  to	  improve	  at	  day	  7	  compared	  to	  day	  1,	  conversely	  mean	  phagocytosis	  in	  the	  prednisolone-­‐treated	  patients	  was	  seen	  to	  fall	  at	  day	  7	  and	  when	  the	  day	  7-­‐	  day	  1	   fold	  change	  were	  compared	  between	  the	  prednisolone-­‐exposed	  and	  non-­‐exposed	   groups	   a	   significant	   difference	  was	   observed.	  When	   this	   is	   taken	   into	  account	   along	   with	   the	   fact	   that	   STOPAH	   [98]	   showed	   serious	   infections	  occurred	  in	  13%	  of	  patients	  treated	  with	  prednisolone	  versus	  7%	  of	  those	  who	  did	   not	   receive	   prednisolone,	   this	   perhaps	   reinforces	   the	   concern	   that	  prednisolone	  therapy	  may	  be	  increasing	  the	  risk	  of	  infection	  in	  some	  individuals.	  Furthermore,	  prednisolone	  did	  not	  appear	  to	  temper	  the	  inflammatory	  response	  as	   measured	   by	   neutrophil	   ROS	   production,	   plasma	   lactoferrin	   or	   IL-­‐8.	   There	  was,	  however,	  a	  trend	  to	  a	  reduction	  in	  plasma	  IL-­‐6	  in	  the	  prednisolone-­‐treated	  group.	  Much	  of	  the	  literature	  on	  the	  effect	  of	  prednisolone	  on	  neutrophils	  comes	  from	   the	   respiratory	   and	   rheumatology	   fields.	   One	   study,	   however,	   has	  previously	   evaluated	   the	   effect	   of	   corticosteroids	   on	   some	  neutrophil	  markers,	  function	   and	   plasma	   IL-­‐8	   levels	   in	   15	   patients	  with	  AAH;	   Taieb	   et	  al	  observed	  that	   stimulated	  neutrophil	  CD11b	  and	  CD62L	  expression	  and	  H202	  production	  returned	  to	  the	  levels	  seen	  in	  ARC	  and	  HC	  after	  28	  days	  of	  steroid	  therapy	  [61].	  In	   addition	   the	   authors	   noted	   that	   during	   steroid	   therapy,	   plasma	   IL-­‐8	   levels	  were	  seen	  to	   fall	  as	  early	  as	  day	  14.	  This	  study	  did	  not	   include	  a	  group	  of	  AAH	  patients	   unexposed	   to	   steroid	   treatment	   as	   controls	   and	   although,	   small	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numbers,	   my	   data	   would	   suggest	   that	   the	   decrease	   in	   plasma	   cytokine	   levels	  seen	  may	   be	   part	   of	   the	   natural	   disease	   course	   and	   not	   influenced	   by	   steroid	  therapy.	  Neutrophil	   phagocytosis	  was	   not	   examined	   in	  Taieb’s	   study.	   I	   did	   not	  sequentially	  investigate	  PBMC	  profiles	  or	  the	  IFN	  gamma/IL-­‐10	  skew,	  it	  is	  likely	  that	  the	  balance	  of	  cytokines	  in	  an	  individual	  is	  of	  key	  importance	  with	  regard	  to	  outcome	   and	   avoidance	   of	   infection	   and	   large	   comprehensive	   studies	   are	  required	  for	  further	  interrogation	  of	  this.	  In	  addition,	  five	  patients	  I	  studied	  were	  recruited	  from	  other	  centres	  and	  the	  treatment	  received	  was	  not	  known	  to	  me	  at	  the	   time	   of	   data	   analyses,	   re-­‐analyses	   with	   this	   information	   may	   strengthen	  results.	  	  	  Neutrophil	   adherence	   has,	   many	   years	   ago,	   been	   found	   to	   be	   reduced	   by	  corticosteroids,	   whereas	   no	   effect	   was	   seen	   on	   chemotaxis	   [212].	   In	   severe	  steroid	  dependent	  asthma,	  prednisolone	  had	  no	  effect	  on	  neutrophil	  markers	  or	  on	  myeloperoxidase	   and	   neutrophil	   elastase	   release	   from	   purified	   neutrophils	  [213].	  Steroids	  are	  known	  to	  inhibit	  apoptosis	  and	  increase	  survival	  in	  many	  cell	  types	  [214].	  During	  my	  study,	  I	  began	  to	  develop	  apoptosis	  experiments	  but	  at	  a	  late	   stage	   and	   therefore	   failed	   to	   analyse	   any	  meaningful	   numbers	   of	   patients,	  this	   however,	   would	   be	   an	   additional	   aspect	   that	   might	   ultimately	   add	   to	   the	  understanding	   of	   the	   pathophysiology	   of	   AAH.	   The	   work	   would	   have	   been	  greatly	  enhanced	  if	  neutrophil	  lifespan	  studies	  had	  been	  concurrently	  conducted.	  	  Unfortunately,	   the	  numbers	  of	  patients	  studied	  were	   too	  small	   to	  allow	  further	  sub-­‐group	  analyses	  of	   innate	   immune	  function	  in	  steroid-­‐responders	  compared	  to	  non-­‐responders	  and	  this,	  of	  course,	  would	  be	  of	  particular	  interest.	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  The	   longer	   time-­‐points	   of	   follow-­‐up	   can	   only	   point	   towards	   trends	   given	   the	  numbers	  studied,	  but	  these	  highlight	  the	  individual	  dynamic	  course	  which,	  much	  like	   clinical	   outcome,	   is	   difficult	   to	   predict	   at	   the	   outset	   of	   illness.	   The	   day	   of	  presentation	  to	  hospital	  and	  previous	  presentations	  are	  also	  of	  importance.	  	  In	   conclusion,	   this	   study	   provides	   further	   evidence	   of	   the	   potential	   negative	  immunosuppressive	  effects	  of	  prednisolone	  and	  the	  heterogeneity	   in	   individual	  trajectory	  within	   this	   disease	  which	  may	  well	   be	   influenced	   by	   past	   pathogen	  exposure	  and	  endotoxin	  tolerance.	  	  	  These	  clinical	  findings	  thus	  led	  me	  to	  ask	  further	  questions,	  including	  why	  does	  ALD	   induce	   neutrophil	   dysfunction	   and	   do	   other	   derangements	   in	   neutrophil	  function	   contribute	   to	   the	   state	   of	   immunoparesis	   in	   ALD	   and	   these	   form	   the	  basis	  of	  chapters	  5	  and	  6.	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5 	  Use	  of	   the	  HL-­‐60	  cell	   line	   to	  examine	  mechanisms	  
of	   neutrophil	   dysfunction	   and	   the	   relationship	  
between	  neutrophils,	  ethanol	  and	  the	  liver	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5.1 Background	  Primary	  neutrophils	  are	  difficult	  to	  use	  in	  culture	  as	  they	  have	  a	  short	  life-­‐span	  and	   are	   easily	   activated.	   Under	   certain	   conditions	   the	   HL-­‐60	   cell	   line	  differentiates	  toward	  a	  neutrophil-­‐like	  cell.	  	  As	  described	  in	  chapter	  1,	  the	  HL-­‐60	  cells	   have,	   therefore,	   been	   used	   to	   examine	   neutrophil	   biology	   and	   certain	  inflammatory	  conditions,	  but	  not	  previously	  in	  ALD.	  	  My	  clinical	  observations	  posed	  further	  questions	  including	  why	  does	  ALD	  induce	  neutrophil	   dysfunction	   and	   do	   other	   derangements	   in	   neutrophil	   function	  contribute	  to	  the	  state	  of	  immunoparesis	  in	  this	  condition?	  The	  HL-­‐60	  cells	  were	  thus	  used	  in	  this	  part	  of	  the	  study	  to	  further	  examine	  the	  relationship	   between	   neutrophils,	   ethanol	   and	   the	   liver.	   Through	   this	   work,	  further	  questions	  regarding	  neutrophil	  biology	  were	  encountered,	  shedding	  light	  on	   previously	   unknown	   aspects	   of	   neutrophil	   interactions	   both	   in	   health	   and	  ALD,	  discussed	  in	  chapter	  6.	  
5.2 Aim	  of	  the	  investigation	  The	   first	   aim	   of	   this	   study	   was	   to	   grow	   and	   differentiate	   the	   HL-­‐60	   cells	   and	  characterise	  phenotype	  and	  function	  of	  the	  differentiated	  and	  non-­‐differentiated	  cells.	   The	   second	   aim	   was	   to	   examine	   the	   impact	   of	   ethanol	   and	   metabolised	  ethanol	   on	  neutrophil	   phenotype	   and	   function.	   Finally,	   given	   that	   type	   I	   and	   II	  interferon	  receptors,	  specifically,	  the	  IL-­‐10	  receptor,	  which	  is	  a	  subunit	  for	  IFN-­‐λ,	  are	  present	  on	  neutrophils	  I	  questioned	  whether	  the	  differentiated	  cells	  express	  the	   IFN-­‐λ	   receptor.	   At	   this	   point	   there	   was	   not	   a	   single	   published	   study	  describing	  IFN-­‐λ	  receptor	  expression	  or	  the	  effect	  of	  IFN-­‐λ	  on	  neutrophils.	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Modulation	  of	  function	  was	  then	  examined	  which	  led	  to	  IFN-­‐λ	  analysis	  on	  human	  neutrophils	  and	  the	  work	  detailed	  in	  chapter	  6.	  
5.3 Methods	  
5.3.1 HL-­‐60	  cell	  culture	  Cells	   were	   thawed	   and	   re-­‐suspended	   in	   culture	  medium	   as	   described	   in	   2.19.	  Cells	   were	  maintained	   initially	   in	   20%	   FBS,	   then	   transferred	   to	   10%	   FBS	   and	  maintained	  between	  0.1-­‐1	  million	  cells/mL.	  
5.3.2 HL-­‐60	  differentiation	  and	  characterisation	  Optimisation	  of	  differentiation	  was	  performed	  using	  different	  concentrations	  of	  DMSO	   (0.75%,	   1.25%	   and	   1.5%)	   and	   different	   time-­‐frames	   of	   exposure.	   The	  expression	  of	  CD14,	  CD16,	  CD11b,	  TLR2,	  TLR4,	  TLR9,	  CD181	  and	  CD182	  on	  the	  differentiated	  and	  non-­‐differentiated	  cells	  were	  examined	  by	  FACS	  as	  described	  in	  chapter	  2.	  The	  Phagotest	  and	  Phagoburst	  experiments	  were	  adapted	   for	  use	  on	  the	  differentiated	  cells,	  described	  in	  the	  appendix.	  
5.3.3 HL-­‐60	  ethanol	  exposure	  The	   phenotype	   and	   function	   of	   the	   differentiated	   HL-­‐60	   cells	   was	   assessed	  following	   culture	   with	   ethanol	   in	   concentrations	   of	   10mM,	   50mM,	   100mM,	  250mM	   and	   500mM.	   In	   these	   experiments,	   hepatocyte	   (VL17A)	   metabolized	  ethanol	  was	  also	  used	  (courtesy	  of	  Dr	  Elena	  Palma	  Institute	  of	  Hepatology).	  
5.3.4 Interferon	  lambda	  stimulation	  Phagocytosis	   of	   the	   differentiated	   HL-­‐60	   cells	   was	   examined	   following	   pre-­‐treatment	  with	  recombinant	  IFN-­‐λ1	  (IL-­‐29)	  (100ng/mL	  for	  1	  hour).	  	  
172	  	  
5.4 Results	  
5.4.1 HL-­‐60	  differentiation	  and	  characterisation	  Table	   5.1	   outlines	   the	   HL-­‐60	   cell	   viability	   post	   thaw	   and	   pre-­‐culture.	   Five	  passages	  were	  thawed	  for	  use,	  two	  were	  discarded	  due	  to	  contamination.	  
Table	  5-­‐1	  HL-­‐60	  viability	  pre-­‐culture	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Figure	  5.1	  demonstrates	  the	  growth	  curve	  of	  the	  cell	  passages.	  Cells	  were	  divided	  regularly	  so	  that	  cell	  concentration	  did	  not	  exceed	  1	  million	  cells/mL.	  
	  
Figure	  5.1	  HL-­‐60	  growth	  curve.	  P	  delineates	  the	  passage	  of	  cells	  with	  cell	  concentration	  expressed	  as	  
million	  per	  mL.	  HL-­‐60	  cells	  were	   initially	  cultured	  with	  1.5%	  DMSO	   for	  7	  days.	  Growth	  of	  cells	  exposed	   to	   DMSO	   was	   seen	   to	   reduce	   compared	   to	   those	   in	   culture	   medium	  alone	   (Figure	   5.2).	   There	   were	   no	   dead	   cells	   seen	   in	   either	   condition	   when	  counted	  with	  trypan	  blue.	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Figure	  5.2	  HL-­‐60	  cell	  differentiation	  with	  1.5%	  DMSO.	  DMSO;	  dimethyl	  sulfoxide.	  Med;	  medium.	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Morphological	   alterations	   of	   HL-­‐60	   during	   differentiation	   include	   shrinkage	   in	  cell	  size	  and	  decreased	  nuclear-­‐cytoplasmic	  ratio	  (Figures	  5.3	  -­‐	  5.6).	  	  Other	   features	   include	   increased	  nuclear	   segmentation	   and	   replacement	  of	   the	  coarse	  azurophilic	  granules	  with	  smaller	  specific	  granules.	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Figure	  5.3	  Microscopy	  photograph	  of	  HL-­‐60	  cells,	  passage	  8	  at	  day	  1	  in	  medium.	  
	  




Figure	  5.5	  Microscopy	  photograph	  of	  HL-­‐60	  cells,	  passage	  8	  at	  day	  7	  in	  medium.	  
	  
	  
Figure	  5.6	  Microscopy	  photograph	  of	  HL-­‐60	  cells,	  passage	  8	  at	  day	  7	  in	  1.5%	  DMSO.	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After	  exposure	  to	  1.5%	  DMSO	  for	  7	  days,	  in	  addition	  to	  the	  shrinkage	  of	  cells	  and	  slowed	   growth,	   the	   percentage	   of	   cells	   positive	   for	   CD11b,	   a	   marker	   of	  differentiation	  increased	  from	  20%	  to	  70%	  in	  all	  passages.	  1.5%	  DMSO	  exposure	  also	   increased	   the	  proportion	  of	  CD16	  positive	   cells.	  When	   the	  population	  was	  examined	   using	   the	   neutrophil	   gating	   strategy,	   the	   CD16	   positive	   and	   CD11b	  positive	   percentage	   of	   cells	   increased	  upon	  1.5%	  DMSO	  exposure	   (Figure	   5.7).	  When	   several	   passages	   were	   exposed	   to	   increasing	   concentrations	   of	   DMSO	  (0.75%,	   1.25%,	   1.5%)	   the	   highest	   concentration	   of	  DMSO	  used	   resulted	   in	   the	  highest	  percentage	  of	  cells	  positive	  for	  CD16	  and	  CD11b.	  	  
	  
Figure	  5.7	  CD16	  and	  CD11b	  positive	  percentage	  of	  cells.	  	  An	  increase	  in	  proportion	  of	  cells	  positive	  for	  both	  markers	  was	  seen	  after	  exposure	  to	  DMSO	  compared	  to	  the	  cells	  kept	  in	  medium	  alone.	  The	  individual	  lines	  represent	  individual	  passages.	  	  	  Cells	   were	   then	   exposed	   to	   1.5%	   DMSO	   for	   5,	   6	   or	   7	   days	   and	   phenotype	  examined.	  CD14	  receptor	  expression	  was	  also	   induced	  by	  DMSO	  exposure,	  but,	  unlike	   CD16	   and	   CD11b	   expression	   change,	   the	   fold	   change	   reduced	   with	   the	  number	  of	  days	  of	  exposure	  (Figure	  5.8	  and	  5.9).	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Figure	  5.8	  CD16	  and	  CD11b	  positive	  population	  fold	  change	  in	  DMSO	  exposed	  cells	  compared	  to	  cells	  




Figure	  5.9	  Fold	  change	  in	  surface	  expression	  markers	  on	  differentiated	  HL60.	  The	  CD16	  and	  CD11b	  positive	  cells	  were	  gated.	  	  Fold	   change	   in	   the	   population	  positive	   for	   both	  CD14	   and	  CD16	   amongst	   this	   population	   on	   exposure	   to	  DMSO	  at	  day	  5,	  day	  6	  and	  day	  7	  (top)	  was	  seen	  to	  reduce	  with	  time.	  	  In	  contrast,	  fold	  change	  in	  the	  CD14	  negative	  and	  CD16	  positive	  population	  on	  exposure	  to	  DMSO	  at	  day	  5,	  day	  6	  and	  day	  7	  (bottom)	  was	  seen	  to	  increase	  with	  time.	  	  	   	  
181	  	  
Differentiated	  and	  non-­‐differentiated	  cells	  were	  found	  to	  express	  TLR2,	  4	  and	  9	  (Figures	  5.10	  –	  5.12).	  The	  CD181	  receptor	  was	  minimally	  expressed	  by	  the	  HL-­‐60	   cells	   and	   exposure	   to	   DMSO	   resulted	   in	   a	   variable	   response	   between	  passages.	   The	   CD182	   receptor,	   in	   comparison	   to	   CD181,	   was	   expressed	   on	   a	  higher	  percentage	  of	  cells	  and	  DMSO	  induced	  expression	  (Figure	  5.13).	  
	  





Figure	  5.11	  TLR4	  expression	  on	  HL60	  cells.	  TLR4	  positive	  percentage	  of	  CD16	  and	  CD11b	  positive	  population	  (top),	  cells	  exposed	  to	  1.5%	  DMSO	  for	  6	  days	   compared	   to	   cells	   kept	   in	   culture	  medium	  alone.	   TLR4	  positive	   percentage	   of	   the	  whole	   population	  (bottom),	  cells	  exposed	  to	  1.5%	  DMSO	  for	  6	  days	  compared	  to	  cells	  kept	  in	  culture	  medium	  alone.	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Figure	  5.13	  CD181	  and	  CD182	  expression	  on	  HL60	  cells.	  CD181	  positive	  percentage	  of	  HL-­‐60	  cells	  (top),	  cells	  exposed	  to	  1.5%	  DMSO	  for	  6	  days	  compared	  to	  cells	  kept	   in	   culture	  medium	   alone.	   CD182	   positive	   percentage	   of	   cells	   (bottom	   graph),	   cells	   exposed	   to	   1.5%	  DMSO	  for	  6	  days	  compared	  to	  cells	  kept	  in	  culture	  medium	  alone.	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Using	  the	  Phagoburst	  kits,	  very	  high	  levels	  of	  resting	  burst	  were	  seen	  with	  both	  the	  differentiated	  and	  non-­‐differentiated	  cells	  on	  several	  passages.	  	  Phagocytic	   activity	  was	   examined	   following	   differentiation	  with	   0.75,	   1.25	   and	  1.5%	   DMSO	   as	   outlined	   in	   figure	   5.14.	   Initially	   200uL	   of	   labeled	   E.	   coli	  was	  cultured	  with	   100,	   000	   cells	   for	   4	   hours.	   (A	   ratio	   of	   2000	   bacteria	   to	   cell	  was	  recommended	   by	   kit	   manufacturers).	   A	   low	   number	   of	   events	   were	   obtained	  when	   the	   cells	   positive	   for	   CD16	   and	   11b	   were	   analysed.	   The	   whole	   cell	  population	  was	  additionally	  studied	  in	  sequential	  experiments.	  	  
	  
Figure	  5.14	  Phagocytic	  Activity	  of	  HL-­‐60	  cells,	  Phagocytosis	  of	  HL-­‐60	  cells,	  non-­‐differentiated	  (medium)	  and	  differentiated	  (cells	  cultured	  with	  0.75,	  1.25	  and	   1.5%	  DMSO	   for	   6	   days).	   The	   red	   line	   represents	   the	  whole	   population,	   the	   blue	   line	   represents	   the	  population	  of	  CD16	  and	  11b	  positive	  cells.	  	  Next,	   experiments	   were	   performed	   using	   a	   titration	   of	   E.	   coli	   and	   phagocytic	  activity	  was	  seen	  with	  lower	  concentrations	  of	  E	  coli	  (Figure	  5.15).	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Figure	  5.15	  Titration	  of	  E.coli	  for	  HL-­‐60	  phagocytosis	  experiments.	  	  The	   top	   graph	   represents	   the	  phagocytic	   activity	   of	   the	  CD16	  and	  CD11b	  positive	  population	  of	   the	  non-­‐differentiated	   cells	   (blue),	   the	   cells	   exposed	   to	   1.25%	   DMSO	   (red)	   and	   the	   cells	   exposed	   to	   1.5%	   DMSO	  (green).	  The	  bottom	  graph	  represent	  the	  phagocytic	  activity	  of	  the	  whole	  population	  of	  cells.	  Condition	  1	  –	  control,	  2-­‐	  200uL	  E.coli,	  3	  -­‐	  100uL	  E.coli,	  4	  -­‐	  50uL	  E.coli.	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Based	  on	  both	  phenotype	  and	   function	  data,	   it	  was	  decided	   that	   conditions	   for	  differentiation	  for	  ongoing	  experiments	  would	  be	  exposure	  of	  the	  HL-­‐60	  to	  1.5%	  DMSO	  for	  6	  days.	  Differentiated	  cells	  generally	  showed	  higher	  phagocytic	  activity	  than	   the	   non-­‐differentiated	   cells;	   the	   latter	   were	   also	   seen	   to	   phagocytose	  however.	   Phagocytosis	  was	   also	   examined	  using	   opsonised	   and	  non-­‐opsonised	  bacteria,	   on	   ice	   and	   at	   37	   degrees	   centigrade.	   The	   differentiated	   cells	   showed	  reduced	  phagocytosis	  with	  non-­‐opsonised	  bacteria	  at	  37	  degrees	  (Figure	  5.16).	  Cells	  were	  noted	  to	  phagocytose	  on	  ice	  and	  this	  was	  seen	  when	  lower	  volumes	  of	  
E.	  coli	  were	  used.	  Cells	  were	  viewed	  with	  fluorescent	  microscopy	  following	  E.	  coli	  exposure.	  When	  cells	  were	  kept	  on	   ice	   the	  bacteria	  was	  predominantly	  seen	  to	  be	   adherent	   to	   the	   cell	   surface	   as	   opposed	   to	   the	   cells	   cultured	   at	   37	   degrees	  where	  the	  labeled	  bacteria	  were	  seen	  to	  be	  internalised	  (Figures	  5.18	  and	  5.19).	  	  
	  
Figure	   5.16	   Phagocytosis	   of	   opsonised	   and	   non-­‐opsonised	   E.coli	  on	   ice	   and	   at	   37	   degrees	   of	   the	  	  
differentiated	  and	  non-­‐differentiated	  cells.	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Figure	  5.17	  Microscopy	  of	  HL-­‐60	  cells	  and	  labelled	  E.	  coli	  on	  ice.	  When	  cells	  were	  kept	  on	  ice	  bacteria	  were	  adherent	  to	  the	  cell	  surface.	  	  
	  
Figure	  5.18	  Microscopy	  of	  HL-­‐60	  cells	  and	  labelled	  E.	  coli	  incubated	  at	  37	  degrees.	  	  Bacteria	  is	  seen	  within	  cells	  with	  evidence	  of	  NET	  formation.	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5.4.2 Impact	  of	  ethanol	  on	  HL-­‐60	  cells	  	  Culture	   of	   the	   differentiated	  HL-­‐60	   cells	  with	   ethanol	   and	   VL17A-­‐metabolised	  ethanol	  resulted	  in	  reduced	  expression	  of	  CD16,	  CD11b,	  TLR2	  and	  4.	  There	  was	  no	  change	  seen	  in	  the	  expression	  of	  TLR9.	  Increasing	  concentrations	  of	  ethanol	  were	   found	   to	   reduce	   phagocytic	   activity	   of	   the	   cells	   (Figure	   5.19).	   VL17A-­‐metabolised	  ethanol	  reduced	  phagocytic	  activity	  of	  the	  differentiated	  HL-­‐60	  cells	  compared	   to	   differentiated	   HL-­‐60	   control	   cells	   and	   cells	   exposed	   to	   the	  supernatant	   of	   the	   non-­‐ethanol	   treated	   VL17A	   cell	   line	   (Figure	   5.20).	   VL17A-­‐metabolised	   ethanol	   further	   reduced	   phagocytosis	   of	   the	   differentiated	   HL-­‐60	  cells	  compared	  to	  ethanol	  alone	  (Figure	  5.20).	  
	  	  
Figure	  5.19	  Differentiated	  HL-­‐60	  cell	  phagocytic	  capacity	  reduced	  with	  increasing	  concentration	  of	  









Figure	   5.20	   Differentiated	   HL-­‐60	   phagocytic	   activity	   reduced	   on	   exposure	   to	   VL17A-­‐metabolised	  
ethanol.	  	  There	  was	   no	   difference	   in	   phagocytic	   activity	   between	   control	   cells	   and	   cells	   cultured	  with	   supernatant	  from	  the	  VL17A	  line,	  not	  exposed	  to	  ethanol.	  Phagocytic	  activity	  of	  the	  differentiated	  HL-­‐60	  cells	  following	  exposure	  to	  ethanol	  and	  VL17A-­‐metabolised	  ethanol.	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5.4.3 Modulation	  of	  differentiated	  HL-­‐60	  function	  by	  interferon	  lambda	  First,	  differentiated	  HL-­‐60	  cells	  were	  examined	  for	  the	  IL-­‐10	  receptor	  and	  IL28	  receptor	   α	   chain	   (IFN-­‐λr)	   using	   FACS.	   The	   cells	   expressed	   IL-­‐10	   but	   did	   not	  express	   the	   IFN-­‐λr.	   Several	   passages	   were	   analysed	   and	   intracellular	   and	  extracellular	   staining	   for	   IFN-­‐λr	  was	   performed.	   Following	   pre-­‐treatment	  with	  recombinant	  IFN-­‐λ1	  phagocytosis	   increased	  by	  10-­‐20%	  (Figure	  5.22).	  This	  was	  confirmed	  on	  the	  analyses	  of	  several	  passages	  of	  cells.	  	  
	  
Figure	  5.21	  FACS	  plots	  of	  the	  differentiated	  HL-­‐60	  cells	  quantifying	  phagocytosis	  post	  treatment	  with	  
IFN-­‐λ1.	  	  Top	   left	   –	   control	   differentiated	  HL-­‐60	   cells	   not	   cultured	  with	   labelled	  E.	  coli.	  Middle	   left	   and	   top	   right	   –	  differentiated	   HL-­‐60	   cells	   phagocytosing.	   Bottom	   left	   and	   bottom	   right	   –	   increased	   phagocytosis	   of	   the	  differentiated	  HL-­‐60	  cells	  following	  treatment	  with	  IFN-­‐λ1.	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5.5 Discussion	  After	   optimisation	   it	   was	   possible	   to	   differentiate	   the	   HL-­‐60	   cells	   towards	   a	  neutrophil-­‐phenotype.	   One	   of	   my	   early	   concerns	   was	   that	   a	   significant	  proportion	  of	  cells	  became	  CD14	  positive.	  CD14	  is	  a	  myeloid	  cell	  differentiation	  antigen	  expressed	  primarily	  by	  monocytes	  and	  macrophages.	  Studies	  in	  the	  early	  1990s,	  however,	  showed	  that	  neutrophils	  also	  express	  CD14	  and	  can	  respond	  to	  LPS	  through	  a	  similar	  pathway	  as	  monocytes	  [215].	  I	  demonstrated	  that	  the	  fold	  change	  in	  CD14	  gradually	  reduced	  as	  the	  number	  of	  days	  the	  cells	  were	  exposed	  to	   DMSO	   increased;	   this	   was	   in	   contrast	   to	   the	   CD16	   and	   CD11b	   fold	   change.	  Exposure	   to	   1.5%	   DMSO	   for	   6	   days	   was	   eventually	   chosen	   as	   the	   optimal	  differentiation	   conditions	   given	   the	   combination	   of	   phenotypic	   and	   function	  data.	  The	  time-­‐frame	  was	  also	  influenced	  by	  the	  practical	  aspects	  of	  planning	  and	  completing	   my	   experiments.	   Various	   conditions	   for	   neutrophil	   differentiation	  have	  been	  described	  [160],	  the	  use	  of	  DMSO	  and	  all-­‐trans-­‐retinoic	  acid (ATRA)	  being	   the	   most	   common.	   ATRA,	   however,	   does	   not	   induce	   the	   expression	   of	  CD16,	   CD66	   and	   CD88	   antigens,	   normally	   expressed	   on	   granulocytes	   [216]	   on	  HL60	  cells.	  I	  therefore	  did	  not	  go	  on	  to	  use	  this	  agent	  for	  differentiation.	  	  I	  demonstrated	  that	  these	  cells	  expressed	  many	  of	  the	  key	  receptors	  examined	  in	  the	  human	  study.	   In	  particular,	   these	  cells	  may	  act	  as	  a	  good	  model	   for	   further	  study	   of	   TLR9	   as	   this	   was	   highly	   expressed	   pre-­‐	   and	   post-­‐differentiation.	   The	  expression	  of	  TLRs,	  however,	  does	  not	  appear	  to	  be	  a	  marker	  of	  differentiation	  of	  these	  cells,	  at	  least	  toward	  a	  neutrophil-­‐like	  state.	  A	  previous	  study	  found	  TLR4	  expression	   to	   be	   only	   slightly	   induced	   in	   ATRA-­‐treated	   HL-­‐60	   cells	   (HL-­‐60-­‐
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derived	   granulocytic	   cells),	   and	   strongly	   induced	   in	   IFN-­‐γ-­‐treated	   HL-­‐60	   cells	  (HL-­‐60-­‐derived	  monocytic	  cells)	  [217].	  Both	  HL-­‐60	  cells	  and	  differentiated	  HL-­‐60	  were	  found	  to	  phagocytose,	  however,	  the	   differentiated	   cells	   did	   show	   higher	   phagocytic	   activity.	   It	   was	   possible	   to	  reduce	  the	  ratio	  of	  bacteria	  to	  cell	  recommended	  by	  the	  kit	  manufacturers.	  The	  labeled	  E.	  coli	  supplied	   in	  the	  phagotest	  kits	   is	  opsonised	  with	   immunoglobulin	  and	  complement	  of	  pooled	  sera.	  When	  phagocytosis	  was	  examined	   in	   the	  most	  physiological-­‐like	   conditions	   –	   using	   opsonised	   E.	   coli	   at	   37	   degrees	   –	  phagocytosis	  of	  the	  differentiated	  HL-­‐60	  cells	  of	  greater	  than	  60%	  was	  observed.	  Perhaps,	   unsurprisingly,	   there	   was	   a	   marked	   decrease	   in	   this	   when	   non-­‐opsonised	   bacteria	  was	   used	   at	   37	   degrees.	   This	   acts	   as	   further	   evidence	   that	  these	   cells	   have	   been	   differentiated	   toward	   a	   granulocyte-­‐like	   state.	  Phagocytosis	  was	   observed	  when	   cells	  were	   kept	   on	   ice	   and	   it	  was	  postulated	  that	  bacteria	  were	  adherent	  to	  the	  cell	  surface	  rather	  than	  internalised	  in	  these	  conditions.	  This	  was	  indeed	  confirmed	  on	  fluorescent	  microscopy	  of	  cells.	  This	  is	  a	  drawback	  when	  using	  the	  flow	  cytometric	  opsonophagocytosis	  assays	  and	  it	  is,	  of	   course,	   recognised	   that	   these	   assays	   measure	   binding	   and/or	   phagocytosis	  and	  not	  necessarily	  killing	  of	  bacteria	  [160].	  	  	  Despite	  modifications	   of	   the	   conditions,	   high	   levels	   of	   baseline	   oxidative	   burst	  were	  observed	  both	  in	  the	  medium	  and	  differentiated	  cells.	  It	  was	  therefore	  not	  meaningful	  to	  examine	  burst	  induced	  by	  E.coli	  or	  other	  stimulants,	  and	  this	  was	  one	   of	   the	   limitations	   of	   this	   work.	   The	   labeling	   and	   quantitative	   analysis	   of	  myeloperoxidase	   or	   the	   examination	   of	   culture-­‐supernatants	   for	   pro-­‐inflammatory	  cytokines	  could	  potentially	  be	  used	  as	  a	   surrogate	   for	  examining	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resting	   burst	   and	   the	   influence	   of	   certain	   agents	   on	   these	   cells.	   This	   would,	  however,	  need	  further	  exploration.	  	  There	  appeared	  to	  be	  a	  direct	  effect	  of	  ethanol	  on	  the	  cell	  surface	  markers,	  with	  resultant	  reduced	  expression.	  There	  have	  been	  limited	  studies	  investigating	  the	  direct	   impact	  of	  ethanol	  on	  neutrophil	  phenotype	  and	  function.	  This	   is	  perhaps	  reflective	  of	  the	  difficulty	  of	  excluding	  other	  factors	  in	  such	  analyses.	  One	  study	  performed	   in	   critically	   ill	   non-­‐trauma	   patients	   compared	   C-­‐reactive	   protein	  (CRP)	   values,	   circulating	   subsets	   of	   white	   blood	   cells,	   and	   neutrophil	   CD64	  indexes	   recorded	   at	   admission	   to	   the	   intensive	   care	  unit	   between	  abstinent	   or	  moderate	  drinkers,	  patients	  with	  acute	  on	  chronic	  alcohol	  exposure,	  and	  patients	  with	   acute	   exposure	   but	   not	   chronically	   exposed	   to	   alcohol.	   Values	   for	   CRP,	  circulating	  neutrophils,	  and	  neutrophil	  CD64	  indexes	  were	  significantly	  lower	  in	  patients	   acutely	   exposed	   compared	  with	   the	   other	   patients	   [218].	   The	   authors	  also	  found	  increased	  numbers	  of	  circulating	  B	  and	  T	  lymphocytes	  in	  the	  patients	  with	  acute	  exposure	   to	  alcohol	   and	  concluded	   that	   acute	  alcohol	  may	  diminish	  inflammation	  in	  these	  patients.	  Despite	  the	  recognition	  of	  the	  impact	  of	  ethanol	  on	  innate	  and	  adaptive	  immunity	  in	  patients	  with	  cirrhosis	  there	  have	  been	  few	  studies	  that	  have	  attempted	  to	  look	  at	  the	  direct	  impact	  of	  ethanol.	  No	  change	  was	  seen	  on	  intracellular	  TLR9	  following	  ethanol	  exposure.	  Although	  much	  more	  work	  would	  be	  needed	  to	  investigate	  the	  increased	  TLR9	  I	  detected	  in	  my	  AAH	  patients,	   the	   lack	   of	   induction	  by	   ethanol	   on	   these	   cells	   potentially	  points	  towards	  other	  factors,	  such	  as	  DAMPs,	  as	  discussed	  in	  chapter	  3,	  being	  the	  predominant	  driver	  for	  the	  increase	  seen	  and	  these	  cells	  could	  be	  used	  further	  to	  explore	   this.	   For	   example,	   the	   cells	   could	   be	   examined	   after	   exposure	   to	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stimulants	  thought	  to	  be	  involved	  in	  sterile	  inflammation.	  One	  of	  the	  benefits	  of	  using	  the	  cells	  was	  that	  extended	  culture	  with	  ethanol	  was	  possible.	  	  	  Ethanol	  appeared	  to	  have	  a	  negative	   impact	  on	  phagocytosis	  and,	   interestingly,	  the	   VL17A-­‐metabolised	   ethanol	   decreased	   phagocytosis	   further.	   From	   the	  limited	   experiments	   performed	   it	   is	   difficult	   to	   postulate	  what	   it	   is	  within	   the	  hepatocyte-­‐metabolised	   ethanol	   that	   could	   be	   potentiating	   the	   negative	   effect	  and	  this	  would	  be	  interesting	  to	  look	  at.	  Most	  studies	  investigating	  the	  impact	  of	  ethanol	   on	   neutrophil	   function	   have	   looked	   at	   short-­‐term	   exposure.	   Animal	  studies	  have	  reported	  mixed	  effects	  of	  ethanol	  on	  neutrophil	  function	  [219,	  220].	  When	   the	   influence	   of	   acute	   ethanol	   on	   phagocytic	   function	   of	   neutrophils	  against	   Klebsiella	   Pneumoniae	   in	   humans	   was	   investigated,	   the	   phagocytic	  function,	  as	  well	  as	  other	  neutrophil	  functions,	  such	  as	  adhesion,	  chemotaxis,	  and	  oxygen	  metabolism,	  were	   suppressed	  with	   acute	   ethanol	   intoxication	   [221].	  Of	  course,	   mimicking	   the	   environment	   of	   the	   milieu	   of	   the	   circulating	   AAH	  neutrophils	   is,	   in	   vitro,	   difficult,	   as	   is	   mimicking	   the	   environment	   of	   chronic	  ethanol	  use	  but	  these	  cells	  could	  be	  used	  in	  further	  experimental	  models	  to	  allow	  the	   investigation	   of	   specific	   aspects	   of	   neutrophil	   biology	   in	   this	   context.	   In	  addition	   they	   could	   be	   used	   in	   co-­‐culture	   with	   the	   VL17A	   cells	   (Figure	   5.23),	  whereby	   the	   impact	   of	   certain	   stimulants	   and	   therapies	   could	   be	   further	  examined	  by	  assessing	  neutrophil	   function	  and	  hepatocyte	  death	   in	  both	  direct	  and	  indirect	  cultures.	  	  I	  did	  not	  examine	  the	  differentiated	  HL-­‐60	  cells	  post	  LPS-­‐exposure	  and	  given	  my	  previous	   findings	  and	   the	   likely	   importance	  of	   endotoxin	   tolerance	   in	  ALD	   this	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was	   a	   significant	   limitation	   of	   this	   part	   of	   the	   work.	   This,	   in	   itself,	   is	   another	  research	   project	   and	   would	   need	   to	   include	   the	   exploration	   of	   whether	   these	  cells	  provided	  a	  viable	  model	  for	  7-­‐day	  and	  extended	  periods	  of	  culture.	  The	  cells	  have	  previously	  been	  evaluated	  for	  their	  suitability	  as	  an	   in	  vitro	  model	  system	  to	  study	  the	  responses	  of	  neutrophils	  to	  TLR2/4	  ligand	  exposure,	  the	  incubation	  period	  used	  was	  chosen	  as	  4	  hours	  [222].	  Given	  the	  evolving	  importance	  of	  the	  microbiome	   and	   different	   ‘favourable’	   and	   ‘non-­‐favourable’	   strains	   of	   bacteria	  this	  could	  also	  be	  examined	  within	  this	  model.	  In	  addition,	  the	  cells	  could	  also	  be	  used	   to	   further	   explore	   neutrophil-­‐responses	   to	   fungal	   pathogens	   clearly	   of	  importance	  in	  ALD	  [223].	  	  There	   are,	   of	   course,	   limitations	   encountered	   with	   the	   use	   of	   the	   HL-­‐60	   cells.	  Despite	   careful	   handling	   of	   the	   cells,	   there	   was	   variability	   seen	   between	   the	  passages.	  They	  represent	  a	  cancer-­‐cell	  line	  and	  despite	  differentiation	  of	  the	  cells	  this	   would	   need	   to	   be	   kept	   in	   mind	   specifically	   when	   evaluating	   certain	  therapies.	  With	  reference	   to	  some	  of	  my	  previous	   findings	   in	   the	   initial	  human	  study,	  the	  HL-­‐60	  cells	  lack	  lactoferrin	  mRNA.	  This	  could	  potentially	  be	  used	  to	  an	  advantage,	   however,	   in	   terms	   of	   assessing	   the	   contribution	   of	   lactoferrin	   to	  microbicidal	  activity	  or	  inflammation	  for	  example.	  	  	  Despite	   the	   limitations	   of	   these	   cells,	   in	   my	   work	   their	   study	   enabled	   an	  exploration	   of	   basic	   neutrophil	   biology.	   The	   exploration	   of	   the	   IFN-­‐λ	   receptor	  and	   exogenous	   IFN-­‐λ	   effect	   led	   to	   further	   questions	   regarding	   the	   relationship	  between	  neutrophils	  and	  IFN-­‐λ	  which	  is	  discussed	  in	  chapter	  6.	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Figure	  5.22	  Potential	  co-­‐culture	  model:	  neutrophil	  cell	  line	  
and	  /	  or	  isolated	  neutrophils	  from	  some	  ALD	  patients	  are	  co-­‐
cultured	  with	  hepatoma	  cell	  lines	  in	  direct	  and	  indirect	  
culture.	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6 	  The	   neutrophil-­‐interferon	   lambda	   relationship	   in	  
alcohol-­‐related	  liver	  disease	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6.1 Background	  IFN-­‐λ	   has	   a	   restricted	   cell-­‐response	   pattern	   and	   is	   thought	   to	   be	   of	   specific	  importance	   in	   antiviral	   protection	   at	   epithelial	   surfaces.	   Very	   little	   is	   known	  about	  the	  role	  of	  IFN-­‐λ	  in	  bacterial	  infections	  and	  the	  relationship	  between	  this	  class	   of	   cytokine	   and	   neutrophil	   function.	   Recently,	   Blazek	   et	   al.	   have	  demonstrated	   that	   IL-­‐28A	   targets	   neutrophil	   chemotaxis	   and	   impacts	   upon	  pathology	   in	   a	   mouse	   model	   of	   inflammatory	   arthritis	   [183].	   The	   interplay	  between	  IFN-­‐λ	  and	  neutrophils	  in	  other	  diseases	  has	  not	  been	  explored	  and	  the	  question	   as	   to	  whether	  neutrophils	   produce	   IFN-­‐λ	  both	   in	  healthy	   and	  disease	  states	  remains	  unanswered.	  	  
6.2 Aim	  of	  the	  investigation	  The	  first	  aim	  was	  to	  examine	  previously	  collected	  plasma	  samples	  from	  patients	  with	  ALD	  for	  IFN-­‐λ1.	  	  Next,	  healthy	   control	  blood	  was	   cultured	  with	  various	   stimulants	   to	  determine	  whether	   neutrophil	   IFN-­‐λr	   was	   present	   and	   whether	   an	   IFN-­‐λ	   response	   was,	  indeed,	   induced.	   Following	   results	   from	   the	   above,	   the	   contribution	   of	  neutrophil-­‐specific	  IFN-­‐λ	  in	  anti-­‐bacterial	  immune	  defenses	  in	  patients	  with	  ARC	  was	  examined	  as	  described.	  	  
6.3 Methods	  
6.3.1 High	  sensitivity	  IFN-­‐λ1	  ELISA	  A	  high	  sensitivity	  ELISA	  for	  IFN-­‐λ	  was	  performed	  as	  per	  protocol	  on	  the	  plasma	  of	  HC	  n=5,	  AAH	  patients	  n=5,	  ARC	  patients	  n=10	  and	  patients	  with	  hepatitis	  C	  virus	  (HCV)	  cirrhosis	  n=5.	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6.3.2 Healthy	  control	  IFN-­‐λ	  induction	  experiments	  Whole	   blood	   cultures	   on	   HC	   n=5	   were	   set	   up	   in	   parallel,	   with	   the	   following	  stimulants	  for	  2	  hours:	  1. Gram	  positive	  bacteria	  –	  Pansorbin	  2. Gram	  negative	  bacteria	  –	  E.	  coli	  -­‐	  10	  bacteria	  per	  cell	  3. Poly	  I:C	  	  	  4. Control	  –	  PBS	  One	   set	   of	   the	   above	   samples	   underwent	   neutrophil	   extraction	   using	   the	  MACSxpress	   Neutrophil	   Isolation	   Kit	   (2.9)	   providing	   a	   neutrophil	   fraction	   for	  RNA	   extraction.	   RNA	   was	   extracted	   directly	   from	   the	   other	   4	   samples	   (the	  leukocyte	   fraction).	   RNA	   was	   extracted	   from	   the	   neutrophil	   and	   leukocyte	  fraction	   as	   outlined	   in	   2.20.5.	   Quantitative	   PCR	  was	   carried	   out	   using	   specific	  primers	   and	   probes	   for	   IFN-­‐λ1,	   IFN-­‐λ2/3,	   IFN-­‐λr	   and	   RPLP0	   as	   endogenous	  control	   as	   described	   in	   2.20.6.	   RNA	  was	   also	   extracted	   from	   the	   differentiated	  HL-­‐60	  cells	  to	  include	  in	  the	  IFN-­‐λr	  PCR.	  
6.3.3 IFN-­‐λ	  examination	  post	  E.	  coli	  culture	  in	  ALD	  Patients	   with	   ARC,	   n=11,	   were	   recruited	   and	   compared	   with	   HC,	   n=8.	   Whole	  blood	  was	   incubated	  with	   fixed	  E.	  coli	   at	  a	   concentration	  of	  10	  bacteria/cell	  or	  PBS	   (unstimulated)	   at	   37°C	   for	   2	   hours	   as	   described	   in	   2.21.7.	   Two	   parallel	  cultures	  were	  set	  up	  and	  after	  2	  hours,	  neutrophils	  were	  isolated	  immediately	  as	  described	   previously	   for	   RNA	   extraction	   and	   the	   whole	   blood	   fractions	   (both	  stimulated	  and	  unstimulated)	  were	  stored	   in	  RNAprotect	  Cell	  Reagent	   (Qiagen,	  UK)	   at	   -­‐80°C	   for	   subsequent	   RNA	   extraction.	   RNA	   extraction	   and	   PCR	   were	  performed	   as	   described	   above.	   To	   understand	   whether	   the	   addition	   of	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exogenous	  IFN-­‐λ1,	  -­‐λ2	  or	  -­‐λ3	  could	  alter	  neutrophil	  function	  we	  cultured	  whole	  blood	  with	  recombinant	  cytokines	  and	  assessed	  neutrophil	  cell	  surface	  markers,	  phagocytosis	   and	   oxidative	   burst	   before	   and	   after	   cytokine	   treatment	   as	  described	   in	   2.20.7.	   Plasma	   and	   post-­‐IFN-­‐λ	   supernatants	   were	   collected	   by	  centrifugation	   and	   stored	   at	   -­‐80°C	   for	   subsequent	   cytokine	   quantification	   and	  high	  sensitivity	  IFN-­‐λ1	  ELISA	  as	  previously	  described.	  
6.4 Results	  
6.4.1 High	  sensitivity	  IFN-­‐λ1	  ELISA	  IFN-­‐λ1	  was	  not	  detected	  in	  the	  plasma	  of	  the	  HC.	  It	  was,	  however,	  detected	  in	  4	  out	  of	  the	  15	  patients	  initially	  studied;	  3	  ARC	  and	  1	  AAH.	  The	  highest	  level	  was	  seen	  in	  a	  patient	  recovering	  from	  Streptococcus	  Gordonii	  SBP.	  
6.4.2 Healthy	  control	  IFN-­‐λ	  induction	  IFN-­‐λr	   mRNA	   expression	   was	   demonstrated	   in	   the	   neutrophil	   population	   and	  also	  in	  the	  differentiated	  HL-­‐60	  cells.	   IFN-­‐λ1	  and	  IFN-­‐λ2/3	  mRNA	  was	  detected	  in	  the	  neutrophil	  fraction	  only	  after	  whole	  blood	  stimulation.	  E.	  coli	  was	  found	  to	  be	  the	  strongest	  stimulant	  compared	  to	  Poly	  I:C	  and	  the	  Gram-­‐positive	  stimulant	  used.	  
6.4.3 Neutrophil-­‐specific	  production	  of	  IFN-­‐λ1	  is	  deficient	  in	  advanced	  ARC	  Baseline	  clinical	  characteristics	  of	  the	  patients	  studied	  are	  outlined	  in	  table	  6.1.	  None	  of	  the	  patients	  had	  clinical	  infection	  at	  the	  time	  of	  sampling.	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  Expression	  of	  mRNA	  encoding	   IFN-­‐λ1	  was	  detected	  only	  after	  stimulation	  with	  
E.	  coli	   in	   purified	   neutrophils	   and	   the	   total	   leukocyte	   fraction	   in	   both	  HCs	   and	  patients	  (Figure	  6.1a).	  In	  contrast,	  E.	  coli	  challenged	  IFN-­‐λ2/3	  was	  undetectable	  or	  minimally	   detectable	   within	   the	   neutrophil	   and	   leukocyte	   fractions	   in	   both	  groups	  of	  subjects	  (Figure	  6.1c).	  IFN-­‐λr	  was	  detected	  basally	  and	  also	  following	  stimulation	  in	  the	  neutrophil	  and	  leukocyte	  fractions	  (Figure	  6.1d).	  The	   most	   notable	   findings	   were	   seen	   in	   the	   neutrophil	   expression	   of	   IFN-­‐λ1.	  Amongst	   the	   patients	   two	   groups	   emerged;	   those	   who	   did	   not	   have	   E.	  coli-­‐stimulated	   induction	  of	   IFN-­‐λ1	  (Group	  1)	  and	  those	  who	  did	  (Group	  2)	  (Figure	  6.1a,	   6.1b),	   although	   at	   a	   significantly	   lower	   level	   than	   the	   HCs	   (Figure	   6.2a).	  
E.	  coli	  stimulated	   neutrophil	   expression	   of	   IFN-­‐λ1	   in	   Group	   1	  was	   significantly	  less	  than	  in	  controls	  (p=0.001)	  and	  Group	  2	  (p=0.002)	  (Figure	  6.2a).	  On	  further	  group	  analyses	  it	  was	  observed	  that	  bacterially	  challenged	  production	  of	  IFN-­‐λ1	  in	   the	   leukocyte	   fraction	  was	   also	   compromised	   in	   Group	   1	   (p=0.029)	   (Figure	  6.2c).	   Interestingly,	  Group	  1	  had	   significantly	  higher	  Child-­‐Pugh	   score	  and	  AST	  compared	   to	   Group	   2	   (p=0.029	   and	   p=0.015,	   respectively).	   Therefore	   patients	  
Table	  6-­‐1	  Baseline	  clinical	  characteristics	  of	  the	  patients	  examined	  for	  neutrophil-­‐specific	  IFN-­‐λ	  
response	  post	  E.	  coli	  challenge	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that	  failed	  to	  induce	  IFN-­‐λ1	  response	  to	  bacterial	  challenge	  had	  more	  advanced	  liver	  disease.	  The	  increased	  Child-­‐Pugh	  stage	  may	  also	  reflect	  higher	  circulating	  endotoxin	  levels	  (Table	  6.2).	  Neutrophil	  resting	  oxidative	  burst	  was	  significantly	  higher	   in	   Group	   1	   compared	   to	   Group	   2	   (p=0.047)	   and	   plasma	   IL-­‐8	   was	  significantly	  higher	  in	  Group	  1	  compared	  to	  Group	  2	  (p=0.017).	  The	  profound	  difference	  observed	  in	  IFN-­‐λ1	  between	  the	  patient	  groups	  was	  not	  mirrored	   in	   the	   neutrophil	   or	   leucocyte	   expression	   of	   IFN-­‐λ2/3	   and	   IFN-­‐λr	  expression	   (Figure	  6.1c,	   6.1d).	  However,	  within	   the	  patient	   cohort	   there	  was	   a	  more	   variable	   response	   in	   neutrophil	   IFN-­‐λr	   expression	   compared	   to	   HCs	  (Figure	  6.1d).	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Figure	  6.1	  Deficient	  neutrophil	  mRNA	  expression	  of	  IFN-­‐λ1	  upon	  E	  coli	  stimulation.	  	  (a)	  E	  coli	  induced	  production	  of	  IFN-­‐λ1	  mRNA	  in	  purified	  neutrophils	  and	  total	  leukocytes,	  expressed	  as	  ΔCT	  to	  control	  gene,	  in	  healthy	  controls	  and	  patients.	  Wilcoxon	  matched-­‐pairs	  sign	  rank	  test	  was	  used	  to	  analyse	  the	  data.	  (b)	  Two	  groups	  are	  seen	  within	  the	  patient	  cohort	  when	  neutrophil	  IFN-­‐λ1	  mRNA	  is	  analysed,	  with	  markedly	  different	  response	  to	  E	  coli.	  Mann-­‐Whitney	  test	  was	  used	  to	  analyse	  the	  data.	  (c)	  Minimal	  change	  was	  observed	   in	  neutrophil	   and	   total	   leukocyte	   IFN-­‐λ2/3	  mRNA	   following	  E	  coli	   in	  both	  healthy	   controls	  and	  patients.	  Wilcoxon	  matched-­‐pairs	   sign	   rank	   test	  was	  used	   to	   analyse	   the	  data.	   (d)	   IFN-­‐λr	  mRNA	  was	  detected	  in	  purified	  neutrophils	  and	  total	  leukocytes	  basally	  and	  after	  stimulation	  in	  both	  healthy	  controls	  and	   patients,	   there	  was	   no	   correlation	   between	   IFN-­‐λ1	   and	   IFN-­‐λr	  mRNA	   induction.	  Wilcoxon	  matched-­‐pairs	  sign	  rank	  test	  was	  used	  to	  analyse	  the	  data.	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Figure	  6.2	  IFN-­‐λ1mRNA	  expression,	  represented	  as	  ΔΔCT	  post-­‐	  and	  pre-­‐	  stimulation	  with	  E.	  coli.	  	  (a)	  Patients	  were	  seen	  to	  divide	  into	  two	  distinct	  Groups;	  Group	  1	  who	  did	  not	  show	  stimulated	  induction	  of	  IFN-­‐λ1	   mRNA	   and	   Group	   2	   who	   did	   demonstrate	   induction,	   although	   at	   a	   lower	   level	   than	   the	   healthy	  controls.	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  multiple	  comparisons	  was	  used	  to	  analyse	  the	  data.	  (b)	  There	  was	  no	   difference	   in	   the	   change	   in	   leukocyte	   IFN-­‐λ1	   mRNA	   post	   stimulation	   between	   healthy	   controls	   and	  patients.	  However,	  on	  further	  analyses,	  Group	  1	  did	  show	  reduced	  induction	  whilst	  Group	  2	  showed	  similar	  induction	  to	  healthy	  controls	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  multiple	  comparisons	  was	  used	  to	  analyse	  the	  data.	  (c).	  Grey	  lines	  indicate	  the	  median	  value;	  whiskers	  indicate	  the	  interquartile	  range.	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Table	  6-­‐2	  Clinical	  and	  neutrophil	  function	  data	  for	  group	  1	  and	  group	  2	  patients.	  	  
Group	  1	  –	  patients	  who	  lacked	  interferon-­‐λ1	  induction	  upon	  E.	  coli	  stimulation,	  Group	  2	  –	  patients	  
who	  had	  E.	  coli-­‐stimulated	  induction	  of	  IFN-­‐λ1.	  
Parameter	  
Group	   1	   vs	  
Group	  2	   Group	  1	   Group	  2	  
(p-­‐value)	   (median	  -­‐	  [IQR])	   (median	  -­‐	  [IQR])	  
Age	  y	   0.074	   45.0	   -­‐	   [40.5,	  52.5]	   56.0	   -­‐	   [46.0,	  61.0]	  
Bilirubin	  μmol/L	   0.015	   372.0	   -­‐	   [67.5,	  719.5]	   19.0	   -­‐	   [15.0,	  37.0]	  
Albumin	  g/L	   0.163	   25.0	   -­‐	   [24.5,	  31.5]	   33.0	   -­‐	   [28.0,	  39.0]	  
Child	  Pugh	  score	   0.029	   12.0	   -­‐	   [10.0,	  14.5]	   9.0	   -­‐	   [8.0,	  10.3]	  
AST	  IU/L	   0.015	   126.0	   -­‐	   [70.8,	  167.0]	   50.0	   -­‐	   [33.0,	  58.0]	  




0	   -­‐	  
[5178.3,	  
7597.8]	  
E.	  coli(+)	  %	  post	  rIL28A	  *	   0.053	   68.8	   -­‐	   [58.4,	  83.7]	   95.6	   -­‐	   [85.3,	  96.6]	  
E.	  coli(+)	  %	  post	  rIL28B	  *	   0.064	   62.7	   -­‐	   [60.9,	  79.1]	   93.8	   -­‐	   [75.7,	  96.7]	  
Rhodamine	   MFI	  
medium	  #	   0.047	   349.4	   -­‐	  
[305.5,	  
424.7]	   213.3	   -­‐	  
[176.7,	  
312.4]	  
Rhodamine	   MFI	   post	  
rIL29	  #	   0.049	   319.2	   -­‐	  
[298.7,	  
431.6]	   238.4	   -­‐	  
[179.5,	  
275.4]	  
Rhodamine	   MFI	   post	  
rIL28A	  #	   0.045	   326.1	   -­‐	  
[283.6,	  
465.8]	   241.1	   -­‐	  
[167.1,	  
258.9]	  
Rhodamine	   MFI	   post	  
rIL28B	  #	   0.069	   319.2	   -­‐	  
[278.1,	  
448.0]	   232.9	   -­‐	  
[163.0,	  
289.1]	  
*	  ‘E.	  coli	  (+)	  %’	  represents	  neutrophil	  phagocytic	  activity.	  
#	  ‘Rhod	  MFI’	  represents	  neutrophil	  production	  of	  reactive	  oxygen	  species.	  
Unpaired	  t	  test	  was	  used	  to	  analyse	  group	  1	  and	  2	  clinical	  data	  (normal	  data).	  
Mann-­‐Whitney	  test	  was	  used	  to	  analyse	  group	  1	  and	  group	  2	  experimental	  data.	  	  IFN-­‐λ1	   was	   not	   detected	   by	   ELISA	   in	   the	   plasma	   samples	   or	   post-­‐E.	   coli	  supernatant	  samples.	  	  Incubation	   of	   whole	   blood	   with	   IFN-­‐λ1,	   -­‐λ2	   or	   -­‐λ3	   did	   not	   alter	   neutrophil	  expression	  of	  CD11b,	  CD16,	  CD182,	  TLR2	  or	  TLR4.	  No	  clear	   trend	  was	  seen	  on	  the	   expression	  of	  PSGL-­‐1	  or	  CD62L.	  Group	  1	  had	  higher	  baseline	   resting	  burst	  than	  group	  2.	  There	  were	  no	  clear	  trends	  seen	  on	  phagocytosis	  or	  oxidative	  burst	  following	  treatment	  with	  IFN-­‐λ1,	  -­‐λ2	  or	  -­‐λ3.	  In	  addition,	  no	  changes	  in	  pro-­‐	  and	  anti-­‐inflammatory	  cytokine	  production	  were	  observed	  post-­‐treatment.	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6.5 Discussion	  After	   confirming	   IFN-­‐λr	   mRNA	   expression	   on	   neutrophils	   and	   that	   neutrophil	  IFN-­‐λ1	  and	  IFN-­‐λ2/3	  mRNA	  could	  be	  induced,	  the	  patient	  study	  was	  designed.	  At	  this	  point	  there	  was	  not	  a	  single	  study	  describing	  IFN-­‐λr	  expression	  or	  the	  effect	  of	  lambda	  on	  neutrophils.	  The	  data	  reported	  herein	  identifies	  human	  neutrophils	  as	  producers	  of	  IFN-­‐λ1	  in	  response	  to	  bacterial	   infection	  and	  reveal	  a	  previously	  unknown	  impairment	  in	  neutrophil	   function	   in	   ARC.	   Marked	   differences	   in	   production	   of	   IFN-­‐λ1	   in	  response	   to	   E.	  coli	  were	   seen	   within	   the	   patient	   cohort	   compared	   to	   HCs	   and	  those	   who	   lacked	   production	   had	   significantly	   more	   advanced	   liver	   disease.	  Given	   the	  magnitude	  of	  difference	  seen	   this	  may	  be	  of	  greater	  significance	   in	  a	  larger	   cohort.	   Although	   the	   marked	   impairment	   in	   IFN-­‐λ1	   production	   in	   our	  patients	   was	   seen	   in	   the	   neutrophil	   fraction,	   on	   further	   analyses	   the	   patients	  who	  were	   not	   seen	   to	   induce	  neutrophil	   IFN-­‐λ1	   in	   response	   to	  E.	  coli	  also	   had	  significantly	   less	   induction	   of	   leukocyte	   IFN-­‐λ1.	   This	   perhaps	   supports	   the	  concept	   of	   cross-­‐talk	   between	   neutrophils	   and	   the	   adaptive	   immune	   system;	  more	  work	   is	   required	   to	   investigate	   this	   finding.	   It	   is	   important	   to	   note	   that	  neutrophils	  have	  low	  RNA	  content	  and	  so	  do	  not	  constitute	  the	  majority	  of	  RNA	  within	  the	  leukocyte	  fraction	  given	  the	  volumes	  of	  blood	  used.	  A	  difference	   in	   confirmed	   infection	  between	   the	   two	  groups	  was	  not	   seen,	   this	  would	  require	  a	  larger	  study	  population.	  	  It	   is	   difficult	   to	   postulate	   why	   the	   profound	   difference	   observed	   in	   IFN-­‐λ1	  between	   the	   patient	   groups	   was	   not	   mirrored	   in	   the	   neutrophil	   or	   leucocyte	  expression	   of	   IFN-­‐λ2/3	   and	   IFN-­‐λr	   expression.	   On	   review	   of	   the	   literature,	   a	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complete	  understanding	  of	  the	  difference	  between	  IFN-­‐λ1	  and	  IFN-­‐λ2/3	  has	  not	  yet	  been	  reached.	  My	  data	  would	  suggest	  that	  perhaps	  the	  IFN-­‐λ2/3	  is	  of	  more	  relevance	   in	   the	   total	   leukocyte	  response	  rather	   than	  being	  neutrophil-­‐specific.	  Within	  the	  patient	  cohort	  there	  was	  a	  more	  variable	  response	  in	  neutrophil	  IFN-­‐λr	  expression,	  and	  with	  the	  study	  of	  a	   larger	  number	  of	  patients	  this	  may	  be	  of	  further	  interest.	  	  There	   was	   no	   correlation	   between	   induction	   of	   IFN-­‐λ1	   and	   IFN-­‐λr	   mRNA.	   In	  addition,	  unlike	  in	  the	  HL-­‐60	  cells,	  incubation	  of	  whole	  blood	  with	  recombinant	  IFN-­‐λ	  did	  not	   impact	   on	  neutrophil	   phagocytosis	   or	  oxidative	  burst.	  This	   leads	  me	   to	   believe	   that	   the	   IFN-­‐λ1	   produced	   is	   likely	   to	   be	   biologically	   active	  elsewhere,	   potentially	   at	   epithelial	   surfaces,	   rather	   than	   eliciting	   an	   autocrine	  response.	   By	   inference,	   the	   lack	   of	   production	   may	   be	   an	   additional	   factor	  exacerbating	   the	   lack	   of	   protection	   at	   the	   gut	   epithelium	   and	   contributing	   to	  bacterial	  translocation	  which	  is	  thought	  to	  be	  a	  key	  driver	  of	  immunoparesis	  in	  advanced	   liver	   cirrhosis.	   This	   may,	   in	   fact,	   be	   in	   conjunction	   with	   important	  effects	  on	  the	  enteric	  virome.	  The	  study	  of	  IFN-­‐λ1	  at	  the	  gut	  epithelial	  surface	  of	  patients	  with	  ALD	  warrants	  investigation	  and	  may	  be	  of	  particular	  importance	  in	  patients	  with	   cirrhosis	   secondary	   to	   the	   synergistic	   effects	   of	   alcohol	   and	  viral	  hepatitis.	   An	   effect	   on	   whole	   blood	   cytokine	   production	   2	   hours	   post	  recombinant	   IFN-­‐λ	   incubation	   was	   not	   seen.	   This	   could	   be	   explained	   by	   the	  timeframe	  used	  which	  may	  be	  too	  narrow	  for	  the	  synthesis	  of	  de	  novo	  cytokines	  or	   support	   the	   concept	   that	   IFN-­‐λ	   is	   more	   active	   at	   epithelial	   surfaces.	  Alternatively,	  this	  could	  support	  the	  thought	  that	  in	  vivo	   lambda	  treatment	  may	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not	  induce	  or	  exacerbate	  an	  inflammatory	  response	  and	  this	  would	  be	  of	  interest	  to	  study	  in	  larger	  numbers	  and	  using	  a	  range	  of	  duration	  of	  treatment	  in	  vitro.	  Treatment	   of	   whole	   blood	   with	   IFN-­‐λ1,	   -­‐λ2	   or	   -­‐λ3	   did	   not	   alter	   neutrophil	  expression	  of	  CD11b,	  CD16,	  CD182,	  TLR2	  or	  TLR4.	  There	  was	   a	  more	  variable	  response	   in	   the	   expression	   of	   PSGL-­‐1	   and	   CD62L;	   these	   markers	   influence	  neutrophil	  migration	   and	   endothelial	   cell-­‐interaction,	   and	   again,	   this	  would	   be	  useful	  to	  study	  in	  larger	  numbers.	  It	  would	  be	  of	  interest	  to	  examine	  post-­‐IFN-­‐λ	  treated	  lymphocyte	  and	  monocyte	  function,	  and,	  in	  retrospect,	  the	  PBMCs	  could	  have	   been	   collected	   and	   stored	   post-­‐treatment	   for	   later	   analyses	  which	  would	  have	  added	  to	  this	  study.	  	  The	  lack	  of	  detection	  of	  IFN-­‐λ	  in	  the	  second	  ELISA	  and	  particularly	  the	  lack	  in	  the	  post	  E.	  coli	  supernatants	  in	  the	  HC	  may	  be	  explained	  by	  transient	  presence	  of	  the	  protein,	   indeed	   most	   of	   the	   published	   data	   refer	   to	   mRNA	   rather	   than	   the	  protein.	   If	   pure	   neutrophil	   supernatant	   was	   analysed	   this	   may	   have	   given	  different	   results.	   This	   would	   require	   further	   analyses	   including	   patients	   in	   a	  septic	  phase	  or	  recovering	  from	  sepsis.	  In	  this	  study,	  a	  cohort	  of	  patients	  with	  decompensated	  ARC	  were	  examined,	  two	  of	   the	   patients	   had	   superimposed	   AAH;	   these	   two	   patients,	   perhaps	  unsurprisingly,	  fell	  into	  Group	  1.	  Given	  our	  findings	  and	  the	  findings	  of	  Blazek	  et	  
al.	  there	  may	  be	  clinical	  benefit	  in	  the	  analyses	  of	  a	  large	  cohort	  of	  patients	  with	  acute	   severe	   AAH,	   the	   progression	   to	   which	   remains	   poorly	   understood	   with	  limited	  treatment	  options.	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In	   conclusion,	   these	   findings	   confirm	   an	   IFN-­‐λ	   response	   in	   non-­‐viral	   infection,	  clarify	   the	  neutrophil	   as	   a	  producer	  of	   IFN-­‐λ	  and	   reveal	   a	  previously	  unknown	  deficient	   IFN-­‐λ	   production	   in	   ARC	   which	   requires	   further	   exploration.	  Elucidation	   of	   these	   mechanisms	   may	   have	   important	   implications	   for	  therapeutic	   developments	   in	   an	   era	   of	   multi-­‐drug	   resistance	   and	   within	   the	  spectrum	  of	  ALD.	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7 	  General	  Discussion	  and	  Future	  Work	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Here	  follows	  a	  discussion	  of	  the	  most	  salient	  results	  from	  each	  section	  of	  work.	  I	  have	  included	  a	  critique	  and	  the	  limitations	  of	  each	  chapter	  within	  each	  section,	  and	  concluded	  with	  where	  I	  see	  the	  focus	  of	  future	  work	  in	  ALD.	  	  
Neutrophils	   from	   AAH	   patients	   display	   increased	   ROS	   and	   lactoferrin	  
release	  and	  anti-­‐bacterial	  activities	  are	  dysfunctional	  (Chapter	  3).	  Neutrophils	  were	   confirmed	   to	   be	   activated	   in	   AAH.	   The	   novel	   finding	   of	   high	  circulating	  levels	  of	  lactoferrin	  seen	  in	  AAH	  compared	  to	  ARC	  supports	  this	  and,	  with	   larger	   cohorts,	   could	   potentially	   be	   used	   to	   differentiate	   those	   with	  superimposed	   AAH	   from	   those	   without	   the	   condition.	   Reduced	   antibacterial	  functions	  were	   seen	   across	   the	   spectrum	   of	   patients	   I	   examined.	   Downstream	  signaling,	   for	  example,	  post	  TLR4	  activation	  was	  not	  evaluated	   in	   these	  studies	  and	   further	   clarification	   of	   the	   pathways	   triggered	   or	   perhaps	   inadequately	  triggered	   require	   further	   investigation.	   A	   key	   question	   is	   whether	   the	  neutrophils	   within	   the	   liver	   vasculature	   behave	   in	   a	   similar	   way	   to	   the	  peripheral	   neutrophils;	   this	   was	   not	   addressed	   in	   my	   work.	   As	   discussed	   in	  chapter	  3	  the	  analyses	  of	  liver	  biopsies	  may	  provide	  some	  information	  regarding	  this,	   as	   would	   analyses	   within	   animal	   models,	   which	   are	   continually	   being	  improved	   [224].	   Intravital	   confocal	   microscopy,	   which	   allows	   observation	   of	  biological	   processes	   in	   vivo	   at	   high	   resolution,	   may	   also	   be	   another	   mode	   of	  exploring	  this.	  	  	  The	  potential	  for	  neutrophil	  elastase	  to	  induce	  bystander	  tissue	  damage	  has	  been	  recognised	  for	  many	  years	  [225].	  Given	  the	  recent	   interest	   in	  NET	  formation	  in	  liver	   injury	   and,	   in	   particular,	   the	   finding	   that	   liver	   damage	   was	   reduced	   (by	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80%)	   if	   NET	   production	  was	   blocked	   [144],	   this	   seems	   a	   ripe	   area	   for	   further	  analyses	   in	   AAH.	   A	   key	   question	   that	   stems	   from	   this	   work	   is	   whether	   AAH	  indeed	  has	  an	   infective	   trigger.	  One	  way	  to	   increase	  our	  understanding	  around	  this	   is	   with	   longitudinal	   analyses	   and	   the	   comparison	   of	   a	   large	   number	   of	  patients	  with	  pre-­‐	  or	  early	  AAH	  with	  a	  population	  of	  heavy	  alcohol-­‐drinkers	  who	  do	  not	  develop	  the	  condition;	  only	  then	  will	  some	  of	  the	  protective	  factors	  come	  to	  light.	  Neutrophil	  cell	  maturity	  in	  AAH	  and	  apoptotic	  pathways	  including	  ‘clear-­‐up’	  mechanisms	  are	  additional	  areas	  of	  research	  development	  which	  may	  add	  to	  the	  understanding	  of	  the	  pathophysiology	  in	  this	  condition.	  	  	  
AAH	  T	   cells	   express	   high	   levels	   of	   immune	   inhibitory	   receptors,	   produce	  
lower	   levels	   of	   interferon	   gamma,	   and	   have	   increased	   IL-­‐10	   production,	  
these	  effects	  can	  be	  reversed	  by	  blocking	  PD1	  and	  TIM3,	  which	  increase	  the	  
antimicrobial	  activity	  of	  T	  cells	  and	  neutrophils	  (Chapter	  3).	  The	  work	  on	  PD1-­‐TIM3,	  published	  in	  Gastroenterology,	  defined	  the	  potential	  for	  a	   new	   therapeutic,	   highlighted	   by	   the	   editor	   [226].	   The	   immunosuppression	  rather	   than	   the	   initial	   cytokine	   storm	   may	   be	   the	   predominant	   driver	   of	  mortality	  and	  research	  on	  agents	  to	   improve	  outcome	  should	  perhaps	  focus	  on	  this	  aspect	  alongside	  targets	  to	  improve	  regeneration	  within	  the	  liver.	  	  The	   numbers	   I	   studied	   were	   unfortunately	   too	   small	   to	   provide	   clear-­‐cut	  outcome	   correlations,	   or	   to	   allow	   analysis	   of	   the	   subgroups	   of	   prednisolone-­‐treated	  versus	  non-­‐prednisolone	  exposed	  groups.	  Neutrophil-­‐TLR4	   fold	  change	  post-­‐LPS	   stimulation	   was,	   however,	   significantly	   lower	   amongst	   the	   6-­‐month	  non-­‐survivors	  compared	  to	  the	  6-­‐month	  survivors.	  This	  provides	  further	  support	  for	  endotoxin	  tolerance	  and	  the	  potential	  negative	  impact	  of	  this	  in	  AAH.	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The	  impact	  of	  prednisolone	  on	  neutrophil	  function	  in	  AAH	  (Chapter	  4).	  A	  notable	  finding	  in	  my	  sequential	  analyses	  appeared	  to	  be	  the	  negative	  impact	  of	   steroids	   on	   phagocytosis.	   Vergis	   et	   al.	   show	   that	   in	   patients	   treated	   with	  prednisolone,	   infection	   exerts	   an	   independent	   effect	   on	   mortality	   by	   90	   days;	  furthermore	   the	  authors	  speculate	   that	  7	  days	  of	  prednisolone	   therapy	  may	  be	  enough	  to	  impair	  host	  immunity	  to	  allow	  development	  of	  serious	  infection,	  and	  that	   discontinuation	   of	   steroids	   after	   7	   days	   may	   be	   unable	   to	   reverse	   the	  damage	   [97].	   Correlation	   of	   bacterial	   DNA	   with	   neutrophil	   functional	   assays	  would	  be	  of	   interest;	  and	  my	  data	  support	   the	  need	  for	   further	  stratification	  of	  patients	   for	   steroid-­‐prescribing.	   In	   summary,	   the	   effect	   of	   prednisolone	   on	  neutrophil	   function	   appeared	   detrimental	   at	   an	   in	   vitro	   level	   without	   the	  potential	   benefits	   of	   suppressing	   inflammation,	   as	   there	   was	   no	   impact	   on	  neutrophil	  ROS	  or	  lactoferrin	  release.	  	  
The	  differentiated	  HL-­‐60	  cells	  express	  many	  of	  the	  key	  receptors	  examined	  
in	   the	   human	   study	   and	   could	   be	   used	   to	   further	   investigate	   neutrophil	  
dysfunction	  and	  the	  impact	  of	  individual	  drivers	  in	  ALD	  (Chapter	  5).	  The	  HL-­‐60	  cells	  could	  be	  used	  in	  further	  models,	  for	  example,	  co-­‐culture	  systems	  as	   discussed	   in	   chapter	   5.	   The	   impact	   of	   ethanol	   and	   hepatocyte-­‐metabolised	  ethanol	   on	   phagocytosis	   is	   of	   interest	   and	   perhaps	   links	   in	   with	   the	   lower	  phagocytosis	  seen	  in	  the	  AA	  patients	  compared	  to	  the	  ABA.	  In	  a	  recent	  review	  on	  sepsis	  in	  ALD	  it	  is	  stated	  that	  the	  impact	  of	  alcoholic	  aetiology	  and	  active	  alcohol	  consumption	   on	   infection-­‐related	   short-­‐term	   mortality	   in	   cirrhosis	   is	   unclear	  [227].	  Although	   there	  have	  been	   studies	   examining	   the	   impact	  of	   alcohol,	   both	  acute	  and	  chronic,	  on	  bacterial	  translocation	  in	  healthy	  individuals	  [228],	   there	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are	   few	   studies	   that	   have	   examined	  direct	   ethanol	   effect	   on	   the	   bone	  marrow.	  Given	   the	   key	   role	   that	   immune	   cells	   play	   in	   ARC	   and	   specifically	   in	   AAH	   this	  would	   seem	   important	   to	   further	  understand.	  The	   impact	  of	  LPS	  on	   the	  HL-­‐60	  cells	  was	  not	   further	  examined	  and	   this	   is	  a	   limitation	  of	   this	  work.	  No	  change	  was	  seen	  on	  HL-­‐60	  TLR9	  expression	  following	  ethanol	  exposure.	  Although	  much	  more	  work	  would	  be	  needed	  to	  investigate	  the	  increased	  TLR9	  I	  detected	  in	  my	  AAH	  patients,	   the	   lack	  of	   induction	  by	  ethanol	  on	   these	   cells	  potentially	  points	  towards	   other	   factors,	   such	   as	  DAMPs,	   playing	   a	   role,	   and	   these	   cells	   could	   be	  used	  to	  examine	  this.	  	  	  Endothelial-­‐neutrophil	  interactions	  may	  add	  to	  the	  understanding	  of	  why	  certain	  individuals	  develop	  this	  condition.	  In	  retrospect,	  it	  would	  have	  been	  of	  potential	  use	   to	   have	   broadened	   the	   analyses	   of	   the	   neutrophil	   cell	   surface	   markers	   to	  include	  the	  selectins,	  such	  as	  PSGL-­‐1,	  in	  my	  initial	  cohort	  of	  patients.	  This	  could	  then	   have	   been	   correlated	   with	   the	   plasma	   selectin	   analyses.	   Interest	   in	   gene	  sequencing	   of	   the	   CXCL	   family	   of	   chemokines	   in	   AAH	   is	   growing	   and	   may	  ultimately	  serve	  as	  both	  biomarker	  and	  therapeutic	  target.	  	  	  
Neutrophil-­‐specific	   production	   of	   interferon-­‐λ1	   is	   deficient	   in	   advanced	  
alcohol-­‐related	  liver	  cirrhosis	  (Chapter	  6).	  In	  my	  final	  results	  chapter	  the	  contribution	  of	  neutrophil-­‐specific	  IFN-­‐λ,	  in	  anti-­‐bacterial	   host	   immune	   defense	   is	   reported.	   This	   pathway	   is	   strikingly	  compromised	   in	   patients	   with	   severe	   ARC.	   Little	   is	   known	   about	   IFN-­‐λ	   in	   the	  context	   of	   bacterial	   infection	   and	   the	   neutrophil-­‐IFN-­‐λ	   relationship	   both	   in	  health	  and	  disease	  states	  has	  been	  largely	  unexplored.	  The	  findings	  confirm	  the	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role	  of	  IFN-­‐λ	  in	  non-­‐viral	  infection,	  clarify	  the	  neutrophil	  as	  a	  producer	  of	  IFN-­‐λ	  and	   reveal	   a	   previously	   unknown	   deficient	   IFN-­‐λ	   production	   in	   advanced	   ARC	  which	  may	  have	  implications	  for	  the	  future	  advances	  in	  the	  management	  of	  this	  condition.	  Whilst	  this	  study	  includes	  a	  small	  number	  of	  patients,	  the	  differences	  seen	  are	  marked	  and	  likely	  to	  be	  of	  greater	  significance	  in	  a	  larger	  cohort.	  Work	  is	  ongoing	  to	  further	  recruit	  AAH	  patients	  so	  that	  the	  above	  results	  can	  be	  built	  upon,	   and	   the	   manuscript	   is	   in	   preparation.	   Given	   the	   lack	   of	   treatment	  strategies	   to	   address	   bacterial	   infections,	   in	   an	   era	   of	   multi-­‐drug	   resistance,	   I	  believe	  this	  work	  is	  of	  wide	  interest	  given	  the	  new	  understanding	  it	  adds	  to	  the	  field	   of	   neutrophil	   biology	   and	   host	   immunity	   in	   bacterial	   infection.	   A	   recent	  study	  has	  demonstrated	  a	  dual	  effect	  of	   IFN-­‐λ	  on	  both	   the	   innate	  and	  adaptive	  arms	  of	  the	  immune	  response	  in	  vivo	  during	  chronic	  viral	  infection	  [229].	  IFN-­‐λ	  requires	   further	   assessment	   in	   the	   different	   stages	   of	   ALD,	   with	   increased	  patient	   numbers.	   This	   will	   potentially	   add	   to	   the	   understanding	   of	   the	   link	  between	   innate	   and	   adaptive	   immunity	   in	   this	   condition,	   and	   the	   relevance	   of	  this	  on	  the	  pathogenenesis	  of	  the	  different	  clinical	  stages.	  Longitudinal	  study	  will	  also	  deepen	  understanding	  of	  ALD	  and	  sepsis	  susceptibility.	  Genotyping	  patients	  in	   relation	   to	   IFN-­‐λ	   signaling	  may	   also	  prove	   to	   be	   of	   clinical	   relevance	   in	   this	  group.	  This	  will	  allow	  tailored	  patient	  care,	  more	  effective	  use	  of	  antimicrobials	  and	  further	  identification	  of	  targets	  for	  therapy.	  	  A	  recently	  published	  study	  demonstrate	  an	  important	  role	  of	  fungal	  dysbiosis	  in	  the	   development	   of	   ALD	   [230];	   translocation	   of	   fungal	   β-­‐glucan	   induced	   liver	  inflammation	   via	   the	   C-­‐type	   lectin-­‐like	   receptor,	   CLEC7A,	   on	  Kupffer	   cells	   and,	  possibly,	   other	   bone-­‐marrow	   derived	   cells.	   Subsequent	   increases	   in	   IL-­‐1β	  
217	  	  
expression	   and	   secretion	   contributed	   to	   hepatocyte	   damage.	   ARC	   patients	   had	  increased	   systemic	   exposure	   to	   mycobiota	   and	   the	   levels	   of	   exposure	   and	  immune	   response	   correlated	   with	   mortality.	   It	   would	   seem	   that	   further	   work	  into	   fungal	   exposure	   in	   the	  AAH	  patients	   is	   of	  worth,	   both	   in	   terms	  of	   seeking	  triggers	   of	   disease,	   and,	   also	  with	   regard	   to	   improving	   outcome	   once	   patients	  have	  developed	  the	  condition.	  If	  transplantation	  for	  this	  group	  of	  patients	  were	  to	  become	  increasingly	  practiced,	  research	  into	  this	  area	  would	  be	  of	  additional	  benefit.	  The	  study	  of	  not	  just	  the	  microbiome	  but	  also	  of	  the	  virome	  and	  fungal	  species	  and	  interplay	  between	  these	  is	  of	  key	  importance	  I	  believe,	  particularly	  with	  regard	  to	  the	  trigger	  of	  AAH.	  IFN-­‐λ	  may	  be	  an	  important	  link	  between	  these	  compartments	  and	  critical	  in	  homeostatic	  mechanisms.	  	  	  
Summary	  of	  results	  After	  confirming	  the	  activation	  of	  neutrophils	  and	  the	  blunted	  response	  to	  LPS	  in	  AAH,	   the	   potential	   for	   reversibility	   of	   this	   dysfunction	   was	   examined.	   Greater	  understanding	   of	   why	   certain	   patients	   enter	   a	   harmful	   compensatory	   anti-­‐inflammatory	   response	   syndrome	   is	   clearly	   important;	   and	   the	   evolution	   of	  disease	   and	   impact	   of	   prednisolone	   was	   studied	   in	   Chapter	   4.	   Although	  more	  work	   is	   needed,	   the	   potential	   negative	   immunosuppressive	   effects	   of	  prednisolone	  were	  highlighted.	  The	  individual	  trajectory	  within	  the	  disease	  and	  the	   influence	   of	   endotoxin	   tolerance	   was	   seen.	   These	   clinical	   findings	   led	   to	  further	   questions,	   specifically	   do	   other	   derangements	   in	   neutrophil	   function	  contribute	   to	   the	   state	   of	   immunoparesis	   in	   ALD	   and	   is	   there	   a	   stronger	   link	  between	  this	  immune	  compartment	  and	  the	  gut	  or	  at	  epithelial	  surfaces.	  The	  HL-­‐60	  cells	  enabled	  the	  exploration	  of	  basic	  neutrophil	  biology	  and	  the	  exploration	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of	   the	   lambda	   receptor	   led	   to	   further	   questions	   regarding	   the	   relationship	  between	   neutrophils	   and	   IFN-­‐λ.	   My	   final	   results	   chapter	   identifies	   human	  neutrophils	  as	  producers	  of	  IFN-­‐λ1	  in	  response	  to	  bacterial	  infection	  and	  reveals	  a	  previously	  unknown	  impairment	  in	  neutrophil	  function	  in	  ARC.	  	  
Concluding	  remarks	  In	  my	   earlier	   chapters	   I	   have	   alluded	   to	   the	   difficulty	   of	   follow-­‐up	   of	   patients	  which	   limited	   interpretation	  of	   some	  results.	  This	  would	  need	   to	  be	   taken	   into	  account	  when	  designing	   future	  studies.	  To	   identify	   triggers	  of	  AAH	  and,	  also	   to	  learn	  more	  about	  moderate	  AAH,	   for	   example	   those	  with	   a	  Maddrey’s	   score	  of	  20-­‐32	   who	   still	   have	   significant	   mortality	   at	   90	   days,	   large	   scale	   studies	   are	  required	   which	   include	   excess	   alcohol	   drinkers.	   Studies	   should	   not	   just	   be	  limited	   to	   those	   who	   already	   have	   severe	   AAH.	   This	   collaborative	   approach	  would	  also	   facilitate	  pharmacologic	  addiction	   trials	   in	  alcohol	  use	  disorder	  and	  ALD.	   I	  believe	   that	   further	  work	  on	  sarcopenia	  and	  outcomes	   including	  steroid	  response	   is	   of	   interest,	   and	   of	   particular	   importance	   at	   a	   time	   where	  transplantation	  for	  non-­‐responders	  may	  be	  considered.	  A	  team	  approach	  to	  wide	  research	  aims	  for	  this	  group	  should	  be	  adopted	  as	   in	  clinical	  practice	  and,	  with	  this,	  over	  time,	  the	  burden	  of	  morbidity	  and	  mortality	  for	  these	  patients	  may	  be	  improved.	   Limitations	   accepted,	   I	   hope	   that	   my	   results	   have	   added	   to	   the	  understanding	  of	   this	   condition,	  which	  has	  been,	   to	   some	  extent,	   neglected	   for	  many	  years.	  It	  is	  pleasing	  to	  see	  that	  the	  tide	  is	  changing;	  with	  increased	  interest	  in	   defining	   appropriate	   end-­‐points,	   collaborative	   studies	   and	   potential	   novel	  therapeutic	  development.	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Appendices	  	  
Antibodies	  used	  for	  characterisation	  of	  neutrophil	  phenotype	  
Antibody	  
(Fluorochrome)	  
Clone	   Reactivity	   Supplier	   Concentration	   Dilution	  
CD16	  	  (PE)	   3G8	   Human	   BD	  Biosciences,	  UK	   100	  Tests	   1:500	  CD11b	  	  (APC-­‐Cy7)	   ICRF44	   Human	   BD	  Biosciences,	  UK	   100	  Tests	   1:500	  CD282	  (Alexafluor	  488)	   11G7	   Human	   BD	  Biosciences,	  UK	   100	  Tests	   1:500	  TLR4	  	  (Biotin-­‐conjugated)	   HTA125	   Human	   BD	  Biosciences,	  UK	   100	  Tests	   1:500	  Streptavidin	  (PE-­‐Cy7)	   -­‐-­‐	   Human	   BD	  Biosciences,	  UK	   0.2	  mg/mL	   1:500	  TLR9	  	  (APC)	   eB72-­‐1665	   Human	   BD	  Biosciences,	  UK	   100	  Tests	   1:500	  	  
Ethanol-­‐treated	  HL-­‐60	  phagocytosis	  Cells	  were	  spun	  down	  at	  250	  g	  for	  5	  minutes	  and	  seeded	  to	  1	  x106	  cells/mL	  in	  their	  old	  culture	  media	  and	  100	  µL	  added	  per	  tube	  (total	  cell	  number	  per	  tube	  1	  x	  105).	  Ethanol	  (10,	  50,	  100,	  250,	  500	  mM)	  or	  100	  µL	  of	  supernatant	  (control	  24	  hr,	  EtOH	  24	  hr)	  was	  added	  to	  the	  cells	  and	  incubated	  for	  90	  minutes	  at	  37oC/5%	  CO2.	  	  After	  this	  time,	  50	  µL	  E.coli-­‐FITC	  was	  added	  and	  cells	  incubated	  at	  37oC/5%	  CO2	  for	  240	  minutes,	  prior	  to	  being	  washed	  twice	  and	  then	  analyzed	  on	  the	  FACS	  canto	  II.	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